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Abstract: By the time a patient first presents with symptoms of Parkinson’s disease at the clinic, a significant proportion 
(50-70%) of the cells in the substantia nigra (SN) has already been destroyed. This degeneration progresses until, within a 
few years, most of the cells have died. Except for rare cases of familial PD, the initial trigger for cell loss is unknown. 
However, we do have some clues as to why the damage, once initiated, progresses unabated. It would represent a major 
advance in therapy to arrest cell loss at the stage when the patient first presents at the clinic. Current therapies for Parkin-
son’s disease focus on relieving the motor symptoms of the disease, these unfortunately lose their effectiveness as the neu-
rodegeneration and symptoms progress. Many experimental approaches are currently being investigated attempting to al-
ter the progression of the disease. These range from replacement of the lost neurons to neuroprotective therapies; each of 
these will be briefly discussed in this review. The main thrust of this review is to explore the interactions between dopa-
mine, alpha synuclein and redox-active metals. There is abundant evidence suggesting that destruction of SN cells occurs 
as a result of a self-propagating series of reactions involving dopamine, alpha synuclein and redox-active metals. A potent 
reducing agent, the neurotransmitter dopamine has a central role in this scheme, acting through redox metallo-chemistry to 
catalyze the formation of toxic oligomers of alpha-synuclein and neurotoxic metabolites including 6-hydroxydopamine. It 
has been hypothesized that these feed the cycle of neurodegeneration by generating further oxidative stress. The goal of 
dissecting and understanding the observed pathological changes is to identify therapeutic targets to mitigate the progres-
sion of this debilitating disease. 
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1. INTRODUCTION 
  Classified as the second most common neurodegenera-
tive disorder, Parkinson’s disease (PD) is a debilitating mo-
tor related disease and is presently incurable. Resulting from 
a gradual progressive degeneration of nigrostriatal neurons, 
PD affects approximately 1% of the population over 50 years 
of age [333]. 
  The pathological characteristics of PD require careful 
differential diagnosis of specific features which are only con-
firmed post mortem. Determined by microscopic examina-
tion, the key pathological characteristics of PD are loss of 
nigral neurons (and loss of pigmentation in this area), and the 
presence of insoluble proteinaceous cytoplasmic inclusions 
termed Lewy bodies (LB) and Lewy neurites in the remain-
ing cells. The inclusions are rich in the fibrils of the pre-
synaptic protein alpha synuclein (-synuclein) and ubiquitin 
which are thought to arise from the failure of normal degra-
dation in the proteasome pathway (see section 2.3) [197, 
280, 381]. Motor symptoms that are associated with the dis-
ease are most likely to be caused by a loss of dopamine (DA) 
producing cells within the substantia nigra pars compacta 
(SN), in particular, in the interconnections between the SN 
and the caudate and putamen. The five nuclei which com-
prise the basal ganglion are; Substantia Nigra (SN), Globus 
Pallidus (GP), Subthalamic Nucleus (STN), Caudate Nucleus 
(CN), and Putamen (CPu). The CPu seems to be the most  
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affected structure, losing up to 95% of dopaminergic inputs 
compared to 80% in the caudate nucleus [184, 214]. Animal 
models that have shown dynamic rearrangement of the do-
paminergic terminals after lesioning suggests that this is 
likely to be occurring in the preclinical stages of the human 
disease [114].  
  In recent times, a new concept in the progression of PD 
has emerged [45] proposing that a number of nuclei are in-
volved before the SN. The first appearance of disease related 
symptoms correlates with functional deficits in the lower 
brainstem and olfactory bulb, then dysfunction progresses up 
the brainstem to produce classical PD [45]. Changes in other 
nuclei are observed and are thought to be secondary to the 
primary disease [175, 176]. The disease progresses until cor-
tical and cognitive changes develop. In this review we will 
focus on interventions which may prevent the chronic de-
generation of the dopaminergic neurons of the SN. 
  Clinical behavioral symptoms of PD are linked to uncon-
trolled motor deficits such as akinesia (absence of movement 
or temporary paralysis), bradykinesia (abnormal slowness of 
movement), abnormalities in gait, resting tremor and rigidity. 
Cognitive dysfunction such as speech, executive function 
and memory loss can also develop as later symptoms.  
  The study by Braak and colleagues (2003) [45] has also 
shown that patients that exhibit early stage dysfunction (such 
as REM sleep disturbance, restless leg syndrome) go on to 
develop PD within 20 years. In the future, these clinical de-
velopments may identify patients that would be suitable can-
didates for neuroprotective therapies before the SN cells are 
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  PD is a progressive neurodegenerative disease with up to 
10% of the remaining dopaminergic cells dying each year 
[295]. It has been suggested that this progression of the dis-
ease explains the loss of responsiveness to drug therapies 
such as L-dihydroxyphenylalanine (L-DOPA), ultimately 
failing as the number of DA producing cells falls below a 
critical level [111]. Most patients benefit from L-DOPA 
without complications for only approximately five years 
from the commencement of treatment. Subsequently, the side 
effects of the treatment become apparent with the percentage 
of motor fluctuations and dyskinesia ranging from 10% of 
patients at 5 years, up to 80–90% in later years [265, 266]. 
Some researchers within the field suggest that pharmacologi-
cal intervention with neuroprotective therapies in the pre-
clinical stage of PD will have a better chance of prolonging 
near normal function in patients [200, 264]. New diagnostic 
tools are currently being developed with several able to pro-
vide diagnosis at an earlier stage than is commonly achieved 
at present [380, 431]. With our expanded clinical perspective 
on parkinsonism, there is a real chance of utilizing new neu-
roprotective therapies when they become available. Current 
studies have hypothesized an interaction of multi-factorial 
risk factors which can cause the disease. These can be classi-
fied as: genetic, environmental, metabolic (oxidative stress; 
reactive species (RS) production) and biochemical (protein 
aggregation). New diagnostic techniques and promising neu-
roprotective pharmacological agents are becoming a reality 
enabling the next stage in PD therapy, slowing down the 
progression of SN cell loss in the disease. This review fo-
cuses on the possible contributing factors that cause PD, in 
order to discuss possible strategies to intervene and to slow 
the progression of PD. 
2. PUTATIVE CAUSES AND RISK FACTORS IN-
VOLVED IN PD 
  Various contributing factors such as drugs of abuse, in-
dustrial/agricultural chemicals and genetic mutations have all 
been known to cause PD or PD type symptoms in humans. 
Therefore animal models that utilize these factors are valu-
able tools to help identify the molecular mechanisms of neu-
rodegeneration that are associated with PD. The exact 
mechanistic trigger that causes loss of nigral cells found in 
sporadic PD remains unknown. Many studies have revealed 
that in combination with a genetic predisposition, contribut-
ing factors for oxidative stress (due to the dysregulation in 
metabolic homeostasis) are involved with the degenerative 
processes. Although only a minor proportion of these PD 
patients (<10%) harbor all known genetic deficits, investiga-
tion of these mutations may reveal the mechanisms through 
which a therapeutic target could be identified [400]. With 
this caveat in mind, the genetic mutations point toward the 
direction of possible pharmacological targets.  
2.1. Genetic Factors 
  PD is primarily a sporadic disorder that is believed to be 
‘multi-factorial’ occurring through the involvement of inter-
actions between genetic and environmental factors. Epide-
miological studies have shown that while sporadic PD occurs 
at a later onset of 60 years of age, familial onset tends to 
develop at a younger age (<50 years), and occurs in ap-
proximately 1% of all PD cases [333]. Thus, genetic muta-
tions alone cannot explain the majority of disease cases. 
However, mutations in specific genes in familial PD have 
given emphasis to particular genes involved in the molecular 
pathogenesis of parkinsonism. Six gene loci have been iden-
tified that have a PD pathological phenotype (see Table 1). 
Mutations in the -synuclein (-syn),  Parkin, PTEN- In-
duced putative Kinase 1 (PINK1), DJ-1, Leucine rich repeat 
kinase 2 (LRRK2), ATP13A2 and UCH-L1 genes have all 
been shown to be involved in familial PD.  
-synuclein  
  Specifically enriched in the adult brain, the -synuclein 
protein is ubiquitously expressed within the central nervous 
system (CNS) in neurons and glia and is localized in neu-
ronal structures [198]. Belonging to a structurally homolo-
gous protein family which includes - and -synuclein, its 
function has not been well defined. Recent publications have 
implicated -synuclein as a neurotransmitter modulator regu-
lating vesicle handling (recycling and docking) [121, 122, 
228], synaptic transmission and re-uptake [249]. Structural 
assays have determined that -synuclein has the potential to 
bind to phospholipids particularly on synaptic vesicles [80, 
300]. The binding to phospholipids occurs through the N- 
amphiphatic domain which is a highly conserved region. -
Synuclein knockout animals have deficits in expression of 
synaptic-associated proteins as well as a reduction in synap-
tic vesicles [50], but surprisingly only subtle behavioral defi-
cits. Most recently, other novel functions have shown -
synuclein as a protein trafficking chaperone as defects in the 
gene obstructs ER-Golgi vesicular trafficking [74]. This evi-
dencesuggests that -synuclein plays an essential role in dif-
ferent cellular functions which may be disrupted in PD and 
other diseases where -synuclein aggregates are present such 
as Dementia with Lewy Bodies (DLB) and Multiple System 
Atrophy (MSA) - (synucleinopathies). The parkinsonian 
disease phenotype to genotype correlation was firstly linked 
to a mutation in the -synuclein gene derived from an Italian 
kindred [333, 334]. The penetrance in this family alone was 
85%, comprising of a single point mutation, a G to A con-
version at position 209 which ultimately changed the amino 
acid code from an Alanine to Threonine at residue 53 
(A53T). Since then, two other point mutations (A30P and 
E46K) have been characterized and shown to segregate with 
the disease. Whole gene duplication [58, 195] and triplica-
tion resulting in over-expression of wild type -synuclein 
[368] have been found to cause familial PD, all increase the 
rate of onset and rate of disease progression [301]. The A53T 
mutation increases the mean rate of onset of PD (to ap-
proximately 46 years of age), muscle rigidity and bradykine-
sia being the prominent clinical features [14]. Systematic 
mutational screening of the -synuclein gene revealed an-
other mutation, A30P, which displayed similar features to 
those observed in sporadic cases, with classic fundamental 
behavioural deficits associated with L-DOPA responsive   
PD [227]. Unlike the other missense mutations identified in 
this gene, the E46K mutation is linked to LB with dementia 
[440] which is associated with amyloid fibrilization [156]. 
The mutations in -synuclein (A53T, A30P) can form fila-
ments at an increased rate in vitro [72]. Wild type -
synuclein undergoes oligomerization when DA is present (in 
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soluble, but are not amyloidogenic [53]. In the presence   
of iron and copper, wild type -synuclein can rapidly   
form soluble SDS resistant oligomers but the formation of 
amyloidogenic  -synuclein aggregates can be completely 
inhibited by the addition of DA [53]. This strongly suggests 
that DA acts as a dominant modulator of -synuclein aggre-
gation [53]. The structural morphology of the aggregates of 
-synuclein differs across genetic mutation species and when 
copper or iron is present [28]. Interestingly, the three muta-
tions have been shown to reside in potential metal binding 
sites (for both copper and iron) which could alter the binding 
of metal-protein complexes, this may be important in fibril 
formation [29]. In its native state, -synuclein is an unfolded 
protein [143, 409, 423] due to an overall low net hydropho- 
Table 1.  Genes and their Associated Mutations that have been Identified in PD 
Gene Function
Major Muta-
tions Identified
Mode of 
Inheritance
Clinical Pathology (Human)
Pathology In 
Vivo Model
-Syn [198, 
333] 
(PARK1)
Possibly func-
tions as a neuro-
transmitter  
modulator
A53T, A30P, 
E46K
Autosomal 
dominant
Similar to spo-
radic PD, early 
onset
SN depigmentation, DA loss, 
gliosis, LB & neuritis [382]
Increases in amyloidal fibrilla-
tion and tau inclusion [156]
LBs
DA loss, LB are 
present in areas 
which are not 
associated with 
PD [204, 227]
Parkin 
(PARK2)
E3 Ubiquitin 
protein ligase 
[361]
EX3-7DEL
EX4DEL
T240N
[169, 170, 215, 
256, 273]
Autosomal 
recessive
Early onset, slow 
progression 
parkinsonism 
[361]
Variations in the presence of 
LB
Data not available
(PARK3) Unknown Data not available
Autosomal 
dominant
Data not avail-
able
Data not available Data not available
(PARK4) See -Syn above
-Syn  Triplica-
tion 
(up to 4 full cop-
ies)
Autosomal 
dominant
Early Onset PD
Nigral and locus coeruleus 
degeneration,  presence of LB 
in hippocampus, locus coer-
uleus and cortices [297, 368]
Data not available
UCH L1 
(PARK5)
C-terminal ubiq-
uitin  hydrolyse 
and, ubiquitin 
ligase  [241, 250]
V66M, S18Y, 
I93M [261, 262, 
290, 351, 393, 
401, 430, 444]
Autosomal 
dominant
PD Data not available
Mutant mice 
display gracile 
axonal dystrophy 
[213]
PINK1 
(PARK6)
Mitochondrial 
serine/threonine 
kinase [230, 231]
H271Q, L347P, 
1573TTAG, 
1602CAA, 
R279H, DEL 
EX6-8, T313M, 
A217N
L489P, L347P, 
E240K, A340T
[132, 402, 420]
Autosomal 
recessive
Similar to atypi-
cal sporadic PD, 
early onset
Data not available
PINK1 silencing 
showed rapid eye 
degeneration and 
progressive DA 
loss in a droso-
phila model [419, 
435]
DJ-1 
(PARK7)
Protection against
oxidative stress 
[196, 286, 288]
14-KB DEL, 
L166P, M26I, 
D149A, G64D, 
E163K + 18-BP 
DUP
Autosomal 
recessive
Early onset PD Data not available
DJ-1 null mice 
showed no loss of 
striatal DA neu-
rons [213]
LRRK2 
(PARK8)
Protein kinase 
(unknown sub-
strates)
R1441G, 
Y1699C, 
R1441C, 
L1122V, 
G2019S, I2020T, 
R1441H, 
G2385R, P755L, 
[85]
Autosomal 
dominant
PD
LB, nigral degeneration with-
out LB,
And tau aggregation [452]
Data not available12    Current Neuropharmacology, 2009, Vol. 7, No. 1 George et al. 
bicity [408]. However, like many amyloidogenic proteins 
such as the beta amyloid protein (A), the -synuclein pro-
tein has a propensity to aggregate specifically in vitro to 
form higher order soluble oligomers, an intermediate species, 
which in turn further polymerizes into fibrils. Insoluble fila-
mentous aggregates of -synuclein are the major component 
of LB in PD and other neurodegenerative synucleinopathies 
[381]. There is no clear evidence that demonstrates if the 
development of LB occurs as the cause or a result of the dis-
ease and it remains to be established whether the toxic form 
of -synuclein is a soluble oligomer, as has been postulated 
for A in Alzheimer’s disease, or the classic insoluble fibrils. 
The oligomeric species is considered to be the most neuro-
toxic, possibly by causing vesicle permeability [416]. On the 
other hand the accelerated pathology of the -synuclein mu-
tants (particularly A53T), is associated with an increased rate 
of self-fibrilization [301].  
Parkin  
  Parkin (PARK2) mutants have been linked to autosomal 
recessive juvenile parkinsonism. An array of mutations in-
cluding deletions [170, 215, 256], multiplications, rear-
rangements, missense and several point mutations have now 
been reported. Parkin mutants present as a wide range of 
clinical PD phenotypes but differ from idiopathic PD as they 
tend to be more early onset, with slow progression and neu-
ronal death in the absence of LB formation (see Table 1)
[361]. Shimura and colleagues (2000) [361] showed that 
Parkin is an E3 ubiquitin ligase the loss of functional activity 
of which leads to protein accumulation. E3 proteins attach 
polyubiquitin chains to target proteins that are to be degraded 
by the proteasome. Mutations that have been described result 
in greatly diminished Parkin production which in turn results 
in the failure of Parkin associated substrates to be degraded. 
However, this fact seems to be confounded as the survival of 
DA neurons in Parkin knockout mice remains unaffected 
[145]. 
PINK1 
  PINK1 was first identified in cancer expression profiles 
[407] and shown to be localized to mitochondria by both 
immunofluorescence and western blot analysis [411]. In a 
study of three PD kindreds, two families harbored a mutation 
within the kinase domain of the PINK1 gene; a missense 
mutation and a nonsense mutation. To date, around 40 muta-
tions have been characterized (see Table 1), most of which 
have not yet been correlated to a neuropathological pheno-
type in human PD cases. Many mutations have been discov-
ered in late onset cases, equivalent to sporadic PD cases [4] 
and also to atypical early onset PD. Mutations found in 
PINK1 in early onset cases maybe the second most common 
mutation after Parkin to induce parkinsonism [168]. How-
ever, pathogenic PINK1 mutants seem to be a rare cause of 
early onset PD [344]. The potential PINK1 substrates seem 
to phosphorylate mitochondrial proteins that may act to pre-
serve mitochondrial integrity [411]. However, these target 
substrates remain unknown. Expression of mutant forms of 
PINK1 are said to be loss of function mutations, which sug-
gests that the potential kinase activity of PINK1 is required 
and therefore highlights the relevance of mitochondrial dys-
function as one of the processes that mediate PD. 
  Expression of mutations in this mitochondrial kinase, 
demonstrates a heterogeneous spectrum of pathological phe-
notypes ranging from early onset to late onset PD. Less than 
10% of PINK1 protein has been shown to be found in LB 
which could be due to poor solubility of the protein and a 
greater propensity for its aggregation in culture [23]. There 
have been no post mortem studies looking at the neuropa-
thology of PINK1 mutation carriers.  
LRRK2 
  Mutations in the LRRK2 gene have been identified in 
both the sporadic and familial forms of PD and display an 
autosomal dominant inheritance pattern of PD [452]. More 
than 30 mutations in the LRRK2 gene have now been re-
ported and many of these reside within a highly conserved 
functional domain of the protein [85, 86, 452]. It has been 
determined that LRRK2 possesses kinase activity but little is 
known about its phosphorylation substrates and its specific 
role in PD pathogenesis. Expression of LRRK2 is shown in 
all tissues and at low levels in the brain [316]. The average 
age of onset in familial cases is the late 50s and 60s, indicat-
ing that of all the genes identified in familial PD cases, this 
gene bears the closest resemblance to sporadic forms of the 
disease. Varying pathological phenotypes have been ob-
served in PD patients with mutations in LRRK2 and may 
reflect multiple roles or target substrates for this protein. 
DJ-1
  DJ-1 mutants were first reported in a consanguineous 
Dutch family [413]. The first mutation identified in this fam-
ily was a homozygous exon 1 to 5 deletion [413] which ef-
fectively caused a deletion of the entire protein. Another 
reported pathogenic homozygous mutation L166P showed 
co-segregation with PD in an Italian family [44]. Other re-
ports of DJ-1 mutants (see Table 1) have been described. The 
loss of function from specific mutations has been shown to 
cause autosomal recessive early onset PD. Mutations in DJ-1 
are extremely rare occurring in approximately 1-2% of early 
onset familial cases [3]. There have so far been no reports of 
any DJ-1 mutations in late onset sporadic cases [3]. DJ-1 is 
suggested to be co-localized in the mitochondria [446], and 
is more predominantly up-regulated under high oxidative 
stress conditions [38]. DJ-1 related cellular processes in-
clude, attenuating oxidation [196, 286, 288], RNA binding 
[181], cell transformation, and androgen receptor signaling 
[331]. The role of DJ-1 in neuroprotection against the oxida-
tive stress response is of particular interest to PD. Drosophila 
models which lack DJ-1 show increased susceptibility to 
oxidative stress and environmental toxins such as paraquat 
and rotenone [235, 320]. It has been shown that loss of DJ-1 
alone cannot sufficiently induce parkinsonism but increases 
the susceptibility of DA neurons under an oxidative envi-
ronment [213]. 
UCH-L1 
  The only mutation described in the UCH-L1 gene was 
the I93M mutation found in a German family [240]. One 
other reported polymorphism (S18Y) was found in exon 3 of 
UCH-L1 [247] but is suggested to be non-pathogenic since it 
is found in about 20% of the Caucasian population [247]. 
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morphological phenotype in PD. However, in vivo transgenic 
mice models with this mutation display gracile axonal dys-
trophy. This autosomal disease results in axonal degenera-
tion [389], A protein and accumulation of ubiquitinated 
proteins within the sensory and motor systems [347, 389]. 
  UCH-L1 has a high sequence homology to the gene fam-
ily that hydrolyzes ubiquitin c-terminals to form monomeric 
ubiquitin (ubiquitin hydrolase) [241]. It has been suggested 
that UCH-L1 may have multi-functional capabilities includ-
ing the recycling of ubiquitin by hydrolyzing ubiquitinated 
proteins and ubiquitin ligase activity [250].  
2.2. Environmental Toxins 
  While the genetic contribution to the disease seems to be 
only a small proportion of cases, environmental factors are 
thought to play a pivotal role in PD etiology. In the early 
1980’s it was suspected that exogenous neurotoxins caused 
PD-like symptoms. These gave rise to correlative studies 
which suggest that long term exposure to common pesticides 
cause PD-like symptoms. Mitochondrial dysfunction plays a 
vital role in DA neuron degeneration. Mitochondrial ineffi-
ciency is considered to be a result of oxidative stress and is 
proposed as a primary mechanism for nigral loss following 
exposure to a range of substances [399]. These neurotoxic 
agents potentially elicit their effects on mitochondria. 
  Large scale cohort studies of both chronic and low dose 
exposures to pesticides have shown a 70% increase in risk of 
developing PD compared to people not exposed to these 
chemicals [13]. As both farmers and non-farmers seem to 
share the same level of risks associated with PD and pesti-
cide exposure, Ascherio and colleagues (2006) [13] suggests 
that non-farmers could have been exposed to harmful pesti-
cides while gardening. It is becoming apparent that common 
chemicals, such as Paraquat and Rotenone, could be impli-
cated in some of the PD cases. 
2.2.1. Agricultural Toxins 
  Paraquat (PQ; N,N'-Dimethyl-4,4'-bipyridinium dichlo-
ride) is a potential neurotoxin as it has the ability to cross the 
blood brain barrier [75, 427]. PQ is thought to participate in 
redox cycling as it can be easily reduced to form free 
radicals, resembling a structural analogue of a known neuro-
toxic metabolite 1-methyl-4-phenylpyridinium ion (MPP
+). 
Like MPP
+, PQ selectively destroys dopaminergic neurons. 
Animal models have shown that systemic [276] and long 
term infusion of PQ has a toxic effect on rodent dopaminer-
gic neurons [312]. PQ causes a loss of TH positive neurons 
together with loss of striatal terminal projections, decreases 
in Dopamine transporter (DAT) and accelerated fibrilization 
of -synuclein [260, 410].  
 The  insecticide  Rotenone is widely used as an in vivo
animal model of inducing PD. It is thought that the rotenone 
model is of key importance as the specific neuropathology 
reflects the selective loss of DA neurons in the SN and LB 
formation [27, 287, 399]. However the specificity of the 
model has been called into question as neurodegeneration 
has also been observed in non-dopaminergic systems [182]. 
Rats chronically infused with rotenone show severe behav-
ioral deficits characteristic of PD including an unsteady gait 
and bradykinesia [7, 8]. Chronic low doses of rotenone also 
show an increase in oxidative stress markers as well as -
synuclein positive LB [360]. Similar behavioral observations 
have been shown in mice treated with rotenone which do not 
exhibit LB inclusions or other pathological changes [342]. 
  Rotenone induces the cellular death cascade via inhibi-
tion of the mitochondrial metallo-protein complex I [27, 359, 
360] resulting in oxidative phosphorylation dysfunction. 
Rotenone causes the inhibition of complex I throughout the 
brain, however not all investigations have shown loss of SN 
neurons [27]. The presence of oxidative metabolites in sam-
ples from PD tissue is similar to those oxidative metabolites 
produced by rotenone suggests that oxidative stress could 
play an important role in the chain of events leading to PD 
[399]. 
2.2.2. Drugs of Abuse and Parkinsonism 
  Drug-induced parkinsonism has been reported in both 
humans and in animal models [116]. The commonly abused 
amphetamine derivatives have been reported to damage 
catecholamine neurons in both humans and in animal models 
of the disease [193]. Abuse of drugs such as amphetamine, 
ecstasy and cocaine are known to induce alterations in stri-
atal DA [220] with specific effects on Tyrosine Hydroxylase 
(TH) positive cells [220, 377, 403] in mice models. Drugs of 
these sorts have specific modes of action which make them 
potential catalysts for PD: i) amphetamine inhibits DA up-
take causing a marked elevation in extracellular DA. ii) A 
single dose of cocaine results in elevated levels of hydrogen 
peroxide and lipid peroxidation products for up to 50 hours 
[96]. iii) There is increased DA turnover as the result of DA 
and its metabolites causing an elevation in extracellular DA 
[319]. iv) The increase in DA production due to ampheta-
mine generates a toxic cascade of free radicals [77]. v) Post 
mortem brain tissue from human chronic cocaine abusers 
exhibit over-expression of -synuclein mRNA with a three 
fold increase in the -synuclein protein levels in dopaminer-
gic neurons [269] although no data are available on the 
histopathology of abusers [93]. vi) Amphetamine and similar 
drugs have been shown to redistribute DA into the cytoplasm 
where it can be oxidized into semi-quinones and other oxida-
tive metabolites [117]. vii) Drug induced toxicity has been 
shown to form inclusions containing -synuclein specifically 
within the SN [116]. While the use of recreational drugs has 
raised the possibility of an associated increased risk of de-
veloping PD, this link has not been clearly established using 
population based studies.  
2.2.3. MPTP 
  In the early 1980’s, drug addicts who tried to manufac-
ture their own drugs, instead synthesized MPTP and devel-
oped a syndrome symptomatically very similar to sporadic 
PD (L-DOPA responsive, progressive, with neuronal inclu-
sions) [233, 234]. This neurotoxin has subsequently been 
extensively used in non-human primates to replicate the car-
dinal symptoms of PD [354]. Although rodents are more 
resistant to MPTP than primates, they have contributed 
greatly to the understanding of the mechanisms of toxicity. 
Rodents are commonly employed in developing a new gen-
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toms of PD [287]. To date, most of the work on MPTP using 
mice demonstrates that cell death following acute exposure 
of the toxin occurs in two phases: initial cell death com-
mences within hours after the insult [166], peaking at around 
5 days [199] with the second phase lasting  21-28 days [36, 
95, 192]. Like most animals models, the acute MPTP model 
does not reflect all aspects of the human disease. For exam-
ple, acute intoxication with MPTP does not result in inclu-
sions within the SN [118, 395] which suggests that DA neu-
rons are dying before protein aggregation can occur. More 
recently, rodent models that employ chronically administered 
MPTP, exhibit intracellular -synuclein-positive electron 
dense inclusions [118]. Chronic MPTP administration is 
shown to up regulate the expression, the nitration and also 
the aggregation of -synuclein within the SN [414]. Con-
versely, animals that lack -synuclein are spared and have 
been shown to be protected against the toxic effects of 
chronic MPTP treatment [116]. This suggests that the uptake 
of MPTP is rapid due to high affinity DA re-uptake trans-
porters. The conversion of MPTP into MPP
+ by Monoamine 
Oxidase B (MAO-B) allows the reduced form to affect mito-
chondrial metabolism eventually leading to the inhibition of 
complex I and release of cytochrome c from the inner mem-
brane of the mitochondria [237]. This model is one of the 
keystones of the oxidative stress hypothesis for PD. 
2.3. Protein Aggregation  
  The failure to clear damaged and cytotoxic protein ag-
gregates is often a common feature of most neurodegenera-
tive disorders including PD. Proteasome dysfunction has 
been observed in dopaminergic neurons in PD patients [278] 
and cortical neurons in AD cases [208]. Mutations in genes 
encoding proteins within the ubiquitin proteasome system 
(parkin and UCH-L1) further link this pathway to PD. Func-
tional and structural deficits within the proteasome pathway 
prevent protein clearance, leading to proteolytic stress [278]. 
There has been growing speculation that proteasome dys-
function  via proteolytic stress could be the underlying 
mechanism of LB formation and neurodegeneration in the 
SN in both familial and sporadic PD [278-282].  
  As the cellular machinery for protein degradation or re-
pair becomes overwhelmed in the disease, failure of this 
pathway leads to protein accumulation and ultimately cell 
death [415]. It is clear that an abundance of damaged pro-
teins which occur through oxidation or nitration processes 
can lead to proteasome inhibition as seen in sporadic PD 
cases. Proteasome inhibition seems to initially affect DA neu-
rons by modifying DA re-uptake [281, 299]. In cell culture 
models, the presence of oxidative products such as hydrogen 
peroxide (H2O2) and peroxynitrite (ONOO
-) inhibits the ac-
tivity of the 20S proteasome [339]. Excessive levels of oxi-
dative modifications to the proteasome causes a decrease in 
proteolysis, decreases in solubility, stabilization of proteins 
via cross-linkages and protein aggregation [142, 314]. How-
ever, what remains unclear is whether the precise nature of 
LB formation is a systemic defense mechanism acting as a 
neuroprotectant or is a result of the disease.  
2.4. Oxidative Stress and Parkinson’s Disease 
  Neurodegeneration is a multifaceted process and the 
mechanisms that result in cellular death are linked to events 
that cause oxidative stress. Although there is much evidence 
in favor of this hypothesis; there is no definitive study. In the 
current section, the discussion focuses on: the markers of 
oxidative stress that have been observed in PD; how the cell 
becomes stressed; what oxidative damage does to cells; and 
cellular defense mechanisms to help overcome oxidative 
stress.  
  Oxidative stress is a key pathological process that is 
common to all neurodegenerative diseases. While oxidative 
stress occurs over the entire brain, the nigral environment 
appears to be more sensitive to oxidative stress [10, 62, 92, 
104, 139, 142, 164, 259, 358, 436]. Although loss of DA 
producing neurons is seen in both normal aging individuals 
and PD cases it has been hypothesized that these catechola-
minergic neurons are particularly susceptible to oxidative 
stress [67, 68, 119].  
 Oxidativestress markers have been observed in SN speci-
mens in many PD studies. Oxidative biomarkers shown to be 
elevated in PD brain tissue include: 4-hydroxy-2-nonenal 
(HNE) [437], protein carbonyls [9] and 8-hydroxyguanosine 
(8-OHG) [445]. Reduction and protection of remaining neu-
rons from oxidative stress is currently the focus of the phar-
maceutical industry with the aim of developing new classes 
of therapeutic agents for PD. In this review, reactive species 
(RS) will be used as a broad term of all reactive species in-
cluding nitration species. In normal healthy aerobes, O2 is 
utilized for cellular respiration processes by the mitochondria 
[164]. Mitochondria are a major source of RS production as 
leakage of electrons from the electron transport chain are 
slowly accepted by O2 producing free radicals including the 
superoxide radical (O2
￿). Superoxide is chemically inactive 
however, if allowed, substantial production of this species 
can cause biological damage. The covalent bonding of O2
￿ to 
nitroxide (NO) forms peroxynitrite (ONOO
-) which under 
physiological conditions can be very reactive and can oxi-
dize lipids [338], DNA [391] and proteins [40, 95, 257]. Su-
peroxide can also be converted to other RS products such as 
H2O2 and hydroxyl radicals (OH
￿) which may in turn attack 
other macromolecules such as proteins, lipids, sugars, and 
polynucleotides which are susceptible to oxidative damage. 
The abundance of O2
￿ and ONOO
- can accelerate the oxidi-
zation of iron or copper sulfur clusters found in many pro-
teins that require these clusters for functional activity [209, 
210]. Superoxide has been demonstrated to “leach” iron from 
metalloenzymes, increasing the free iron content [209]. The 
presence of these free redox active metals can in turn accel-
erate RS production. Excessive accumulation of H2O2 and 
O2
￿ in the presence of catalytically reduced transition metals 
such as iron, copper and manganese can generate a potent 
hydroxyl radical species OH
￿ via Fenton chemistry (1). 
Fe
2+ + H2O2  Fe
3+ + OH
￿- + OH
-    (1) 
  Superoxide as well as ascorbic acid and thiols can re-
reduce oxidized metals via the Haber-Weiss reaction to pro-
duce OH
￿ from H2O2. Purines and pyrmidines in DNA and 
RNA can be attacked by the hydroxyl radical, producing 
irreparable breakages and oxidized RNA products such as   
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  Radicals can remove H
+ from polyunsaturated side 
chains found in membrane lipids. The effect of lipid peroxi-
dation is dramatic, causing disruption of membrane fluidity 
allowing the leakage of molecules that normally cannot cross 
the membrane. Metal ions can also rapidly induce lipid per-
oxidation by continually removing H
+ in fatty acid side 
chains resulting in toxic hydrocarbons and aldehydes (malo-
naldehydes and 4-HNE). Byproducts of lipid peroxides such 
as HNE have a high affinity for and inactivate integral pro-
teins such as Ca
2+ and K
+ ion channels and receptors [54] 
and glutamate transporters leading to a greater excitatory 
effect and possible excitotoxicity [39, 323].  
  DA is highly reactive and produces RS through two 
pathways. In the first instance, DA can undergo oxidation in 
the presence of molecular oxygen to form H2O2, 6-OHDA, 
quinone intermediates and O2
￿ (see Fig. 1). The generation of 
oxidized DA metabolites can further feed into the redox cy-
cle, leading to the amplification of RS products eventuating 
in neuronal death. In vivo models have shown that DA oxida-
tive metabolites, in particular 6-OHDA, can induce toxicity 
by generating RS and initiating caspase activation [11]. Sec-
ondly, DA can also be broken down by MAO-B through 
deamination to produce H2O2 [67].Further redox cycling can 
be driven by excess O2
￿ which reacts with both DA and metal 
ions to produce more RS. 
  It is inevitable that aerobic organisms produce RS. RS 
can be cleared under normal conditions by the anti-oxidative 
enzymatic activity of catalase, Copper/Zinc superoxide dis-
mutase (Cu/Zn SOD) or glutathione (GSH) peroxidase. The 
importance of these enzymes has been demonstrated in 
transgenic and knockout mice [130, 405]. Cu/ZnSOD, cata-
lase and GSH peroxidase transgenic mice have been tested in 
both the MPTP and the 6-OHDA lesion models and data 
demonstrate that there is increased susceptibility to oxidative 
stress in the absence of these protective proteins [218, 443] 
while over expression of these proteins result in increased 
protection [335]. Anti-oxidant systems are essential for de-
fense against cellular endogenous or exogenous oxidants. A 
decrease in total GSH has been reported in PD post mortem
SN tissue [63, 322, 365, 374]. The homeostatic balance of 
RS production to anti-oxidative mechanisms is shifted as the 
cell becomes burdened and stressed. Elevation in RS [62, 64, 
119, 177, 202, 436, 437] and perturbation of anti-oxidative 
mechanisms ultimately leads to cellular death of individual 
cells and it is widely hypothesized that there is a feed for-
ward system that leads to progressive neurodegeneration of 
the nucleus [12, 353]. A decrease in total GSH has been re-
ported in PD post mortem tissue [63, 365] where the de-
crease has been observed specifically within the SN [63, 322, 
365, 374]. Neurons seem to be more susceptible to oxidative 
damage as (i) neuronal membranes are rich in polyunsatu-
Fig. (1). An Oxidative stress model suggesting the roles of Iron (metals), -synuclein and Dopamine (DA) in the propagation of neuron-
degeneration in PD (modified from [41]). The stars indicate the points on the pathways that MPAC compounds can influence the reaction. 16    Current Neuropharmacology, 2009, Vol. 7, No. 1 George et al. 
rated side chains which are freely attacked increasing the 
fluidity of the membrane (leaky membrane), (ii) these cells 
express small amounts of anti-oxidant enzymes such as cata-
lase, GSH peroxidase and Cu/ZnSOD compared to other 
cells in the body. Much effort has thus gone into the thera-
peutic intervention of these oxidative processes. 
2.4.1. Metals in PD 
  Transition metals have been implicated in many neuro-
logical diseases such as Alzheimer’s disease (AD) [49, 274, 
426], Multiple Sclerosis (MS) [242, 284] as well as PD [19, 
20, 90, 92, 259, 375]. Aberrant brain metal levels have been 
associated with normal aging and a variety of diseases how-
ever this is still debated [19, 258].  
  Dopaminergic neurons seem to be highly sensitive to 
oxidative stress providing a potential link to environmental 
exposures of metals and PD susceptibility. Epidemiological 
literature has assessed the potential risk of developing PD 
when exposed to certain metals such as iron, manganese and 
to a lesser degree, copper. The risks reflect the potential of 
redox active metals such as iron and copper acting as cata-
lysts to drive oxidative stress.  
  It is thought that dysregulation in metal ion homeostasis 
acts as a potential catalyst to further produce RS as previ-
ously mentioned. The current section further discusses how 
metal ions and in particular iron and manganese are associ-
ated with PD. 
2.4.1.1. Iron 
  Iron is required for numerous critical biological proc-
esses. These processes are involved in cellular respiration 
pathways, acting as the central core for metallo-proteins, 
neurotransmission and myelination. The balance of iron con-
tent is essential, as excess iron is highly toxic to cells, seen in 
some neurological (PD, AD and MS) and peripheral diseases 
(Haemachomatosis and Friedrich’s Ataxia). 
2.4.1.2. Iron Distribution in the Brain  
  Dynamically, the brain has the capacity to adapt to ab-
normal iron levels and redistribute iron to regions of high 
requirement. An average adult brain has approximately 60 
mg of non-heme iron, with some cerebral regions such as the 
SN, GP, caudate nucleus and putamen retaining the highest 
level of iron [19, 267]. Most of the iron in brain is found 
specifically in neurons as iron is a co-factor for many enzy-
matic reactions (such as the production of DA). Tyrosine 
hydroxylase (TH) is a non-heme iron enzyme which uses 
molecular oxygen to hydroxylate tyrosine to form L-DOPA 
[153]. The brain acquires the critical level of iron necessary 
for human adult stores through breast milk [219]. At birth, 
very little iron is present within the developing brain. How-
ever, cerebral iron levels rapidly increase specifically during 
the early years of life. Approximately 0.3 mg/L of iron is 
found within human breast milk [118] and uptake of iron 
occurs within the first 12 to 18 months of human life. In ro-
dents, the uptake of cerebral iron occurs during the 3
rd week 
post partum [79] and during these critical developmental 
periods; the brain requires iron for normal neurological 
maturation. 
  The manner in which iron is transported into the brain is 
a complex process which is still not well understood. Circu-
lating iron, once oxidized to its ferric state by the serum pro-
tein ceruloplasmin cannot readily cross the blood brain bar-
rier [294]. For iron to be transferred across the BBB, the 
endothelial cells lining the cerebrovasculature require a 
transfer protein Transferrin (Tf) to which the complex (Tf–
iron) binds to transferrin receptors (Tfr) found on the luminal 
side of the membrane. The complex enters the cells via en-
docytosis and is transported to various cell types within the 
brain such as neurons, glia and oligodendrocytes. This proc-
ess is highly regulated by the abundance or the deficiency in 
Tfr and the Tf-iron complex. Transcriptional regulation of 
iron binding proteins transferrin and ferritin is controlled by 
iron regulatory proteins (IRP) which bind to iron responsive 
elements (IRE) on RNA to alter the expression levels [56, 
212]. IRP2 knockout mice develop motor deficits (tremor 
and bradykinesia), progressive neurodegeneration and in-
creases in ferritin levels within affected neurons [236].  
  Ferritin is a common iron storage protein within the brain 
and is expressed in microglia, oligodendrocytes and neurons 
[71, 190]. Ferritin possesses ferroxidase activity that cata-
lyzes the conversion of ferrous iron to ferric iron. Ferritin 
acts to reduce the amount of free cytosolic iron by catalyzing 
iron to its non reactive or ferric state [154]. This mechanism 
prevents iron from being available to participate in Fenton 
chemistry and generating RS.  
  Neuromelanin (NM) is another storage protein with a 
high affinity for iron [441, 442] and is localized within re-
gions of high metabolic turnover such as in DA producing 
neurons in the SN and the noradrenalin neurons in the locus 
coeruleus [42, 349]. Catecholaminergic neurons found in 
primates contain NM, as in humans, but are less visible and 
are not localized within the SN [263]. Rodents possess DA 
and noradrenalin neurons, but these neurons do not appear to 
contain NM [17]. NM is a byproduct of catecholamine me-
tabolism and is synthesized from quinone intermediates 
when cytosolic DA is in excess [390]. It has been suggested 
that NM is a neuroprotectant, preventing degeneration of 
nigral neurons by binding transition metals and other DA 
oxidative products that are abundant in the SN. It has been 
suggested that in situations of high iron overload, NM retains 
iron or other heavy metals within dihydroxyindole groups on 
its chemical backbone. The functional role of NM upon its 
binding to heavy metals is beneficial, by sequestering and 
preventing any free metal ion from participating in Fenton 
chemistry. This role allows the SN neurons to tolerate a 
higher iron load than other neurons within the brain that do 
not possess this protein. However, during the progression of 
PD; the NM molecule reaches saturation. Once the NM iron-
chelating capabilities are saturated the iron-saturated mole-
cule could be available to create RS [102]. NM appears to be 
an important buffering molecule that is involved in DA neu-
ron protection and possibly vulnerability.  
2.4.1.3. Dysregulation in Brain Iron and Neurodegeneration  
  There is an overwhelming consensus that iron accumula-
tion has a pathogenic role and this has been seen in many 
neurological diseases. This highlights the use of metal alter-
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Iron dys-homeostasis is highly evident in post mortem PD 
brains [157]. The association of elevated iron found in park-
insonian brains may be linked to age related changes in re-
dox active metals. Post mortem studies have shown that ni-
gral cells are associated with elevated levels of both ferric 
and ferrous ions within the SN in severe cases of PD [90, 
126]. Furthermore, iron has been shown to accumulate in the 
SN in animals following 6-OHDA and MPTP lesion [112]. 
Iron is potentially pathogenic as it is a highly redox active 
metal and can participate in metallo-redox reactions (as dis-
cussed in section 2.4). Changes in iron homeostasis which 
particularly increase the labile iron pool potentially promote 
neuronal toxicity by catalyzing conversion of a less reactive 
inert species (H2O2) to the highly reactive hydroxyl radical. 
Currently, it is unknown if the dysregulation in iron homeo-
stasis may be a primary or a secondary cause of PD, how-
ever, many genetic and biochemical studies have suggested 
that iron accumulation may be a primary event. 
  Proteins that regulate iron are disrupted in PD patients 
[21, 90, 112]. Mutations in iron regulating or binding pro-
teins have been reported in other iron overloading diseases 
with overlapping clinical features to PD such as neuroferriti-
nopathy, Friedrichs ataxia, and haemochromatosis. Increased 
levels of the iron storage protein ferritin have been shown in 
PD patients [21, 90]. Transgenic animals that express in-
creased ferritin levels within dopaminergic neurons in the 
SN have shown age-related progressive neurodegeneration, 
loss of axonal projections and decreased DA in the striatum 
together with loss of spontaneous movement [76, 206]. Gene 
knockout mouse models of haemochromatosis showed se-
vere deficits in motor performance [147] attributable to the 
CNS. 
  Point mutations near the iron binding site of the TH 
molecule have been found in cases of L-DOPA responsive 
PD and Segawa’s syndrome that results in TH deficiency 
[152]. Furthermore, iron plays a critical role in electron 
transport and the metabolism of various neurotransmitters 
including DA, norepinephrine and GABA as well as in DA 
D2 receptor function [373]. 
  Direct bolus intranigral injection of iron has shown to 
increase the levels of iron within the SN [25, 424] and results 
in severe loss of nigral cells associated with reduced DA 
levels in the striatum and deficits in locomotor activity. The 
risks of high dietary iron at a given critical vulnerable stage 
have been highly correlated to late onset development of PD 
[124, 125, 205]. During brain maturation, dietary iron in-
duced in rat and mice neonates resulted in patterns of PD like 
behavior and nigral cell degeneration in adulthood [124, 
125]. Excess dietary iron post partum, increases the levels of 
iron within the whole brain but to the greatest extent in the 
GP and the SN [330]. The transport of iron to the brain peaks 
between birth and 21 days post partum in neonatal mice, 
with little entering the brain after that time. Feeding a high 
iron diet generates characteristics of PD later in life in these 
animal models [125, 373]. Feeding of 20000 ppm for 12 
weeks causes behavioral dysfunction and severely affects the 
latency in motor activity [373]. Mice that are exposed to a 
high iron diet during neonatal development have an in-
creased susceptibility to oxidative stress and a reduction in 
TH positive cells at 24 months of age [205]. Rodents defi-
cient in neonatal iron are deficient in brain ferritin [167], and 
have reduced cognitive functioning [84, 148, 330]. This evi-
dence notwithstanding, the direct effects of iron during early 
human development and its contribution to a potential in-
crease in susceptibility to PD is a controversial topic that has 
not been fully addressed to date.  
2.4.1.4. Copper 
  The interrelationship with iron and copper has been dis-
cussed in brief in papers [90-92]. Few studies have investi-
gated copper and its role is yet to be established in PD.  
2.4.1.5. Manganese 
  Manganese toxicity, also known as manganism has been 
characterized in miners following long term exposure to 
manganese ore [187-189] and occupational studies have cor-
related welders with a high prevalence of parkinsonian like 
symptoms, such as abnormalities in gait and speech [337] 
following exposure to high levels of manganese from the 
welding rods. One clinical difference between PD and man-
ganism is that manganism produces dystonia [16]. This dif-
ference is attributed to the GP being primarily affected in 
manganism [363] with only minor damage to the SN [432]. 
These commonalities suggest that manganese and iron affect 
the dopaminergic system where they accumulate within these 
regions. Following a 6-OHDA lesion to the SN significantly 
higher levels of manganese were detected in the GP, SN, 
amygdala, hypothalamus, and hippocampus [394]. It has also 
been suggested that the increase in manganese content found 
in the SN after a 6-OHDA lesion directly contributes to the 
accumulation of iron levels within the SN [394]. Like iron, 
manganese can also participate in redox chemistry and gen-
erate RS causing cell death [318]. Evidence demonstrating 
that manganese affects dopaminergic neurons via oxidative 
stress damage to DNA of these neurons [310] include eleva-
tion of DA oxidative metabolites [358] and induction of 
apoptotic pathways in cultured cells [88]. Furthermore, man-
ganese can reduce anti-oxidants such as glutathione (GSH), 
catalase and thiols [87, 246]. 
2.4.1.6. Aluminum  
  The hypothetic role of aluminum and its pathogenic role 
seen in neurodegenerative diseases, has managed to survive 
in the neuroscience field in spite of ambivalent support. 
Aluminum in drinking water was linked to AD, ALS and PD 
until it was discovered that the epidemiological studies were 
inadequately designed and that aluminum is poorly absorbed 
by the digestive system [115]. The presence of aluminum is 
quite low within living organisms, but is highly abundant 
within the environment. Aluminum can be detected in foods, 
pharmaceutical agents (antacids) and can also be found in 
drinking water. Aluminum has been generally considered 
biologically inert. In spite of this, the toxicity of aluminum 
has been well established. Few epidemiological studies have 
made connections between aluminum and neurodegenerative 
diseases such as AD [138, 155, 161, 325, 332, 345], ALS 
and PD [26, 369]. Currently, there is no data that suggests 
aluminum (a trace element) is essential for bodily function. 
While no reliable measurement of total body aluminum con-
tent is available, the body’s acquisition of aluminum is 
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have shown that aluminum can cross the blood brain barrier 
via the aid of a transporter mechanism which included an 
iron carrier molecule transferrin [293]. Historically there has 
been concern, concentrations of aluminum in drinking water 
have been investigated as a potential factor to give rise to 
AD [115, 138, 345, 379]. Whilst there is evidence which 
evinced no relationship [268, 425], a considerable number of 
studies have attempted to defined this link [345]. There is 
pathological data showing elevated aluminum in the spinal 
cord and the hippocampus from ALS and PD with dementia 
[137, 216, 326, 329] and in tissues from PD patients [151, 
180]. However the elevation in aluminum seen in these dis-
eases may not be related to dietary intake. 
  The biological effects of artificially increased aluminum 
in experimental animals [211, 216, 379] is to cause patho-
logical changes; including neurofibrillary tangles which 
closely resemble those in AD, and neuronal loss [137, 211, 
216, 224, 325, 406]. Interestingly, these aluminum treated 
animals showed signs of loss in motor functions found in the 
hind limbs [216] which suggests that aluminum affects other 
modalities in the CNS. Together with iron, aluminum has 
been reported to be significantly concentrated in melanized 
granules within the SN [151, 180]. The presence of alumi-
num and iron accelerate the formation of lipid peroxides 
[159] and thus act in a synergistic fashion. Aluminum can 
participate in chemistry that induces changes in membrane 
fluidity that can facilitate lipid peroxidation [283]. While 
aluminum is redox inactive, a 3 week exposure of rats to 
aluminum salts induced increased levels of RS in cortical 
regions [43]. The speculation that aluminum can potentiate 
and generate a pro-oxidative environment has been sup-
ported by studies suggesting that aluminum can trigger in-
flammation responses [51]. Interestingly, Mendez-Alvarez 
and colleagues (2002) found that in a 6-OHDA animal 
model, the presence of aluminum reduced the OH
￿ produc-
tion and attenuated the neurotoxic effects of the 6-OHDA 
lesion [285] by the prevention of lipid peroxide formation. It 
was concluded that the effects of aluminum accumulation 
could be by binding to 6-OHDA preventing the interaction 
between 6-OHDA and hydrogen peroxide [285], thereby 
reducing the toxic effects of the 6-OHDA.  
  Aluminum toxicity has recently been revisited because of 
its effect in vitro and in animal models but there is little evi-
dence on aluminum has any involvement in PD and it is 
therefore is not considered as a therapeutic target at this 
stage.  
2.5. Integration of Current Models for Therapeutics  
  Dopaminergic neurons appear to be generally under high 
oxidative loads and are thus suspected of being susceptible to 
neurodegeneration. Iron, DA and -synuclein, all co-localize 
to the SN and these factors are implicated in the etiology of 
PD. However it has been substantiated that none of these 
elements alone is sufficient to cause the observed chronic 
neurodegeneration. Elevated iron and DA in the presence of 
increased or altered metabolism of -synuclein, may act syn-
ergistically to propagate a series of reactions that result in 
destruction of SN neurons. To address potential new phar-
macological intervention therapies for drug development, the 
observed changes in metabolism that result in PD must be 
considered.
  The highly favorable oxidative stress environment for 
DA interaction with -synuclein and iron resulting in RS-
mediated toxicity and protein aggregation is one of the most 
likely mechanistic explanations for PD (refer to Fig. (1)). 
Singular constituents of this model such as DA, -synuclein 
or iron alone are not capable of emulating PD-like neurode-
generation. In this section of the review several therapeutic 
targets are highlighted and discussed.  
  DA has been implicated to play a role in the neurodegen-
erative cascade in PD as it is susceptible to oxidation (dis-
cussed in section 2.4). Following a partial lesion of the do-
paminergic SN neurons the remaining neurons compensate 
by increasing the amount of DA produced as well as increas-
ing the rate of DA turnover [383]. In surviving neurons, the 
DA turnover rate is increased by the deamination of DA by 
MAO-B thus increasing the production of H2O2 and oxida-
tive stress metabolites [67]. DA is readily auto-oxidized 
through metallo-redox reactions to produce the neurotoxin 6-
OHDA and further oxidized into quinone intermediates to 
generate O2
￿ [202] (See Fig. 1). As 6-OHDA is analogous to 
catecholamine neurotransmitters, it may be taken up by the 
corresponding reuptake transporters [355] resulting in rapid 
loss of nigral neurons by activation of caspase pathways 
[99]. Direct injection of 6-OHDA into the SN or the medial 
forebrain bundle is widely used in animal models to induce 
parkinsonism [131, 194, 439].  
  Ferrous ions catalyze the formation of oxidized DA, gen-
erating free radicals but also converting oxidative metabo-
lites such as 6-OHDA into melanin [103]. Manganese can 
also participate in the oxidation of DA leading to the genera-
tion of RS [310] which implements further redox (active or 
inactive) metals that can be substituted in this reaction.  
  The familial A53T -synuclein mutant raises cytosolic 
DA which increases the available substrates for this cascade 
[203, 254, 296]. Over-expression of DA metabolic genes 
such as -synuclein accelerate the rate of DA re-uptake via
DAT therefore increasing DA vulnerability [203, 392], fur-
ther RS production and DA induced apoptosis [392].  
-Synuclein mRNA expression has been seen to be only 
elevated within the SN in later stages of PD [61, 158, 414]. 
This effect could be due to the relationship between DA lev-
els and -synuclein that facilitate the transmission of DA. 
Synaptic regulation is shown to be severely affected when -
synuclein expression is altered [412]. In the presence of -
synuclein, DA--synuclein adducts form through the stabili-
zation of protofibrillar structures [73]. This is exacerbated by 
the presence of iron which also triggers aggregation of -
synuclein by changing the protein conformation structure 
from helices into an unfolded beta-sheet structure [313]. The 
fibrillated protein is the major component in LB [154]. For-
mation of protein aggregates is likely to be by the direct as-
sociation between metals and -synuclein.  
  It is interesting to note that the familial mutations of -
synuclein are localized within the metal binding site of -
synuclein and each of these mutations affect metal interac-
tions with the protein [29]. A metal responsive element has 
been demonstrated in the promoter located within the 5’ Un-
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script [129]. This suggests that -synuclein may be a met-
allo-protein which can be manipulated to help treat PD. 
  Metal ions in the presence of DA directly cause -
synuclein protein aggregates [53] and modifications of -
synuclein protein occur in the presence of RS generated by 
Fenton chemistry. Post translational modifications such as 
phosphorylation, glycosylation, oxidation and nitration of -
synuclein promote protein aggregation [139]. Oxidatively 
modified -synuclein and aggregates stabilized through the 
dityrosine cross-linkages are observed in LB [378]. Through 
further oxidization of -synuclein, sequential oligomeriza-
tion is enhanced by the presence of copper [315]. Nitration 
of -synuclein promotes the formation of high order oli-
gomerization [303] which may perforate vesicular mem-
branes such as DA storage synaptic vesicles, resulting in 
leakage of DA into the cytoplasm [255]. In addition, aggre-
gated  -synuclein may over-stimulate TH activity causing 
overproduction of DA, propagating a feed forward degenera-
tive cascade [53, 324]. -synuclein mutants as well as in-
creased levels of normal -synuclein generate RS [239], 
which is accelerated in the presence of DA and increases 
susceptibility of cells to oxidative stress [203]. 
 Mutated  -synuclein has a greater propensity to polymer-
ize  in vitro and -synuclein transgenic mice develop age-
dependent intracellular -synuclein inclusions within aber-
rant areas of the CNS. Further, the expression patterns of 
mutated human -synuclein and the location of inclusions, in 
the various transgenic mouse models, appear to be influ-
enced by the different promoters utilized [270]. Wild type -
synuclein has a half life of 48 hours while the A53T muta-
tion has an approximately 50% longer half life [245] sug-
gesting that these mutant proteins are selectively preventing 
degradation via the lysosome-mediated pathway [78]. 
  Oxidative stress (e.g. from mitochondrial inefficiency, 
anti-oxidant depletion, or transition metal perturbation) pro-
vides conditions under which DA may interact aberrantly 
with  -synuclein and iron resulting in the generation of 
H2O2, oxidation of DA to toxic intermediates such as 6-
OHDA, and aggregation of -synuclein. A self-propagating 
cascade is engendered as oxidative products of these reac-
tions create conditions for further local elevation of DA and 
generation of metal mediated RS. Therefore subsequent sec-
tions discuss how intervening therapies which target these 
interactions may be capable of modulating the disease. 
3. CURRENT TRENDS IN THERAPEUTICS  
  Alleviation of parkinsonian symptoms and functional 
disability is the principal goal of PD management in clinical 
practice. Most patients in early stages of idiopathic PD will 
improve in response to medications that are directed at cor-
rection of the hypo-dopaminergic biochemical deficit and 
enhancement of dopaminergic neurotransmission. This ap-
proach constitutes symptomatic therapy of PD, but the ma-
jority of PD patients will gradually deteriorate. It is thought 
that an ongoing apoptotic death of dopaminergic neurons in 
SN underpins this relentless natural history of PD. Pre-
synaptic dopaminergic terminals in the basal ganglia release 
vesicular DA on demand and also carry out DA reuptake via
the DAT system. Dopaminergic neurons of the SN receive 
innervation from the basal ganglia, thus creating a complex 
feedback loop. This illustrates the role of dopaminergic neu-
rons in biochemical processes and also emphasizes that do-
paminergic neurons are intimately incorporated into neural 
circuits. Neuroprotective therapy sets out to rescue the apop-
totic dopaminergic neurons in SN. Neuroprotective therapy 
still remains mostly an experimental approach, but putative 
neuroprotective drugs may alter the relentless course of PD. 
Detailed synopsis of current symptomatic treatment is out of 
the scope of this review and is dealt with elsewhere [185, 
186]. In this section we summarize only the current most 
common therapeutic pharmacological strategies and focus on 
some experimental neuroprotective therapies currently un-
dergoing human trial.  
3.1. Symptomatic Therapy 
Levodopa 
  At present, Levodopa (L-DOPA or 3, 4-dihydroxy-L-
phenylalanine) is the most useful drug for symptomatic 
treatment of idiopathic PD. Unlike DA, L-DOPA crosses the 
BBB. After oral administration L-DOPA is taken up by the 
dopaminergic neurons and converted into DA by the enzyme 
Aromatic Amino Acid Decarboxylase (AADC).  
  L-DOPA effectively alleviates PD symptoms in the early 
stages of disease. The current “storage hypothesis” holds that 
at this stage of PD the available dopaminergic neurons and 
pre-synaptic dopaminergic terminals maintain the capacity to 
process exogenous L-DOPA and carry out physiological 
handling of synthesized DA [183, 304-306]. It has been sug-
gested that the benefits of L-DOPA wear off with disease 
progression and ongoing death of dopaminergic neurons 
[238]. This view may be misleading due to the inability to 
discriminate against the treatment effects and the natural 
progression of the disease. According to the “storage hy-
pothesis”, in the absence of dopaminergic neurons L-DOPA 
is metabolized into DA by neural cells that lack “dopaminer-
gic machinery”. As a result DA release becomes pulsatile 
rather than continuous and eventually leads to post-synaptic 
changes and development of motor complications [5, 55, 
429]. 
  At present there is some evidence that L-DOPA can be 
neuroprotective to dopaminergic neurons. The Early versus 
Late Levodopa study (ELLDOPA) indicates some neuropro-
tection all be it with diminishes striatal innervation [111]. 
The DATATOP study also suggested that L-DOPA slowed 
the rate of disease progression [1, 57, 183]. In contrast, in
vitro experiments suggest that L-DOPA accelerates degen-
eration of residual dopaminergic neurons through enhanced 
oxidative stress. However, L-DOPA was not toxic to dopa-
minergic neurons in vivo in experimental rodents. Recent 
human trials presented unequivocal evidence that L-DOPA 
treatment did not cause clinical deterioration over a period of 
40 weeks compared to the placebo [69, 110, 229, 298, 385, 
418]. However, the potential long-term effects of L-DOPA 
on dopaminergic neurons remain unclear.  
Direct Agonists of Dopaminergic Receptors (or Dopamine 
Agonists) 
  The rationale for developing this class of drugs was the 
delivery of continuous stimulation of dopaminergic recep-
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fluctuations in long-term. This approach was put forward as 
an alternative to L-DOPA treatment, based on the hypothesis 
that L-DOPA treatment set pulsatile stimulation of post-
synaptic dopaminergic receptors and promoted development 
of motor fluctuations.  
 Numerous  in vitro and in vivo laboratory studies have 
shown neuroprotective potential of dopaminergic agonists 
that can be mediated via several mechanisms including free 
radical scavenging [149, 221], and anti-oxidative properties 
[352, 453]. 
  Data from human trials are not conclusive as to neuropro-
tective properties of DA agonists in PD patients, chiefly be-
cause it is very difficult to discriminate between sympto-
matic and putative neuroprotective effects in the settings of 
clinical trials and requires a sophisticated approach to the 
design and analysis of the study. However, current experi-
ence with PD patients suggests that the impact of direct DA 
agonists on the natural course of PD may not be of a clini-
cally meaningful magnitude [6]. 
3.2. Drugs with Dual, Symptomatic and Neuroprotective 
Effect 
MAO-B Inhibitors 
  There are currently two selective irreversible MAO-B 
inhibitor drugs approved for clinical use, rasagiline (Azilect) 
and selegiline (Deprenyl). Two isoforms of MAO have been 
identified, A and B. In the human brain, MAO-B is the pre-
dominant isoform responsible for the breakdown of DA. 
Selective inhibition of MAO-B results in the elevation of 
synaptosomal DA concentrations. The primary rationale for 
MAO-B inhibition in PD is enhancement of striatal DA 
through inhibition of DA metabolism and the role of MAO-
B inhibitors in symptomatic treatment of PD has been well 
established [317].  
  Interestingly, both selegiline and rasagiline possess po-
tent neuroprotective and anti-apoptotic properties that are not 
related to MAO-B inhibition. This effect has been demon-
strated  in vitro using primary cultures of cortical neurons; 
both drugs enhanced survival of dopaminergic neurons. Neu-
roprotection has been demonstrated in vivo in rodent models 
of Parkinson’s disease. It has been proposed that stabilization 
of mitochondrial membranes, enhancement of intracellular 
anti-oxidant systems and induction of pro-survival genes 
underlies this effect (for review, see www.rasagiline.com). 
  Recently, the interest in neuroprotective properties of 
MAO-B inhibitors has been sparked by the study showing 
that Selegiline slows progression of PD symptoms by about 
35% over 5 years [317]. This suggests that there may be neu-
roprotective effects on the nigro-striatal system. Rasagiline 
has only recently gained FDA approval, but preliminary re-
sults have been promising [366].  
3.3. Cell Based Therapies 
  The neuropathological and neurochemical alterations of 
the dopaminergic nigro-striatal system are responsible for the 
major symptoms of PD (see above section). This constitutes 
the premise of DA cell-replacement therapy, whereby intro-
ducing DA-producing cells into the parkinsonian brain might 
replenish the diminishing levels of DA and alleviate or cure 
PD.  
  Over the last 20 years there has been an enormous re-
search effort in this field of neuroscience. Swedish neurosci-
entists pioneered transplantation experiments in the mid-70’s 
and early 80’s [33, 36, 108]. In early transplantation experi-
ments the grafts of DA-producing cells were placed into the 
striatum because this approach yielded best survival of the 
grafted cells with subsequent dopaminergic reinner-vation of 
the basal ganglia [31, 32, 34, 35, 106, 133]. In parallel, the 
demand grew for the sources of DA-producing cells. Tradi-
tionally, fetal ventral mesencephalic tissue has been used for 
grafting because this region of the developing brain contains 
precursors of dopaminergic cells which differentiate into 
functional DA-producing cells in vivo. Ethical issues essen-
tially preclude large-scale use of the fetal-derived ventral 
mesencephalic tissue. An alternative approach has been de-
veloped, whereby embryonic stem cells or committed neural 
precursors can undergo directed in vitro differentiation into 
DA-producing cells, these are then harvested and used for 
transplantation [37, 248, 346, 387]. 
  Several groups in Europe reported that PD symptoms 
improved following grafting of the fetal mesencephalic tis-
sue into the putamen or head of caudate area of PD patients 
[162, 163]. Based on the promising preliminary results, NIH 
funded the first prospective, double-blind, placebo-controlled 
trial in which 40 PD patients received fetal mesencephalic 
transplants or placebo operations [126]. The functional im-
provement of participants was assessed 12 months following 
grafting using the Unified Parkinson’s Disease Rating Scale 
(UPDRS). Fetal mesencephalic transplants induced statisti-
cally significant improvement in a cohort of patients under 
the age of 60. Long-term follow-up of the participants re-
vealed five patients who underwent transplantation devel-
oped dystonia and dyskinesia. Another prospective, 24-
month, double-blind, placebo-controlled trial of human fetal 
nigral transplantation [311] failed to detect significant differ-
ences between grafted and placebo groups. The incidence of 
dyskinesias was high in this study affecting almost half of 
the patients that had received mesencephalic transplants. 
 Thetwohuman trials are commonly designated as “proof-
of-concept” studies and the negative result are perceived as 
compromising the entire concept of the cell-replacement 
approach. However, several factors have been identified that 
confound interpretation of the negative results of human 
transplantation trials and require further clarification: surgi-
cal technique needs improvement; non-dopaminergic cells 
within fetal tissue transplants also have been implicated in 
post-surgical complications [30, 127, 128]. The current 
mainstream of research is directed at producing a reliable 
and standardized population of DA-producing cells such as 
neural progenitor cells (NPC) that can be used for further 
transplantation trials. 
3.4. Neurosurgical Therapies 
  Neurosurgical interventions have developed symptomatic 
treatments for motor related disorders particularly for ad-
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  With the increasing knowledge of the neuroanatomical 
circuitry, surgical treatments such as precision surgical abla-
tion (pallidotomy and thalamotomy) and Deep Brain Stimu-
lation (DBS) are favorable procedures due to the shortcom-
ings of pharmacological therapies. Surgical ablation therapy 
has been used in many instances until the late 1990’s to re-
duce severe behavioral symptoms such as bradykinesia, dy-
skinesia, and rigidity and to some extent resting tremor. Tar-
gets for functional neurosurgery include the ventral interme-
diate nucleus (ViN), STN or the internal Globus Pallidus 
(GPi). It is though that the reduction of GPi activity through 
ablative surgery rebalances the inhibitory effect of the abun-
dance in striatal GABA due to the loss of DA production. 
  In many models [174] and also human parkinsonism, 
STN and GPi ablation have shown to improve behavioral 
outcomes associated with the disease. The procedure itself is 
irreversible, with serious complications that could lead to 
permanent disability particularly impairment of speech and 
visual modalities. 
  Unilateral pallidotomies are still preformed today without 
any knowledge of the long term effects of the surgery. While 
results of bilateral GPi lesions are indicative of a reduction in 
dyskinesia [81], there is an association with increased risk of 
inherent adverse side effects [81]. Patients with unilateral 
subthalamic lesions showed pronounced improvement par-
ticularly after surgery [321]. However, efficacy was limited 
in that tremors would reoccur in about 20 % of cases. A cur-
rent alternative surgical treatment, high frequency DBS, has 
replaced stereotaxic lesioning. Chronic high frequency 
stimulation of the STN (via ViM) in a pilot study in 1987, 
yielded some promising results by a reduction in extra py-
ramidal side effects [24]. This new treatment paved the way 
for a new type of functional motor disorder neurosurgery 
without subsequent adverse side effects associated with sur-
gical ablation. In PD, the motor deficits are attributed to in-
creased neuronal activity within the STN and the GPi. The 
surgery involves an insertion of an electrode attached to a 
neurostimulator. The neurostimulator sends out electrical 
signals that modulate neuronal circuitry in target areas in the 
brain to inhibit the impulses that give rise to motor dysfunc-
tion. The electrode is placed into a region to address a par-
ticular motor symptom accordingly. DBS is proven to be an 
efficacious treatment in studies that target regions of both the 
STN and GPi. These studies revealed a reduction in symp-
toms such as tremor, bradykinesia and rigidity [217, 388]. 
The stimulation of either the STN [226] or the GPi [2] re-
sulted in significant improvements in UPDRS motor scales.  
  The mechanisms of STN-DBS and GPi-DBS are para-
doxical and still remain unknown. It was hypothesized that 
electrical stimulation of the STN and GPi would suppress 
these structural inputs [101] and would therefore act as a 
counteractive measure of DA replacement therapy. Con-
versely, Stefani and colleagues (2005) [384] questioned this 
mechanism suggesting that STN-DBS increases GPi firing 
rate and synchronizes the STN activity. In a microdialysis 
model of PD, cGMP was used as a measure of glutamate 
transmission and was found to be increased by 6 fold in GPi 
dialysate [384]. 
  Concurrent electrical stimulation is a reversible proce-
dure with fewer surgical complications compared to its le-
sioning counterpart. Follow-up studies of bilateral STN-DBS 
patients showed improvement in motor symptoms [109] 
suggesting that DBS is a beneficial long term treatment. The 
DBS is a useful procedure because it allows the stimulation 
of an affected region without further destruction of brain 
tissue [160]. At the same time, long term stimulation of the 
STN could aid in slowing the disease progression. However, 
this is yet to be confirmed since Hilker and colleagues 
(2005) [179] established that bilateral STN stimulation did 
not alter the rate of disease progression. 
4. NEW THERAPEUTIC STRATEGIES  
  Current therapeutics for PD is neither curative nor pre-
ventative as they only temporarily alleviate some of the 
symptoms of the disease. Drug intervention needs to aim at 
halting the progression of PD. Current treatments of PD are 
successfully improving quality of life but unfortunately 
largely without the ability to control or reduce the rate of 
disease progression. An integrative model that combines the 
putative fundamental aspects of nigral degeneration is 
needed for appropriate therapeutic targeting to potentially 
prevent further DA nigral loss. 
4.1. Gene Therapy 
  With the current knowledge of molecular characterization 
of vital genes involved in the neurodegenerative process, 
several research groups have embarked on using gene ther-
apy to help protect and also repair neuronal damage. Deliv-
erance of protein products is difficult as the BBB limits the 
transfer to the intended destinations. Genetic manipulation 
has many advantageous applications with many vehicles 
aiding in the delivery of the gene target such as viral (lentivi-
rus, adenovirus and herpes virus) or non viral (polyplexes) 
that can infect cells without inducing inflammatory re-
sponses and has the ability to affect both dividing and non 
dividing cells [105, 277]. Furthermore, the regulatory control 
of an element that allows the expression of the gene is the 
primary mechanism for genetic manipulation. Whilst many 
genes have been uncovered acting as potential ‘players’ in 
the degenerative cascade, this has allowed the makings of in 
vivo gene therapy promising a new future treatment for PD. 
The conceptual difficulty in this approach comes from the 
unknown cause of sporadic PD [400]. Once the cause has 
been identified, gene therapy may then take greater promi-
nence. While this interventional approach is still a new con-
cept, only a few genes have been trialed in animal models of 
PD. These gene targets include -synuclein [123, 171, 239, 
350, 451] and Parkin [192, 251, 362, 434]. 
  The use of various neurotrophins in support of the nigral 
neurons has proved effective in various animal models [59, 
70, 225]. The Glial cell line-Derived Neurotrophic Factor 
(GDNF) has shown the propensity to increase the rate of DA 
neuronal survival under neurotoxic cell culture conditions 
[48, 65] and in animal models [59, 70]. Reports of GDNF 
therapy delivered with an adenovirus have been used in ani-
mal models and it was found that GDNF can rescue DA cell 
loss if administered prior to or shortly after delivery of 6-
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in motor behavior is a reflection in significant DA cell re-
covery of function [421, 450] and correlated with a higher 
level of DA production in the striatum [421]. These higher 
levels of DA may occur because of increased TH expression 
[371]. The results from the various clinical trials have not 
beensodefinitive. Lang and colleagues (2006) [232], showed 
that there was no significant clinical benefit in the UPDRS in 
a phase II trial that investigated the effect of intra-putamen 
infusion of GDNF, yet similar studies have shown signifi-
cant progressive improvements in open-label designed trials 
[141, 370]. It has been debated that Lang and colleagues 
(2006) did not adequately take into account the placebo ef-
fect, the catheter design or the rate of delivery of GDNF 
[232]. Further, recalculation of the statistical power showed 
that the power of the study was unable to investigate the ef-
fects of GDNF in PD [191]. In light of these difficulties, 
GDNF properties of promoting cell survival have not been 
adequately tested in trial for neuroprotection therapy as this 
would require a longer period of evaluation and sophisticated 
study design.  
  Preliminary data using gene therapy to target the STN 
instead the SN has showed some promise as a therapy in PD. 
Utilizing a viral expression system, an enzyme (glutamic 
acid decarboxylase) that synthesizes a neurotransmitter 
(GABA) was surgically introduced into the STN of patients 
with PD [113]. The rationale of targeting the STN instead of 
the SN (which is a primary target seen in many gene therapy 
trials) was to functionally increase the production of GABA 
to decrease the aberrant increase in signals to the thalamus 
[113]. Significant improvement was reported clinically with 
the functional restoration of circuitry and improvements in 
motor behavior. Whilst successful in a pilot phase, the ques-
tion of the placebo effect seen in many surgeries has not 
been adequately addressed [82]. The clinical presentation of 
PD symptoms occurs when at least 70% of nigral cells are 
lost. Goals of therapeutic interventions must therefore ad-
dress the recovery and prevent the progressive nature of neu-
ronal death in the SN. GDNF partially fulfils these criteria 
and is therefore an interesting target. However, many factors 
need to be considered: i) Regulated controlled delivery of 
gene products [223]. ii) Transfection is notoriously difficult 
and inefficient in neuronal cultured systems [422] and grow-
ing concerns of random integration posing a risk of insertion 
mutagenesis. iii) Adverse immune reaction [271] and iv) 
How chronic delivery of these “foreign” genetic products 
will be restricted to the correct brain region. Gene therapy 
still has a promising future and remains in an experimental 
stage. These factors need to be carefully tested before its 
emergence as an effective therapy for PD.  
4.2. Anti-Oxidant Based Therapies 
  Over the last decade, neuroprotective approaches for PD 
have been tried in an attempt to slow the rate of disease pro-
gression. There have been a number of intervention strate-
gies focusing on decreasing oxidative stress. Anti-oxidants 
can be naturally found in the diet in the form of vitamins (A, 
C and E), polyphenols, flavonoids and carotenoids. Interest-
ingly, reports of dietary intake (such as high intakes of satu-
rated fats and cholesterols) could possibly influence the sus-
ceptibility of developing PD [172, 173, 201, 253]. Dietary 
anti-oxidants can be found highly in fruits, vegetables, green/ 
black teas and red wine [144, 289], it appears that moderate 
ingestion of these foods results in a reduction in risk of PD 
[144, 252, 353]. The properties of anti-oxidants possesses is 
the ability to scavenge for free radicals such as the hydroxyl 
and the O2
￿ radical [52, 89, 94, 165, 348, 398]. RS damage 
can be prevented by selected flavonoids and related phenols 
(polyphenols) by directly inhibiting both the formation of RS 
[52, 165, 398] and they enzymes that produce them [140]. A 
lot of research to date has focused on the properties of phe-
nols found in tea extracts [348]. These potent anti-oxidants 
have shown to attenuate the toxic effects of 6-OHDA both in 
cultured PC12 cells [244] and an animal model of PD [243].  
  The protection with the use of carotenoids and both vita-
min C (ascorbate) and E (-tocopherol) has been seen in cel-
lular based models of oxidative stress [367]. However these 
findings are inconsistent with the data produced by epidemi-
ological studies. The use of vitamin supplements has been 
assessed in large cohort studies and found that there was no 
association with reduced risks of developing PD [447]. 
Among individuals who have a high intake of foods that 
were rich in vitamin E showed significant reduction in the 
associated risks [83, 136, 144]. Other studies had not found 
this association [12, 353].  
  Clinical based trials have investigated the use of anti-
oxidants in PD patients. One of the first of its kind Deprenyl, 
and  -tocopherol Anti-oxidant Therapy of Parkinsonism 
(DATATOP) evaluated the use of these agents in a con-
trolled clinical trial setting [1]. The study revealed that -
tocopherol did not benefit in slowing down or reducing the 
severity of symptoms of PD. This result has been suggested 
to be a cause of slow absorption and poor penetration into 
the CNS [1]. Animal models of PD using MPTP evinced 
conflicting views on the effects of vitamin E [150, 340], vi-
tamin C and carotenoids [327, 328, 417]. Vitamin E deficient 
mice have an increased susceptibility to MPTP which se-
verely affected the SN [307]. Dietary intake of vitamin E, C 
and carotenoids in the form of some foods remains consistent 
over a lifetime, and should be regarded and used in a staple 
diet from an earlier age. The supplementations of these vita-
mins are yet to be convincing as a therapy to be used at a 
clinical level.  
  A potential new anti-oxidant agent coenzyme Q10 seem-
ingly has some promise as a therapy in mitochondrial disor-
ders and neurodegenerative diseases. Improvement in pa-
tients with mitochondrial defects is seen biochemically and 
clinically with coenzyme Q10 treatment [46, 47, 308]. In 
neurological diseases that show mitochondrial deficit as a 
clinical and pathological feature, treatment with coenzyme 
Q10 could be of benefit. Serving as a potent anti-oxidant, 
coenzyme Q10 is a lipid soluble molecule which sits in the 
inner membrane of mitochondria and transfers electrons in 
the electron transport chain [404]. The anti-oxidative proper-
ties involve the ability to scavenge and inhibit the formation 
of RS [120, 302, 376]. The neuroprotective effects of coen-
zyme Q10 is seen in many models of neurotoxicity such as 
rotenone [291] and MPTP [22, 66]. These studies revealed 
that in animal lesion models, coenzyme Q10 significantly 
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depletion of striatal DA and the prevention in the formation 
of -synuclein aggregates [66].  
  Phase II PD clinical trial showed a reduction (44%) in 
motor deficits measured by UPDRS using a maximal dose of 
1200mg (per day) [364]. Storch and colleagues (2007) [386] 
attempted to replicate the earlier study with a withdrawal 
phase using participants with middle stage PD in a more 
rigorous study design. The treatment with coenzyme Q10 in 
this study showed no significant motor improvements at a 
dose of 300mg a day [386]. It was concluded that dosage is 
not sufficient enough to have a symptomatic effect at this 
stage of the disease. Further trials need to explore the protec-
tive effects in PD using the anti-oxidant coenzyme Q10 at a 
high dosage and for an extended period of time.  
4.3. Therapeutics that Focus on Metals
  There has been substantial research into pharmacological 
interventions that are involved in the modulation of biomet-
als in neurodegenerative disorders. Iron dysregulation seems 
to play a vital role in disease pathogenesis in PD patients. 
These disruptions in the iron homeostatic mechanism ob-
served in PD offer the potential for future therapeutic inter-
vention. Controlling the bioavailability of metals could pre-
vent not only the generation of RS through metallo-redox 
reactions but also the interaction with other known ‘culprit 
contenders’ such as -synuclein (as shown in Fig. 1). 
4.3.1. Therapies which Target Metal-Associated Proteins 
  As discussed previously in section 2.4.1, ferritin is a pro-
tein that regulates iron storage and can potentially remove 
any free redox active iron that is present within the cell. 
Transgenic mice that express high levels of H-Ferritin have 
been shown to effectively protect the further loss of nigral 
cells in MPTP [207] and paraquat [275] animal models of 
PD. H-Ferritin possesses a modifying oxidase activity, which 
sequesters the iron and converts it to the less bioreactive 
form [205, 207]. This increase in ferroxidase activity reduces 
the free iron pool preventing its further participation in redox 
chemistry [207].  
4.3.2. Metal Chelation Therapies  
  The primary mechanism of chelators is to chemically 
bind metal ions to form complexes rendering the ions less 
reactive and allow removal of these ions via the bloodstream 
for excretion. Pharmacological chelators such as desferrox-
amine have shown some promise in modulating metal ions. 
In vitro studies have shown that Desferal intervenes in mito-
chondrial inhibition by directly enhancing the activation of 
NADH dehydrogenase [438]. Unfortunately, desferroxamine 
has poor penetration through the BBB [448]. New iron 
chelators such as VK-28 were synthesized in order to over-
come potential barrier impermeability. VK-28 has been 
shown to protect nigral cells against 6-OHDA induced le-
sions [357].  
  In an induced proteasome dysfunction animal model, 
chelation therapy with desferroxamine reduced the inhibitory 
effects on proteasome inhibitors [448]. Iron potentially acer-
bates the rapid formation of the -synuclein structure to 
promote high molecular weight insoluble aggregates (see 
section 2.4.1). Proteasome dysfunction in this model of PD is 
relieved by sequestering iron to prevent this aggregation 
from occurring and protect the nigral cells [448]. Pyridoxal 
Isonicotinoyl Hyrdazone (PIH) and 2-Pyridylcarboxaldehyde 
isonicotinoyl Hydrazone (PCIH) share similar potency to 
desferroxamine, possess high and potent chelating activity, 
have the ability to cross the BBB and are highly specific for 
iron overload diseases [178, 341]. PIH and its analogues 
seem to act in a dose-dependant manner in the immobiliza-
tion of iron from ferritin and allowing excretion [433]. 
  The complexity of parkinsonism has been highlighted 
and discussed in this review. An observation of this com-
plexity has lead biochemists to develop bifunctional com-
pounds which have two modes of action. Only recently, new 
compounds have emerged based on known MAO-B inhibi-
tors. These have been synthesized to possess both neuropro-
tective effects and iron chelating properties [449]. M30, 
which has similar structure to that of VK-28, is a hydroxy-
quinoline which acts as both a selective inhibitor of MAO-A 
and MAO-B with chelating capabilities similar to that of 
desferroxamine [15, 134]. Both in vivo and in vitro models 
have shown promising effects to both increase levels of DA 
and prevent further MPTP toxicity [15, 134, 135, 449]. 
While there is potential to synthesize more ‘multi-functional’ 
compounds, however there is a need to develop a more clini-
cal based approach and evaluate the effects of these drugs 
both at a physical and biochemical level. 
4.2.3. Metal Protein Attenuating Compounds (MPAC)  
  Metal protein attenuating compounds (MPAC) may offer 
future therapies for PD. Clioquinol (5-chloro-7-iodo-8-
hydroxyquinoline, CQ) is the prototype MPAC and acts by 
competing with proteins for metal ions [100]. Clioquinol 
(CQ) is an orally bioavailable drug with moderate affinity for 
copper, zinc and iron. Differing from traditional chelators as 
mentioned above, these compounds do not remove metals 
from tissues. CQ appears to act as an ionophore to redistrib-
ute metals from areas of superabundance to those which may 
be deficient. Unlike traditional chelators such as EDTA, CQ 
does not cause bulk excretion of metals but permeates the 
BBB and potently inhibits metal-mediated hydrogen perox-
ide production [18]. CQ and analogues are being investigated 
in a number of conditions in which oxidative stress is a fea-
ture. These include; cancer [97, 98] stroke [272], AD [336, 
343] and PD [207]. 
  This type of therapeutic approach using CQ type MPACs 
appears to be encouraging for AD. Animal trials with 21 
month old transgenic mice over expressing the amyloid pre-
cursor protein (APP) with the Swedish mutation showed a 
significant reduction in A plaques after treatment with CQ 
[60]. A phase II double-blinded clinical trial showed that CQ 
treatment for 36 weeks resulted in a reduction of A1-42 in 
plasma, with minimal cognitive decline [343]. While this 
study had a very small subset which reflected within the non 
significant difference between the groups, these results sup-
port the idea that metals play an important role in neurologi-
cal diseases. 
  There is also proof of concept that MPACs may be useful 
for PD therapeutics. A parkinsonian animal model study 
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prior to induction of lesions resulted in 50% decrease in ni-
gral cell loss compared to animals treated with the parkin-
sonian toxin MPTP alone [207]. An 8 week pretreatment of 
CQ resulted in reduction in iron within the SN in MPTP le-
sioned mice [146]. More recently data showing that CQ 
treatment commencing only 6 hours after induction of the 
lesion is equally effective at attenuating SN lesions provoked 
by intra-nigral injection of 6-OHDA [428] Further the data 
from a neuronal cell line that expresses the A30P mutant 
human  -synuclein was rescued by either catalase or CQ 
[428]. 
CONCLUSION 
  Understanding the causes and the pathology of PD is 
pivotal in identifying specific targets for drug intervention. 
Surgical interventions have a limited niche in the treatment 
of symptoms of PD, while other restorative measures (such 
as gene therapy) are still experimental and pre-clinical. The 
challenge is to develop novel therapeutic agents which are 
capable of slowing SN cell loss and reducing disease pro-
gression. Recent studies into new classes of drugs (such as 
MPACs) have shown that they may intervene with interac-
tions between dopamine, alpha synuclein and redox-active 
metals. This class of therapeutic drug offers a new pharma-
cological approach that could potentially modify the progres-
sion of PD. 
ACKNOWLEDGEMENT 
  This work is funded by The National Health and Medical 
Research Council of Australia (NHMRC), the Australian 
Brain Foundation, Supported by Operational Infrastructure 
Support (OIS) from the Victorian State Government and 
Prana Biotechnology.  
REFERENCES 
[1]  Parkinson’s Disease Study Group. (1993) Effects of tocopherol and 
deprenyl on the progression of disability in early Parkinson's dis-
ease. The Parkinson Study Group. N. Engl. J. Med., 328, 176-183. 
[2]  Parkinson’s Disease Study Group. (2001) Deep-brain stimulation 
of the subthalamic nucleus or the pars interna of the globus pallidus 
in Parkinson's disease. N. Engl. J. Med., 345, 956-963. 
[3]  Abou-Sleiman, P.M., Healy, D.G., Quinn, N., Lees, A.J., Wood, 
N.W. (2003) The role of pathogenic DJ-1 mutations in Parkinson's 
disease. Ann. Neurol., 54, 283-286. 
[4]  Abou-Sleiman, P.M., Muqit, M.M., McDonald, N.Q., Yang, Y.X., 
Gandhi, S., Healy, D.G., Harvey, K., Harvey, R.J., Deas, E., 
Bhatia, K., Quinn, N., Lees, A., Latchman, D.S., Wood, N.W. 
(2006) A heterozygous effect for PINK1 mutations in Parkinson's 
disease? Ann. Neurol., 60, 414-419. 
[5]  Agid, Y., Bonnet, A.M., Ruberg, M., Javoy-Agid, F. (1985) Patho-
physiology of L-dopa-induced abnormal involuntary movements. 
Psychopharmacol. Suppl., 2, 145-159. 
[6]  Ahlskog, J.E. (2003) Parkinson's disease: is the initial treatment 
established? Curr. Neurol. Neurosci. Rep., 3, 289-295. 
[7]  Alam, M., Schmidt, W.J. (2002) Rotenone destroys dopaminergic 
neurons and induces parkinsonian symptoms in rats. Behav. Brain 
Res., 136, 317-324. 
[8]  Alam, M., Schmidt, W.J. (2004) L-DOPA reverses the hypokinetic 
behaviour and rigidity in rotenone-treated rats. Behav. Brain Res.,
153, 439-446. 
[9]  Alam, Z.I., Daniel, S.E., Lees, A.J., Marsden, D.C., Jenner, P., 
Halliwell, B. (1997) A generalised increase in protein carbonyls in 
the brain in Parkinson's but not incidental Lewy body disease. J. 
Neurochem., 69, 1326-1329. 
[10]  Alam, Z.I., Jenner, A., Daniel, S.E., Lees, A.J., Cairns, N., Mars-
den, C.D., Jenner, P., Halliwell, B. (1997) Oxidative DNA damage 
in the parkinsonian brain: an apparent selective increase in 8-
hydroxyguanine levels in substantia nigra. J. Neurochem., 69,
1196-1203. 
[11]  Alves Da Costa, C., Paitel, E., Vincent, B., Checler, F. (2002) 
Alpha-synuclein lowers p53-dependent apoptotic response of neu-
ronal cells. Abolishment by 6-hydroxydopamine and implication 
for Parkinson's disease. J. Biol. Chem., 277, 50980-50984. 
[12]  Anderson, C., Checkoway, H., Franklin, G.M., Beresford, S., 
Smith-Weller, T., Swanson, P.D. (1999) Dietary factors in Parkin-
son's disease: the role of food groups and specific foods. Mov. Dis-
ord., 14, 21-27. 
[13]  Ascherio, A., Chen, H., Weisskopf, M.G., O'Reilly, E., McCullough, 
M.L., Calle, E.E., Schwarzschild, M.A., Thun, M.J. (2006) Pesticide 
exposure and risk for Parkinson's disease. Ann. Neurol., 60, 197-203. 
[14]  Athanassiadou, A., Voutsinas, G., Psiouri, L., Leroy, E., Polymero-
poulos, M.H., Ilias, A., Maniatis, G.M., Papapetropoulos, T. (1999) 
Genetic analysis of families with Parkinson disease that carry the 
Ala53Thr mutation in the gene encoding alpha-synuclein. Am. J. 
Hum. Genet., 65, 555-558. 
[15]  Avramovich-Tirosh, Y., Amit, T., Bar-Am, O., Zheng, H., Fridkin, 
M., Youdim, M.B. (2007) Therapeutic targets and potential of the 
novel brain- permeable multifunctional iron chelator-monoamine 
oxidase inhibitor drug, M-30, for the treatment of Alzheimer's dis-
ease. J. Neurochem., 100, 490-502. 
[16]  Barbeau, A., Inoue, N., Cloutier, T. (1976) Role of manganese in 
dystonia. Adv. Neurol., 14, 339-352. 
[17]  Barden, H., Levine, S. (1983) Histochemical observations on ro-
dent brain melanin. Brain Res. Bull., 10, 847-851. 
[18]  Barnham, K.J., Haeffner, F., Ciccotosto, G.D., Curtain, C.C., Tew, 
D., Mavros, C., Beyreuther, K., Carrington, D., Masters, C.L., 
Cherny, R.A., Cappai, R., Bush, A.I. (2004) Tyrosine gated elec-
tron transfer is key to the toxic mechanism of Alzheimer's disease 
beta-amyloid. FASEB J., 18, 1427-1429. 
[19]  Bartzokis, G., Beckson, M., Hance, D.B., Marx, P., Foster, J.A., 
Marder, S.R. (1997) MR evaluation of age-related increase of brain 
iron in young adult and older normal males. Magn. Reson. Imaging,
15, 29-35. 
[20]  Bartzokis, G., Cummings, J.L., Markham, C.H., Marmarelis, P.Z., 
Treciokas, L.J., Tishler, T.A., Marder, S.R., Mintz, J. (1999) MRI 
evaluation of brain iron in earlier- and later-onset Parkinson's dis-
ease and normal subjects. Magn. Reson. Imaging, 17, 213-222. 
[21]  Bartzokis, G., Tishler, T.A., Shin, I.S., Lu, P.H., Cummings, J.L. 
(2004) Brain ferritin iron as a risk factor for age at onset in neu-
rodegenerative diseases. Ann. N. Y. Acad. Sci., 1012, 224-236. 
[22]  Beal, M.F., Matthews, R.T., Tieleman, A., Shults, C.W. (1998) 
Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydro-
pyridine (MPTP) induced loss of striatal dopamine and dopaminer-
gic axons in aged mice. Brain Res., 783, 109-114. 
[23]  Beilina, A., Van Der Brug, M., Ahmad, R., Kesavapany, S., Miller, 
D.W., Petsko, G.A., Cookson, M.R. (2005) Mutations in PTEN-
induced putative kinase 1 associated with recessive parkinsonism 
have differential effects on protein stability. Proc. Natl. Acad. Sci. 
USA, 102, 5703-5708. 
[24]  Benabid, A.L., Pollak, P., Louveau, A., Henry, S., de Rougemont, 
J. (1987) Combined (thalamotomy and stimulation) stereotactic 
surgery of the VIM thalamic nucleus for bilateral Parkinson dis-
ease. Appl. Neurophysiol., 50, 344-346. 
[25]  Ben-Shachar, D., Youdim, M.B. (1991) Intranigral iron injection 
induces behavioral and biochemical "parkinsonism" in rats. J. Neu-
rochem., 57, 2133-2135. 
[26]  Bergomi, M., Vinceti, M., Nacci, G., Pietrini, V., Bratter, P., Alber, 
D., Ferrari, A., Vescovi, L., Guidetti, D., Sola, P., Malagu, S., 
Aramini, C., Vivoli, G. (2002) Environmental exposure to trace 
elements and risk of amyotrophic lateral sclerosis: a population-
based case-control study. Environ. Res., 89, 116-123. 
[27]  Betarbet, R., Sherer, T.B., MacKenzie, G., Garcia-Osuna, M., 
Panov, A.V., Greenamyre, J.T. (2000) Chronic systemic pesticide 
exposure reproduces features of Parkinson's disease. Nat. Neuro-
sci., 3, 1301-1306. 
[28]  Bharathi, Indi, S.S., Rao, K.S. (2007) Copper- and iron-induced 
differential fibril formation in alpha-synuclein: TEM study. Neuro-
sci. Lett., 424, 78-82. 
[29]  Bharathi, Rao, K.S. (2007) Thermodynamics imprinting reveals 
differential binding of metals to alpha-synuclein: relevance to Park-
inson's disease. Biochem. Biophys. Res. Commun., 359, 115-120. Targeting the Progression of Parkinson’s Disease  Current Neuropharmacology, 2009, Vol. 7, No. 1    25
[30]  Bjorklund, A., Dunnett, S.B., Brundin, P., Stoessl, A.J., Freed, 
C.R., Breeze, R.E., Levivier, M., Peschanski, M., Studer, L., 
Barker, R. (2003) Neural transplantation for the treatment of Park-
inson's disease. Lancet Neurol., 2, 437-445. 
[31]  Bjorklund, A., Gage, F.H., Schmidt, R.H., Stenevi, U., Dunnett, 
S.B. (1983) Intracerebral grafting of neuronal cell suspensions. VII. 
Recovery of choline acetyltransferase activity and acetylcholine 
synthesis in the denervated hippocampus reinnervated by septal 
suspension implants. Acta Physiol. Scand. Suppl., 522, 59-66. 
[32]  Bjorklund, A., Gage, F.H., Stenevi, U., Dunnett, S.B. (1983) In-
tracerebral grafting of neuronal cell suspensions. VI. Survival and 
growth of intrahippocampal implants of septal cell suspensions. 
Acta Physiol. Scand. Suppl., 522, 49-58. 
[33]  Bjorklund, A., Stenevi, U., Dunnett, S.B., Iversen, S.D. (1981) 
Functional reactivation of the deafferented neostriatum by nigral 
transplants. Nature, 289, 497-499. 
[34]  Bjorklund, A., Stenevi, U., Schmidt, R.H., Dunnett, S.B., Gage, 
F.H. (1983) Intracerebral grafting of neuronal cell suspensions. I. 
Introduction and general methods of preparation. Acta Physiol. 
Scand. Suppl., 522, 1-7. 
[35]  Bjorklund, A., Stenevi, U., Schmidt, R.H., Dunnett, S.B., Gage, 
F.H. (1983) Intracerebral grafting of neuronal cell suspensions. II. 
Survival and growth of nigral cell suspensions implanted in differ-
ent brain sites. Acta Physiol. Scand. Suppl., 522, 9-18. 
[36]  Bjorklund, A., Stenevi, U., Svendgaard, N. (1976) Growth of 
transplanted monoaminergic neurones into the adult hippocampus 
along the perforant path. Nature, 262, 787-790. 
[37]  Bjorklund, L.M., Sanchez-Pernaute, R., Chung, S., Andersson, T., 
Chen, I.Y., McNaught, K.S., Brownell, A.L., Jenkins, B.G., 
Wahlestedt, C., Kim, K.S., Isacson, O. (2002) Embryonic stem 
cells develop into functional dopaminergic neurons after transplan-
tation in a Parkinson rat model. Proc. Natl. Acad. Sci. USA, 99,
2344-2349. 
[38]  Blackinton, J., Ahmad, R., Miller, D.W., van der Brug, M.P., 
Canet-Aviles, R.M., Hague, S.M., Kaleem, M., Cookson, M.R. 
(2005) Effects of DJ-1 mutations and polymorphisms on protein 
stability and subcellular localization. Brain Res. Mol. Brain Res.,
134, 76-83. 
[39]  Blanc, E.M., Keller, J.N., Fernandez, S., Mattson, M.P. (1998) 4-
hydroxynonenal, a lipid peroxidation product, impairs glutamate 
transport in cortical astrocytes. Glia, 22, 149-160. 
[40]  Blanchard-Fillion, B., Souza, J.M., Friel, T., Jiang, G.C., Vrana, K., 
Sharov, V., Barron, L., Schoneich, C., Quijano, C., Alvarez, B., 
Radi, R., Przedborski, S., Fernando, G.S., Horwitz, J., Ischiropou-
los, H. (2001) Nitration and inactivation of tyrosine hydroxylase by 
peroxynitrite. J. Biol. Chem., 276, 46017-46023. 
[41]  Blum, D., Torch, S., Nissou, M.F., Verna, J.M. (2001) 6-
hydroxydopamine-induced nuclear factor-kappa B activation in 
PC12 cells. Biochem. Pharmacol., 62, 473-481. 
[42]  Bogerts, B. (1981) A brainstem atlas of catecholaminergic neurons 
in man, using melanin as a natural marker. J. Comp. Neurol., 197,
63-80. 
[43]  Bondy, S.C., Ali, S.F., Guo-Ross, S. (1998) Aluminum but not iron 
treatment induces pro-oxidant events in the rat brain. Mol. Chem. 
Neuropathol., 34, 219-232. 
[44]  Bonifati, V., Rizzu, P., Squitieri, F., Krieger, E., Vanacore, N., van 
Swieten, J.C., Brice, A., van Duijn, C.M., Oostra, B., Meco, G., 
Heutink, P. (2003) DJ-1( PARK7), a novel gene for autosomal re-
cessive, early onset parkinsonism. Neurol. Sci., 24, 159-160. 
[45]  Braak, H., Del Tredici, K., Rub, U., de Vos, R.A., Jansen Steur, 
E.N., Braak, E. (2003) Staging of brain pathology related to spo-
radic Parkinson's disease. Neurobiol. Aging, 24, 197-211. 
[46]  Bresolin, N., Bet, L., Binda, A., Moggio, M., Comi, G., Nador, F., 
Ferrante, C., Carenzi, A., Scarlato, G. (1988) Clinical and bio-
chemical correlations in mitochondrial myopathies treated with co-
enzyme Q10. Neurology, 38, 892-899. 
[47]  Bresolin, N., Bet, L., Ferrante, C., Binda, A., Carenzi, A., Moggio, 
M., Comi, G., Scarlato, G. (1988) Immunological and biochemical 
studies and pilot therapeutic trial with ubidecarenone in Kearns-
Sayre patients. Adv. Neurol., 48, 239-256. 
[48]  Burke, R.E., Antonelli, M., Sulzer, D. (1998) Glial cell line-derived 
neurotrophic growth factor inhibits apoptotic death of postnatal 
substantia nigra dopamine neurons in primary culture. J. Neuro-
chem., 71, 517-525. 
[49]  Bush, A.I., Masters, C.L., Tanzi, R.E. (2003) Copper, beta-
amyloid, and Alzheimer's disease: tapping a sensitive connection. 
Proc. Natl. Acad. Sci. USA, 100, 11193-11194. 
[50]  Cabin, D.E., Shimazu, K., Murphy, D., Cole, N.B., Gottschalk, W., 
McIlwain, K.L., Orrison, B., Chen, A., Ellis, C.E., Paylor, R., Lu, 
B., Nussbaum, R.L. (2002) Synaptic vesicle depletion correlates 
with attenuated synaptic responses to prolonged repetitive stimula-
tion in mice lacking alpha-synuclein. J. Neurosci., 22, 8797-8807. 
[51]  Campbell, A., Yang, E.Y., Tsai-Turton, M., Bondy, S.C. (2002) 
Pro-inflammatory effects of aluminum in human glioblastoma 
cells. Brain Res., 933, 60-65. 
[52]  Cao, G., Sofic, E., Prior, R.L. (1997) Antioxidant and prooxidant 
behavior of flavonoids: structure-activity relationships. Free Radic. 
Biol. Med., 22, 749-760. 
[53]  Cappai, R., Leck, S.L., Tew, D.J., Williamson, N.A., Smith, D.P., 
Galatis, D., Sharples, R.A., Curtain, C.C., Ali, F.E., Cherny, R.A., 
Culvenor, J.G., Bottomley, S.P., Masters, C.L., Barnham, K.J., 
Hill, A.F. (2005) Dopamine promotes alpha-synuclein aggregation 
into SDS-resistant soluble oligomers via a distinct folding pathway. 
FASEB J., 19, 1377-1379. 
[54]  Carini, R., Bellomo, G., Paradisi, L., Dianzani, M.U., Albano, E. 
(1996) 4-Hydroxynonenal triggers Ca2+ influx in isolated rat hepa-
tocytes. Biochem. Biophys. Res. Commun., 218, 772-776. 
[55]  Carta, M., Lindgren, H.S., Lundblad, M., Stancampiano, R., Fadda, 
F., Cenci, M.A. (2006) Role of striatal L-DOPA in the production 
of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem.,
96, 1718-1727. 
[56]  Caughman, S.W., Hentze, M.W., Rouault, T.A., Harford, J.B., 
Klausner, R.D. (1988) The iron-responsive element is the single 
element responsible for iron-dependent translational regulation of 
ferritin biosynthesis. Evidence for function as the binding site for a 
translational repressor. J. Biol. Chem., 263, 19048-19052. 
[57]  Chan, P.L., Nutt, J.G., Holford, N.H. (2007) Levodopa slows pro-
gression of Parkinson's disease: external validation by clinical trial 
simulation. Pharm. Res., 24, 791-802. 
[58]  Chartier-Harlin, M.C., Kachergus, J., Roumier, C., Mouroux, V., 
Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hu-
lihan, M., Waucquier, N., Defebvre, L., Amouyel, P., Farrer, M., 
Destee, A. (2004) Alpha-synuclein locus duplication as a cause of 
familial Parkinson's disease. Lancet, 364, 1167-1169. 
[59]  Chen, Y.H., Harvey, B.K., Hoffman, A.F., Wang, Y., Chiang, 
Y.H., Lupica, C.R. (2007) MPTP-induced deficits in striatal synap-
tic plasticity are prevented by glial cell line-derived neurotrophic 
factor expressed via an adeno-associated viral vector. FASEB J., 
22(1), 261-275. 
[60]  Cherny, R.A., Atwood, C.S., Xilinas, M.E., Gray, D.N., Jones, 
W.D., McLean, C.A., Barnham, K.J., Volitakis, I., Fraser, F.W., 
Kim, Y., Huang, X., Goldstein, L.E., Moir, R.D., Lim, J.T., 
Beyreuther, K., Zheng, H., Tanzi, R.E., Masters, C.L., Bush, A.I. 
(2001) Treatment with a copper-zinc chelator markedly and rapidly 
inhibits beta-amyloid accumulation in Alzheimer's disease trans-
genic mice. Neuron, 30, 665-676. 
[61]  Chiba-Falek, O., Lopez, G.J., Nussbaum, R.L. (2006) Levels of 
alpha-synuclein mRNA in sporadic Parkinson disease patients. 
Mov. Disord., 21, 1703-1708. 
[62]  Chinta, S.J., Andersen, J.K. (2008) Redox imbalance in Parkinson's 
disease. Biochim. Biophys. Acta, 1780(11), 1362-1367. 
[63]  Chinta, S.J., Kumar, M.J., Hsu, M., Rajagopalan, S., Kaur, D., 
Rane, A., Nicholls, D.G., Choi, J., Andersen, J.K. (2007) Inducible 
alterations of glutathione levels in adult dopaminergic midbrain 
neurons result in nigrostriatal degeneration. J. Neurosci., 27,
13997-14006. 
[64]  Chiueh, C.C., Wu, R.M., Mohanakumar, K.P., Sternberger, L.M., 
Krishna, G., Obata, T., Murphy, D.L. (1994) In vivo generation of 
hydroxyl radicals and MPTP-induced dopaminergic toxicity in the 
basal ganglia. Ann. N. Y. Acad. Sci., 738, 25-36. 
[65]  Clarkson, E.D., Edwards-Prasad, J., Freed, C.R., Prasad, K.N. 
(1999) Immortalized dopamine neurons: A model to study neuro-
toxicity and neuroprotection. Proc. Soc. Exp. Biol. Med., 222, 157-
163. 
[66]  Cleren, C., Yang, L., Lorenzo, B., Calingasan, N.Y., Schomer, A., 
Sireci, A., Wille, E.J., Beal, M.F. (2008) Therapeutic effects of co-
enzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of 
Parkinsonism. J. Neurochem., 104, 1613-1621. 26    Current Neuropharmacology, 2009, Vol. 7, No. 1 George et al. 
[67]  Cohen, G. (1987) Monoamine oxidase, hydrogen peroxide, and 
Parkinson's disease. Adv. Neurol., 45, 119-125. 
[68]  Cohen, G. (1990) Monoamine oxidase and oxidative stress at do-
paminergic synapses. J. Neural. Transm. Suppl., 32, 229-238. 
[69]  Colosimo, C., Merello, M., Hughes, A.J., Sieradzan, K., Lees, A.J. 
(1996) Motor response to acute dopaminergic challenge with apo-
morphine and levodopa in Parkinson's disease: implications for the 
pathogenesis of the on-off phenomenon. J. Neurol. Neurosurg. Psy-
chiatry, 60, 634-637. 
[70]  Connor, B., Kozlowski, D.A., Unnerstall, J.R., Elsworth, J.D., 
Tillerson, J.L., Schallert, T., Bohn, M.C. (2001) Glial cell line-
derived neurotrophic factor (GDNF) gene delivery protects dopa-
minergic terminals from degeneration. Exp. Neurol., 169, 83-95. 
[71]  Connor, J.R., Menzies, S.L., St Martin, S.M., Mufson, E.J. (1990) 
Cellular distribution of transferrin, ferritin, and iron in normal and 
aged human brains. J. Neurosci. Res., 27, 595-611. 
[72]  Conway, K.A., Harper, J.D., Lansbury, P.T., Jr. (2000) Fibrils 
formed in vitro from alpha-synuclein and two mutant forms linked 
to Parkinson's disease are typical amyloid. Biochemistry, 39, 2552-
2563. 
[73]  Conway, K.A., Rochet, J.C., Bieganski, R.M., Lansbury, P.T., Jr. 
(2001) Kinetic stabilization of the alpha-synuclein protofibril by a 
dopamine-alpha-synuclein adduct. Science, 294, 1346-1349. 
[74]  Cooper, A.A., Gitler, A.D., Cashikar, A., Haynes, C.M., Hill, K.J., 
Bhullar, B., Liu, K., Xu, K., Strathearn, K.E., Liu, F., Cao, S., 
Caldwell, K.A., Caldwell, G.A., Marsischky, G., Kolodner, R.D., 
Labaer, J., Rochet, J.C., Bonini, N.M., Lindquist, S. (2006) Alpha-
synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in 
Parkinson's models. Science, 313, 324-328. 
[75]  Corasaniti, M.T., Strongoli, M.C., Pisanelli, A., Bruno, P., Rotiroti, 
D., Nappi, G., Nistico, G. (1992) Distribution of paraquat into the 
brain after its systemic injection in rats. Funct. Neurol., 7, 51-56. 
[76]  Crompton, D.E., Chinnery, P.F., Fey, C., Curtis, A.R., Morris, 
C.M., Kierstan, J., Burt, A., Young, F., Coulthard, A., Curtis, A., 
Ince, P.G., Bates, D., Jackson, M.J., Burn, J. (2002) Neuroferriti-
nopathy: a window on the role of iron in neurodegeneration. Blood 
Cells Mol. Dis., 29, 522-531. 
[77]  Cubells, J.F., Rayport, S., Rajendran, G., Sulzer, D. (1994) Meth-
amphetamine neurotoxicity involves vacuolation of endocytic or-
ganelles and dopamine-dependent intracellular oxidative stress. J. 
Neurosci., 14, 2260-2271. 
[78]  Cuervo, A.M., Stefanis, L., Fredenburg, R., Lansbury, P.T., Sulzer, 
D. (2004) Impaired degradation of mutant alpha-synuclein by 
chaperone-mediated autophagy. Science, 305, 1292-1295. 
[79]  Dallman, P.R., Spirito, R.A. (1977) Brain iron in the rat: extremely 
slow turnover in normal rats may explain long-lasting effects of 
early iron deficiency. J. Nutr., 107, 1075-1081. 
[80]  Davidson, W.S., Jonas, A., Clayton, D.F., George, J.M. (1998) 
Stabilization of alpha-synuclein secondary structure upon binding 
to synthetic membranes. J. Biol. Chem., 273, 9443-9449. 
[81]  De Bie, R.M., Schuurman, P.R., Esselink, R.A., Bosch, D.A., 
Speelman, J.D. (2002) Bilateral pallidotomy in Parkinson's disease: 
a retrospective study. Mov. Disord., 17, 533-538. 
[82]  de la Fuente-Fernandez, R., Schulzer, M., Stoessl, A.J. (2004) 
Placebo mechanisms and reward circuitry: clues from Parkinson's 
disease. Biol. Psychiatry, 56, 67-71. 
[83]  de Rijk, M.C., Breteler, M.M., den Breeijen, J.H., Launer, L.J., 
Grobbee, D.E., van der Meche, F.G., Hofman, A. (1997) Dietary 
antioxidants and Parkinson disease. The Rotterdam Study. Arch. 
Neurol., 54, 762-765. 
[84]  Deinard, A.S., List, A., Lindgren, B., Hunt, J.V., Chang, P.N. 
(1986) Cognitive deficits in iron-deficient and iron-deficient ane-
mic children. J. Pediatr., 108, 681-689. 
[85]  Deng, H., Le, W., Guo, Y., Hunter, C.B., Xie, W., Huang, M., 
Jankovic, J. (2006) Genetic analysis of LRRK2 mutations in pa-
tients with Parkinson disease. J. Neurol. Sci., 251, 102-106. 
[86]  Deng, J., Lewis, P.A., Greggio, E., Sluch, E., Beilina, A., Cookson, 
M.R. (2008) Structure of the ROC domain from the Parkinson's 
disease-associated leucine-rich repeat kinase 2 reveals a dimeric 
GTPase. Proc. Natl. Acad. Sci. USA, 105, 1499-1504. 
[87]  Desole, M.S., Esposito, G., Migheli, R., Sircana, S., Delogu, M.R., 
Fresu, L., Miele, M., de Natale, G., Miele, E. (1997) Glutathione 
deficiency potentiates manganese toxicity in rat striatum and brain-
stem and in PC12 cells. Pharmacol. Res., 36, 285-292. 
[88]  Desole, M.S., Sciola, L., Delogu, M.R., Sircana, S., Migheli, R., 
Miele, E. (1997) Role of oxidative stress in the manganese and 1-
methyl-4-(2'-ethylphenyl)-1,2,3,6-tetrahydropyridine-induced apop-
tosis in PC12 cells. Neurochem. Int., 31, 169-176. 
[89]  Devasagayam, T.P., Werner, T., Ippendorf, H., Martin, H.D., Sies, 
H. (1992) Synthetic carotenoids, novel polyene polyketones and 
new capsorubin isomers as efficient quenchers of singlet molecular 
oxygen. Photochem. Photobiol., 55, 511-514. 
[90]  Dexter, D.T., Carayon, A., Javoy-Agid, F., Agid, Y., Wells, F.R., 
Daniel, S.E., Lees, A.J., Jenner, P., Marsden, C.D. (1991) Altera-
tions in the levels of iron, ferritin and other trace metals in Parkin-
son's disease and other neurodegenerative diseases affecting the ba-
sal ganglia. Brain, 114 (Pt 4), 1953-1975. 
[91]  Dexter, D.T., Carayon, A., Vidailhet, M., Ruberg, M., Agid, F., 
Agid, Y., Lees, A.J., Wells, F.R., Jenner, P., Marsden, C.D. (1990) 
Decreased ferritin levels in brain in Parkinson's disease. J. Neuro-
chem., 55, 16-20. 
[92]  Dexter, D.T., Wells, F.R., Lees, A.J., Agid, F., Agid, Y., Jenner, P., 
Marsden, C.D. (1989) Increased nigral iron content and alterations 
in other metal ions occurring in brain in Parkinson's disease. J. 
Neurochem., 52, 1830-1836. 
[93]  Dhopesh, V.P., Yagnik, P.M., Weddington, W.W. (1997) Can 
cocaine abuse cause parkinsonism? Am. J. Addict., 6, 177-179. 
[94]  Di Mascio, P., Devasagayam, T.P., Kaiser, S., Sies, H. (1990) 
Carotenoids, tocopherols and thiols as biological singlet molecular 
oxygen quenchers. Biochem. Soc. Trans., 18, 1054-1056. 
[95]  Di Stasi, A.M., Mallozzi, C., Macchia, G., Petrucci, T.C., Minetti, 
M. (1999) Peroxynitrite induces tryosine nitration and modulates 
tyrosine phosphorylation of synaptic proteins. J. Neurochem., 73,
727-735. 
[96]  Dietrich, J.B., Mangeol, A., Revel, M.O., Burgun, C., Aunis, D., 
Zwiller, J. (2005) Acute or repeated cocaine administration gener-
ates reactive oxygen species and induces antioxidant enzyme activ-
ity in dopaminergic rat brain structures. Neuropharmacology, 48,
965-974. 
[97]  Ding, W.Q., Liu, B., Vaught, J.L., Palmiter, R.D., Lind, S.E. (2006) 
Clioquinol and docosahexaenoic acid act synergistically to kill tu-
mor cells. Mol. Cancer Ther., 5, 1864-1872. 
[98]  Ding, W.Q., Liu, B., Vaught, J.L., Yamauchi, H., Lind, S.E. (2005) 
Anticancer activity of the antibiotic clioquinol. Cancer Res., 65,
3389-3395. 
[99]  Ding, Y.M., Jaumotte, J.D., Signore, A.P., Zigmond, M.J. (2004) 
Effects of 6-hydroxydopamine on primary cultures of substantia 
nigra: specific damage to dopamine neurons and the impact of glial 
cell line-derived neurotrophic factor. J. Neurochem., 89, 776-787. 
[100]  Doraiswamy, P.M., Finefrock, A.E. (2004) Metals in our minds: 
therapeutic implications for neurodegenerative disorders. Lancet 
Neurol., 3, 431-434. 
[101]  Dostrovsky, J.O., Levy, R., Wu, J.P., Hutchison, W.D., Tasker, 
R.R., Lozano, A.M. (2000) Microstimulation-induced inhibition of 
neuronal firing in human globus pallidus. J. Neurophysiol., 84,
570-574. 
[102]  Double, K.L. (2006) Functional effects of neuromelanin and syn-
thetic melanin in model systems. J. Neural. Transm., 113, 751-756. 
[103]  Double, K.L., Ben-Shachar, D., Youdim, M.B., Zecca, L., Ried-
erer, P., Gerlach, M. (2002) Influence of neuromelanin on oxidative 
pathways within the human substantia nigra. Neurotoxicol. Tera-
tol., 24, 621-628. 
[104]  Double, K.L., Gerlach, M., Youdim, M.B., Riederer, P. (2000) 
Impaired iron homeostasis in Parkinson's disease. J. Neural. 
Transm. Suppl., 37-58. 
[105]  Du, B., Wu, P., Boldt-Houle, D.M., Terwilliger, E.F. (1996) Effi-
cient transduction of human neurons with an adeno-associated virus 
vector. Gene Ther., 3, 254-261. 
[106]  Dunnett, S.B., Bjorklund, A., Schmidt, R.H., Stenevi, U., Iversen, 
S.D. (1983) Intracerebral grafting of neuronal cell suspensions. V. 
Behavioural recovery in rats with bilateral 6-OHDA lesions follow-
ing implantation of nigral cell suspensions. Acta Physiol. Scand. 
Suppl., 522, 39-47. 
[107]  Emerit, I., Keck, M., Levy, A., Feingold, J., Michelson, A.M. 
(1982) Activated oxygen species at the origin of chromosome 
breakage and sister-chromatid exchanges. Mutat. Res., 103, 165-
172. Targeting the Progression of Parkinson’s Disease  Current Neuropharmacology, 2009, Vol. 7, No. 1    27
[108]  Emson, P.C., Bjorklund, A., Stenevi, U. (1976) Possible regenera-
tion of gamma-aminobutyric acid-containing fibres into irides 
transplanted into the central nervous system. Nature, 259, 567-570. 
[109]  Erola, T., Heikkinen, E.R., Haapaniemi, T., Tuominen, J., Juolas-
maa, A., Myllyla, V.V. (2006) Efficacy of bilateral subthalamic 
nucleus (STN) stimulation in Parkinson's disease. Acta Neurochir. 
(Wien), 148, 389-394. 
[110]  Fahn, S. (2006) A new look at levodopa based on the ELLDOPA 
study. J. Neural. Transm. Suppl., 419-426. 
[111]  Fahn, S., Oakes, D., Shoulson, I., Kieburtz, K., Rudolph, A., Lang, 
A., Olanow, C.W., Tanner, C., Marek, K. (2004) Levodopa and the 
progression of Parkinson's disease. N. Engl. J. Med., 351, 2498-
2508. 
[112]  Faucheux, B.A., Martin, M.E., Beaumont, C., Hunot, S., Hauw, 
J.J., Agid, Y., Hirsch, E.C. (2002) Lack of up-regulation of ferritin 
is associated with sustained iron regulatory protein-1 binding activ-
ity in the substantia nigra of patients with Parkinson's disease. J. 
Neurochem., 83, 320-330. 
[113]  Feigin, A., Kaplitt, M.G., Tang, C., Lin, T., Mattis, P., Dhawan, V., 
During, M.J., Eidelberg, D. (2007) Modulation of metabolic brain 
networks after subthalamic gene therapy for Parkinson's disease. 
Proc. Natl. Acad. Sci. USA, 104, 19559-19564. 
[114]  Finkelstein, D.I., Stanic, D., Parish, C.L., Tomas, D., Dickson, K., 
Horne, M.K. (2000) Axonal sprouting following lesions of the rat 
substantia nigra. Neuroscience, 97, 99-112. 
[115]  Flaten, T.P. (2001) Aluminium as a risk factor in Alzheimer's dis-
ease, with emphasis on drinking water. Brain Res. Bull., 55, 187-
196. 
[116]  Fornai, F., Lenzi, P., Ferrucci, M., Lazzeri, G., di Poggio, A.B., 
Natale, G., Busceti, C.L., Biagioni, F., Giusiani, M., Ruggieri, S., 
Paparelli, A. (2005) Occurrence of neuronal inclusions combined 
with increased nigral expression of alpha-synuclein within dopa-
minergic neurons following treatment with amphetamine deriva-
tives in mice. Brain Res. Bull., 65, 405-413. 
[117]  Fornai, F., Lenzi, P., Gesi, M., Ferrucci, M., Lazzeri, G., Capobi-
anco, L., de Blasi, A., Battaglia, G., Nicoletti, F., Ruggieri, S., Pa-
parelli, A. (2004) Similarities between methamphetamine toxicity 
and proteasome inhibition. Ann. N. Y. Acad. Sci., 1025, 162-170. 
[118]  Fornai, F., Schluter, O.M., Lenzi, P., Gesi, M., Ruffoli, R., Fer-
rucci, M., Lazzeri, G., Busceti, C.L., Pontarelli, F., Battaglia, G., 
Pellegrini, A., Nicoletti, F., Ruggieri, S., Paparelli, A., Sudhof, T.C. 
(2005) Parkinson-like syndrome induced by continuous MPTP in-
fusion: convergent roles of the ubiquitin-proteasome system and 
alpha-synuclein. Proc. Natl. Acad. Sci. USA, 102, 3413-3418. 
[119]  Fornstedt, B. (1990) Role of catechol autooxidation in the degen-
eration of dopamine neurons. Acta Neurol. Scand. Suppl., 129, 12-
14. 
[120]  Forsmark-Andree, P., Lee, C.P., Dallner, G., Ernster, L. (1997) 
Lipid peroxidation and changes in the ubiquinone content and the 
respiratory chain enzymes of submitochondrial particles. Free 
Radic. Biol. Med., 22, 391-400. 
[121]  Fortin, D.L., Nemani, V.M., Voglmaier, S.M., Anthony, M.D., 
Ryan, T.A., Edwards, R.H. (2005) Neural activity controls the syn-
aptic accumulation of alpha-synuclein. J. Neurosci., 25, 10913-
10921. 
[122]  Fortin, D.L., Troyer, M.D., Nakamura, K., Kubo, S., Anthony, 
M.D., Edwards, R.H. (2004) Lipid rafts mediate the synaptic local-
ization of alpha-synuclein. J. Neurosci., 24, 6715-6723. 
[123]  Fountaine, T.M., Wade-Martins, R. (2007) RNA interference-
mediated knockdown of alpha-synuclein protects human dopa-
minergic neuroblastoma cells from MPP(+) toxicity and reduces 
dopamine transport. J. Neurosci. Res., 85, 351-363. 
[124]  Fredriksson, A., Archer, T. (2007) Postnatal iron overload destroys 
NA-DA functional interactions. J. Neural. Transm., 114, 195-203. 
[125]  Fredriksson, A., Schroder, N., Eriksson, P., Izquierdo, I., Archer, T. 
(2001) Neonatal iron potentiates adult MPTP-induced neurodegen-
erative and functional deficits. Parkinsonism Relat. Disord., 7, 97-
105. 
[126]  Freed, C.R., Greene, P.E., Breeze, R.E., Tsai, W.Y., DuMouchel, 
W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J.Q., 
Eidelberg, D., Fahn, S. (2001) Transplantation of embryonic do-
pamine neurons for severe Parkinson's disease. N. Engl. J. Med.,
344, 710-719. 
[127]  Freed, C.R., Leehey, M.A., Zawada, M., Bjugstad, K., Thompson, 
L., Breeze, R.E. (2003) Do patients with Parkinson's disease benefit 
from embryonic dopamine cell transplantation? J. Neurol.,
250(Suppl 3), III44-46. 
[128]  Freed, W.J. (2004) A perspective on transplantation therapy and 
stem cells for Parkinson's disease. Cell Transplant., 13, 319-327. 
[129]  Friedlich, A.L., Tanzi, R.E., Rogers, J.T. (2007) The 5'-untrans-
lated region of Parkinson's disease alpha-synuclein messengerRNA 
contains a predicted iron responsive element. Mol. Psychiatry, 12,
222-223. 
[130]  Fujimura, M., Morita-Fujimura, Y., Kawase, M., Copin, J.C., Ca-
lagui, B., Epstein, C.J., Chan, P.H. (1999) Manganese superoxide 
dismutase mediates the early release of mitochondrial cytochrome 
C and subsequent DNA fragmentation after permanent focal cere-
bral ischemia in mice. J. Neurosci., 19, 3414-3422. 
[131]  Fulceri, F., Biagioni, F., Lenzi, P., Falleni, A., Gesi, M., Ruggieri, 
S., Fornai, F. (2006) Nigrostriatal damage with 6-OHDA: valida-
tion of routinely applied procedures. Ann. N. Y. Acad. Sci., 1074,
344-348. 
[132]  Fung, H.C., Scholz, S., Matarin, M., Simon-Sanchez, J., Hernan-
dez, D., Britton, A., Gibbs, J.R., Langefeld, C., Stiegert, M.L., 
Schymick, J., Okun, M.S., Mandel, R.J., Fernandez, H.H., Foote, 
K.D., Rodriguez, R.L., Peckham, E., De Vrieze, F.W., Gwinn-
Hardy, K., Hardy, J.A., Singleton, A. (2006) Genome-wide geno-
typing in Parkinson's disease and neurologically normal controls: 
first stage analysis and public release of data. Lancet Neurol., 5,
911-916. 
[133]  Gage, F.H., Bjorklund, A., Stenevi, U., Dunnett, S.B. (1983) In-
tracerebral grafting of neuronal cell suspensions. VIII. Survival and 
growth of implants of nigral and septal cell suspensions in intact 
brains of aged rats. Acta Physiol. Scand. Suppl., 522, 67-75. 
[134]  Gal, S., Fridkin, M., Amit, T., Zheng, H., Youdim, M.B. (2006) 
M30, a novel multifunctional neuroprotective drug with potent iron 
chelating and brain selective monoamine oxidase-ab inhibitory ac-
tivity for Parkinson's disease. J. Neural. Transm. Suppl., 447-456. 
[135]  Gal, S., Zheng, H., Fridkin, M., Youdim, M.B. (2005) Novel multi-
functional neuroprotective iron chelator-monoamine oxidase in-
hibitor drugs for neurodegenerative diseases. In vivo selective brain 
monoamine oxidase inhibition and prevention of MPTP-induced 
striatal dopamine depletion. J. Neurochem., 95, 79-88. 
[136]  Gao, X., Chen, H., Fung, T.T., Logroscino, G., Schwarzschild, 
M.A., Hu, F.B., Ascherio, A. (2007) Prospective study of dietary 
pattern and risk of Parkinson disease. Am. J. Clin. Nutr., 86, 1486-
1494. 
[137]  Garruto, R.M., Fukatsu, R., Yanagihara, R., Gajdusek, D.C., Hook, 
G., Fiori, C.E. (1984) Imaging of calcium and aluminum in neu-
rofibrillary tangle-bearing neurons in parkinsonism-dementia of 
Guam. Proc. Natl. Acad. Sci. USA, 81, 1875-1879. 
[138]  Gauthier, E., Fortier, I., Courchesne, F., Pepin, P., Mortimer, J., 
Gauvreau, D. (2000) Aluminum forms in drinking water and risk of 
Alzheimer's disease. Environ. Res., 84, 234-246. 
[139]  Giasson, B.I., Duda, J.E., Murray, I.V., Chen, Q., Souza, J.M., 
Hurtig, H.I., Ischiropoulos, H., Trojanowski, J.Q., Lee, V.M. 
(2000) Oxidative damage linked to neurodegeneration by selective 
alpha-synuclein nitration in synucleinopathy lesions. Science, 290,
985-989. 
[140]  Gil, B., Sanz, M.J., Terencio, M.C., Ferrandiz, M.L., Bustos, G., 
Paya, M., Gunasegaran, R., Alcaraz, M.J. (1994) Effects of flavon-
oids on Naja naja and human recombinant synovial phospholipases 
A2 and inflammatory responses in mice. Life Sci., 54, PL333-338. 
[141]  Gill, S.S., Patel, N.K., Hotton, G.R., O'Sullivan, K., McCarter, R., 
Bunnage, M., Brooks, D.J., Svendsen, C.N., Heywood, P. (2003) 
Direct brain infusion of glial cell line-derived neurotrophic factor 
in Parkinson disease. Nat. Med., 9, 589-595. 
[142]  Giulivi, C., Davies, K.J. (1993) Dityrosine and tyrosine oxidation 
products are endogenous markers for the selective proteolysis of 
oxidatively modified red blood cell hemoglobin by (the 19 S) pro-
teasome. J. Biol. Chem., 268, 8752-8759. 
[143]  Goedert, M. (1997) Familial Parkinson's disease. The awakening of 
alpha-synuclein. Nature, 388, 232-233. 
[144]  Golbe, L.I., Farrell, T.M., Davis, P.H. (1988) Case-control study of 
early life dietary factors in Parkinson's disease. Arch. Neurol., 45,
1350-1353. 
[145]  Goldberg, M.S., Fleming, S.M., Palacino, J.J., Cepeda, C., Lam, 
H.A., Bhatnagar, A., Meloni, E.G., Wu, N., Ackerson, L.C., Klap-
stein, G.J., Gajendiran, M., Roth, B.L., Chesselet, M.F., Maidment, 
N.T., Levine, M.S., Shen, J. (2003) Parkin-deficient mice exhibit 28    Current Neuropharmacology, 2009, Vol. 7, No. 1 George et al. 
nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. 
Chem., 278, 43628-43635. 
[146]  Goldstein, L.E., Leopold, M.C., Huang, X., Atwood, C.S., Saun-
ders, A.J., Hartshorn, M., Lim, J.T., Faget, K.Y., Muffat, J.A., 
Scarpa, R.C., Chylack, L.T., Jr., Bowden, E.F., Tanzi, R.E., Bush, 
A.I. (2000) 3-Hydroxykynurenine and 3-hydroxyanthranilic acid 
generate hydrogen peroxide and promote alpha-crystallin cross-
linking by metal ion reduction. Biochemistry, 39, 7266-7275. 
[147]  Golub, M.S., Germann, S.L., Araiza, R.S., Reader, J.R., Griffey, 
S.M., Lloyd, K.C. (2005) Movement disorders in the Hfe knockout 
mouse. Nutr. Neurosci., 8, 239-244. 
[148]  Golub, M.S., Hogrefe, C.E., Germann, S.L. (2007) Iron deprivation 
during fetal development changes the behavior of juvenile rhesus 
monkeys. J. Nutr., 137, 979-984. 
[149]  Gomez-Vargas, M., Nishibayashi-Asanuma, S., Asanuma, M., 
Kondo, Y., Iwata, E., Ogawa, N. (1998) Pergolide scavenges both 
hydroxyl and nitric oxide free radicals in vitro and inhibits lipid 
peroxidation in different regions of the rat brain. Brain Res., 790,
202-208. 
[150]  Gong, L., Daigneault, E.A., Acuff, R.V., Kostrzewa, R.M. (1991) 
Vitamin E supplements fail to protect mice from acute MPTP neu-
rotoxicity. Neuroreport, 2, 544-546. 
[151]  Good, P.F., Olanow, C.W., Perl, D.P. (1992) Neuromelanin-
containing neurons of the substantia nigra accumulate iron and 
aluminum in Parkinson's disease: a LAMMA study. Brain Res.,
593, 343-346. 
[152] Goodwill, K.E., Sabatier, C., Marks, C., Raag, R., Fitzpatrick, P.F., 
Stevens, R.C. (1997) Crystal structure of tyrosine hydroxylase at 
2.3 A and its implications for inherited neurodegenerative diseases. 
Nat. Struct. Biol., 4, 578-585. 
[153] Goodwill, K.E., Sabatier, C., Stevens, R.C. (1998) Crystal structure 
of tyrosine hydroxylase with bound cofactor analogue and iron at 
2.3 A resolution: self-hydroxylation of Phe300 and the pterin-
binding site. Biochemistry, 37, 13437-13445. 
[154]  Gotz, M.E., Double, K., Gerlach, M., Youdim, M.B., Riederer, P. 
(2004) The relevance of iron in the pathogenesis of Parkinson's dis-
ease. Ann. N. Y. Acad. Sci., 1012, 193-208. 
[155]  Graves, A.B., Rosner, D., Echeverria, D., Mortimer, J.A., Larson, 
E.B. (1998) Occupational exposures to solvents and aluminium and 
estimated risk of Alzheimer's disease. Occup. Environ. Med., 55,
627-633. 
[156]  Greenbaum, E.A., Graves, C.L., Mishizen-Eberz, A.J., Lupoli, 
M.A., Lynch, D.R., Englander, S.W., Axelsen, P.H., Giasson, B.I. 
(2005) The E46K mutation in alpha-synuclein increases amyloid 
fibril formation. J. Biol. Chem., 280, 7800-7807. 
[157]  Griffiths, P.D., Dobson, B.R., Jones, G.R., Clarke, D.T. (1999) Iron 
in the basal ganglia in Parkinson's disease. An in vitro study using 
extended X-ray absorption fine structure and cryo-electron micros-
copy. Brain, 122 ( Pt 4), 667-673. 
[158]  Grundemann, J., Schlaudraff, F., Haeckel, O., Liss, B. (2008) Ele-
vated alpha-synuclein mRNA levels in individual UV-laser-
microdissected dopaminergic substantia nigra neurons in idiopathic 
Parkinson's disease. Nucleic Acids Res., 36, e38. 
[159]  Gutteridge, J.M., Quinlan, G.J., Clark, I., Halliwell, B. (1985) 
Aluminium salts accelerate peroxidation of membrane lipids stimu-
lated by iron salts. Biochim. Biophys. Acta, 835, 441-447. 
[160]  Haberler, C., Alesch, F., Mazal, P.R., Pilz, P., Jellinger, K., Pinter, 
M.M., Hainfellner, J.A., Budka, H. (2000) No tissue damage by 
chronic deep brain stimulation in Parkinson's disease. Ann. Neurol.,
48, 372-376. 
[161]  Hachinski, V. (1998) Aluminum exposure and risk of Alzheimer 
disease. Arch. Neurol., 55, 742. 
[162]  Hallett, M., Litvan, I. (1999) Evaluation of surgery for Parkinson's 
disease: a report of the Therapeutics and Technology Assessment 
Subcommittee of the American Academy of Neurology. The Task 
Force on Surgery for Parkinson's Disease. Neurology, 53, 1910-
1921. 
[163]  Hallett, M., Litvan, I. (2000) Scientific position paper of the 
Movement Disorder Society evaluation of surgery for Parkinson's 
disease. Task Force on Surgery for Parkinson's Disease of the 
American Academy of Neurology Therapeutic and Technology As-
sessment Committee. Mov. Disord., 15, 436-438. 
[164]  Halliwell, B. (2006) Oxidative stress and neurodegeneration: where 
are we now? J. Neurochem., 97, 1634-1658. 
[165]  Hanasaki, Y., Ogawa, S., Fukui, S. (1994) The correlation between 
active oxygens scavenging and antioxidative effects of flavonoids. 
Free Radic. Biol. Med., 16, 845-850. 
[166]  Hanrott, K., Gudmunsen, L., O'Neill, M.J., Wonnacott, S. (2006) 6-
hydroxydopamine-induced apoptosis is mediated via extracellular 
auto-oxidation and caspase 3-dependent activation of protein 
kinase Cdelta. J. Biol. Chem., 281, 5373-5382. 
[167]  Hansen, T.M., Nielsen, H., Bernth, N., Moos, T. (1999) Expression 
of ferritin protein and subunit mRNAs in normal and iron deficient 
rat brain. Brain Res. Mol. Brain Res., 65, 186-197. 
[168]  Hatano, Y., Li, Y., Sato, K., Asakawa, S., Yamamura, Y., Tomi-
yama, H., Yoshino, H., Asahina, M., Kobayashi, S., Hassin-Baer, 
S., Lu, C.S., Ng, A.R., Rosales, R.L., Shimizu, N., Toda, T., Mi-
zuno, Y., Hattori, N. (2004) Novel PINK1 mutations in early-onset 
parkinsonism. Ann. Neurol., 56, 424-427. 
[169]  Hattori, N., Kitada, T., Matsumine, H., Asakawa, S., Yamamura, 
Y., Yoshino, H., Kobayashi, T., Yokochi, M., Wang, M., Yoritaka, 
A., Kondo, T., Kuzuhara, S., Nakamura, S., Shimizu, N., Mizuno, 
Y. (1998) Molecular genetic analysis of a novel Parkin gene in 
Japanese families with autosomal recessive juvenile parkinsonism: 
evidence for variable homozygous deletions in the Parkin gene in 
affected individuals. Ann. Neurol., 44, 935-941. 
[170]  Hayashi, S., Wakabayashi, K., Ishikawa, A., Nagai, H., Saito, M., 
Maruyama, M., Takahashi, T., Ozawa, T., Tsuji, S., Takahashi, H. 
(2000) An autopsy case of autosomal-recessive juvenile parkin-
sonism with a homozygous exon 4 deletion in the parkin gene. 
Mov. Disord., 15, 884-888. 
[171]  Hayashita-Kinoh, H., Yamada, M., Yokota, T., Mizuno, Y., Mo-
chizuki, H. (2006) Down-regulation of alpha-synuclein expression 
can rescue dopaminergic cells from cell death in the substantia ni-
gra of Parkinson's disease rat model. Biochem. Biophys. Res. Com-
mun., 341, 1088-1095. 
[172]  Hellenbrand, W., Boeing, H., Robra, B.P., Seidler, A., Vieregge, 
P., Nischan, P., Joerg, J., Oertel, W.H., Schneider, E., Ulm, G. 
(1996) Diet and Parkinson's disease. II: A possible role for the past 
intake of specific nutrients. Results from a self-administered food-
frequency questionnaire in a case-control study. Neurology, 47,
644-650. 
[173]  Hellenbrand, W., Seidler, A., Boeing, H., Robra, B.P., Vieregge, 
P., Nischan, P., Joerg, J., Oertel, W.H., Schneider, E., Ulm, G. 
(1996) Diet and Parkinson's disease. I: A possible role for the past 
intake of specific foods and food groups. Results from a self-
administered food-frequency questionnaire in a case-control study. 
Neurology, 47, 636-643. 
[174]  Henderson, J., Doherty, K., Allbutt, H., Billing, R. (2006) Effects 
of pallidotomy on motor symptoms in an animal model of Parkin-
son's disease. Behav. Brain Res., 169, 29-38. 
[175]  Henderson, J.M., Carpenter, K., Cartwright, H., Halliday, G.M. 
(2000) Degeneration of the centre median-parafascicular complex 
in Parkinson's disease. Ann. Neurol., 47, 345-352. 
[176]  Henderson, J.M., Stanic, D., Tomas, D., Patch, J., Horne, M.K., 
Bourke, D., Finkelstein, D.I. (2005) Postural changes after lesions 
of the substantia nigra pars reticulata in hemiparkinsonian mon-
keys. Behav. Brain Res., 160, 267-276. 
[177]  Hermida-Ameijeiras, A., Mendez-Alvarez, E., Sanchez-Iglesias, S., 
Sanmartin-Suarez, C., Soto-Otero, R. (2004) Autoxidation and 
MAO-mediated metabolism of dopamine as a potential cause of 
oxidative stress: role of ferrous and ferric ions. Neurochem. Int.,
45, 103-116. 
[178]  Hershko, C., Avramovici-Grisaru, S., Link, G., Gelfand, L., Sarel, 
S. (1981) Mechanism of in vivo iron chelation by pyridoxal isoni-
cotinoyl hydrazone and other imino derivatives of pyridoxal. J. 
Lab. Clin. Med., 98, 99-108. 
[179]  Hilker, R., Portman, A.T., Voges, J., Staal, M.J., Burghaus, L., van 
Laar, T., Koulousakis, A., Maguire, R.P., Pruim, J., de Jong, B.M., 
Herholz, K., Sturm, V., Heiss, W.D., Leenders, K.L. (2005) Dis-
ease progression continues in patients with advanced Parkinson's 
disease and effective subthalamic nucleus stimulation. J. Neurol. 
Neurosurg. Psychiatry, 76, 1217-1221. 
[180]  Hirsch, E.C., Brandel, J.P., Galle, P., Javoy-Agid, F., Agid, Y. 
(1991) Iron and aluminum increase in the substantia nigra of pa-
tients with Parkinson's disease: an X-ray microanalysis. J. Neuro-
chem., 56, 446-451. Targeting the Progression of Parkinson’s Disease  Current Neuropharmacology, 2009, Vol. 7, No. 1    29
[181]  Hod, Y., Pentyala, S.N., Whyard, T.C., El-Maghrabi, M.R. (1999) 
Identification and characterization of a novel protein that regulates 
RNA-protein interaction. J. Cell Biochem., 72, 435-444. 
[182]  Hoglinger, G.U., Feger, J., Prigent, A., Michel, P.P., Parain, K., 
Champy, P., Ruberg, M., Oertel, W.H., Hirsch, E.C. (2003) 
Chronic systemic complex I inhibition induces a hypokinetic multi-
system degeneration in rats. J. Neurochem., 84, 491-502. 
[183]  Holford, N.H., Chan, P.L., Nutt, J.G., Kieburtz, K., Shoulson, I. 
(2006) Disease progression and pharmacodynamics in Parkinson 
disease - evidence for functional protection with levodopa and 
other treatments. J. Pharmacokinet. Pharmacodyn., 33, 281-311. 
[184]  Hornykiewicz, O., Kish, S.J. (1987) Biochemical pathophysiology 
of Parkinson's disease. Adv. Neurol., 45, 19-34. 
[185]  Horstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, 
A., Kanovsky, P., Larsen, J.P., Lees, A., Oertel, W., Poewe, W., 
Rascol, O., Sampaio, C. (2006) Review of the therapeutic man-
agement of Parkinson's disease. Report of a joint task force of the 
European Federation of Neurological Societies (EFNS) and the 
Movement Disorder Society-European Section (MDS-ES). Part II: 
late (complicated) Parkinson's disease. Eur. J. Neurol., 13, 1186-
1202. 
[186]  Horstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, 
A., Kanovsky, P., Larsen, J.P., Lees, A., Oertel, W., Poewe, W., 
Rascol, O., Sampaio, C. (2006) Review of the therapeutic man-
agement of Parkinson's disease. Report of a joint task force of the 
European Federation of Neurological Societies and the Movement 
Disorder Society-European Section. Part I: early (uncomplicated) 
Parkinson's disease. Eur. J. Neurol., 13, 1170-1185. 
[187]  Huang, C.C., Chu, N.S., Lu, C.S., Chen, R.S., Calne, D.B. (1998) 
Long-term progression in chronic manganism: ten years of follow-
up. Neurology, 50, 698-700. 
[188]  Huang, C.C., Chu, N.S., Lu, C.S., Chen, R.S., Schulzer, M., Calne, 
D.B. (2007) The natural history of neurological manganism over 18 
years. Parkinsonism Relat. Disord., 13, 143-145. 
[189]  Huang, C.C., Lu, C.S., Chu, N.S., Hochberg, F., Lilienfeld, D., 
Olanow, W., Calne, D.B. (1993) Progression after chronic manga-
nese exposure. Neurology, 43, 1479-1483. 
[190]  Hulet, S.W., Heyliger, S.O., Powers, S., Connor, J.R. (2000) Oli-
godendrocyte progenitor cells internalize ferritin via clathrin-
dependent receptor mediated endocytosis. J. Neurosci. Res., 61, 52-
60. 
[191]  Hutchinson, M., Gurney, S., Newson, R. (2007) GDNF in Parkin-
son disease: an object lesson in the tyranny of type II. J. Neurosci. 
Methods, 163, 190-192. 
[192]  Hyun, D.H., Lee, M., Halliwell, B., Jenner, P. (2005) Effect of 
overexpression of wild-type or mutant parkin on the cellular re-
sponse induced by toxic insults. J. Neurosci. Res., 82, 232-244. 
[193]  Iacovelli, L., Fulceri, F., De Blasi, A., Nicoletti, F., Ruggieri, S., 
Fornai, F. (2006) The neurotoxicity of amphetamines: bridging 
drugs of abuse and neurodegenerative disorders. Exp. Neurol., 201,
24-31. 
[194]  Iancu, R., Mohapel, P., Brundin, P., Paul, G. (2005) Behavioral 
characterization of a unilateral 6-OHDA-lesion model of Parkin-
son's disease in mice. Behav. Brain Res., 162, 1-10. 
[195]  Ibanez, P., Bonnet, A.M., Debarges, B., Lohmann, E., Tison, F., 
Pollak, P., Agid, Y., Durr, A., Brice, A. (2004) Causal relation be-
tween alpha-synuclein gene duplication and familial Parkinson's 
disease. Lancet, 364, 1169-1171. 
[196]  Inden, M., Taira, T., Kitamura, Y., Yanagida, T., Tsuchiya, D., 
Takata, K., Yanagisawa, D., Nishimura, K., Taniguchi, T., Kiso, 
Y., Yoshimoto, K., Agatsuma, T., Koide-Yoshida, S., Iguchi-Ariga, 
S.M., Shimohama, S., Ariga, H. (2006) PARK7 DJ-1 protects 
against degeneration of nigral dopaminergic neurons in Parkinson's 
disease rat model. Neurobiol. Dis., 24, 144-158. 
[197]  Irizarry, M.C., Growdon, W., Gomez-Isla, T., Newell, K., George, 
J.M., Clayton, D.F., Hyman, B.T. (1998) Nigral and cortical Lewy 
bodies and dystrophic nigral neurites in Parkinson's disease and 
cortical Lewy body disease contain alpha-synuclein immunoreac-
tivity. J. Neuropathol. Exp. Neurol., 57, 334-337. 
[198]  Jakes, R., Spillantini, M.G., Goedert, M. (1994) Identification of 
two distinct synucleins from human brain. FEBS Lett., 345, 27-32. 
[199]  Jakowec, M.W., Petzinger, G.M. (2004) 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, 
with emphasis on mice and nonhuman primates. Comp. Med., 54,
497-513. 
[200]  Jenner, P., Olanow, C.W. (2006) The pathogenesis of cell death in 
Parkinson's disease. Neurology, 66, S24-36. 
[201]  Johnson, C.C., Gorell, J.M., Rybicki, B.A., Sanders, K., Peterson, 
E.L. (1999) Adult nutrient intake as a risk factor for Parkinson's 
disease. Int. J. Epidemiol., 28, 1102-1109. 
[202]  Jonsson, G., Sachs, C. (1975) Actions of 6-hydroxydopamine qui-
nones on catecholamine neurons. J. Neurochem., 25, 509-516. 
[203]  Junn, E., Mouradian, M.M. (2002) Human alpha-synuclein over-
expression increases intracellular reactive oxygen species levels 
and susceptibility to dopamine. Neurosci. Lett., 320, 146-150. 
[204]  Kahle, P.J., Neumann, M., Ozmen, L., Muller, V., Odoy, S., Oka-
moto, N., Jacobsen, H., Iwatsubo, T., Trojanowski, J.Q., Takahashi, 
H., Wakabayashi, K., Bogdanovic, N., Riederer, P., Kretzschmar, 
H.A., Haass, C. (2001) Selective insolubility of alpha-synuclein in 
human Lewy body diseases is recapitulated in a transgenic mouse 
model. Am. J. Pathol., 159, 2215-2225. 
[205]  Kaur, D., Peng, J., Chinta, S.J., Rajagopalan, S., Di Monte, D.A., 
Cherny, R.A., Andersen, J.K. (2006) Increased murine neonatal 
iron intake results in Parkinson-like neurodegeneration with age. 
Neurobiol. Aging, 28(6), 907-913. 
[206]  Kaur, D., Rajagopalan, S., Chinta, S., Kumar, J., Di Monte, D., 
Cherny, R.A., Andersen, J.K. (2007) Chronic ferritin expression 
within murine dopaminergic midbrain neurons results in a progres-
sive age-related neurodegeneration. Brain Res., 1140, 188-194. 
[207]  Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J.Q., Boon-
plueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M.F., Di-
Monte, D., Volitaskis, I., Ellerby, L., Cherny, R.A., Bush, A.I., 
Andersen, J.K. (2003) Genetic or pharmacological iron chelation 
prevents MPTP-induced neurotoxicity in vivo: a novel therapy for 
Parkinson's disease. Neuron, 37, 899-909. 
[208]  Keller, J.N., Hanni, K.B., Markesbery, W.R. (2000) Impaired pro-
teasome function in Alzheimer's disease. J. Neurochem., 75, 436-
439. 
[209]  Keyer, K., Imlay, J.A. (1996) Superoxide accelerates DNA damage 
by elevating free-iron levels. Proc. Natl. Acad. Sci. USA, 93,
13635-13640. 
[210]  Keyer, K., Imlay, J.A. (1997) Inactivation of dehydratase [4Fe-4S] 
clusters and disruption of iron homeostasis upon cell exposure to 
peroxynitrite. J. Biol. Chem., 272, 27652-27659. 
[211]  Kihira, T., Yoshida, S., Yase, Y., Ono, S., Kondo, T. (2002) 
Chronic low-Ca/Mg high-Al diet induces neuronal loss. Neuropa-
thology, 22, 171-179. 
[212]  Kikinis, Z., Eisenstein, R.S., Bettany, A.J., Munro, H.N. (1995) 
Role of RNA secondary structure of the iron-responsive element in 
translational regulation of ferritin synthesis. Nucleic Acids Res., 23,
4190-4195. 
[213]  Kim, R.H., Smith, P.D., Aleyasin, H., Hayley, S., Mount, M.P., 
Pownall, S., Wakeham, A., You-Ten, A.J., Kalia, S.K., Horne, P., 
Westaway, D., Lozano, A.M., Anisman, H., Park, D.S., Mak, T.W. 
(2005) Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. 
Proc. Natl. Acad. Sci. USA, 102, 5215-5220. 
[214]  Kish, S.J., Shannak, K., Hornykiewicz, O. (1988) Uneven pattern 
of dopamine loss in the striatum of patients with idiopathic Parkin-
son's disease. Pathophysiologic and clinical implications. N. Engl. 
J. Med., 318, 876-880. 
[215]  Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, 
Y., Minoshima, S., Yokochi, M., Mizuno, Y., Shimizu, N. (1998) 
Mutations in the parkin gene cause autosomal recessive juvenile 
parkinsonism. Nature, 392, 605-608. 
[216]  Klatzo, I., Wisniewski, H., Streicher, E. (1965) Experimental pro-
duction of neurofibrillary degeneration. I. Light microscopic obser-
vations. J. Neuropathol. Exp. Neurol., 24, 187-199. 
[217]  Kleiner-Fisman, G., Fisman, D.N., Sime, E., Saint-Cyr, J.A., Lo-
zano, A.M., Lang, A.E. (2003) Long-term follow up of bilateral 
deep brain stimulation of the subthalamic nucleus in patients with 
advanced Parkinson disease. J. Neurosurg., 99, 489-495. 
[218]  Klivenyi, P., Andreassen, O.A., Ferrante, R.J., Dedeoglu, A., Muel-
ler, G., Lancelot, E., Bogdanov, M., Andersen, J.K., Jiang, D., 
Beal, M.F. (2000) Mice deficient in cellular glutathione peroxidase 
show increased vulnerability to malonate, 3-nitropropionic acid, 
and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. J. Neurosci., 20,
1-7. 
[219]  Koeppen, A.H. (1995) The history of iron in the brain. J. Neurol. 
Sci., 134(Suppl), 1-9. 30    Current Neuropharmacology, 2009, Vol. 7, No. 1 George et al. 
[220]  Kogan, F.J., Nichols, W.K., Gibb, J.W. (1976) Influence of meth-
amphetamine on nigral and striatal tyrosine hydroxylase activity 
and on striatal dopamine levels. Eur. J. Pharmacol., 36, 363-371. 
[221]  Kondo, T., Ito, T., Sugita, Y. (1994) Bromocriptine scavenges 
methamphetamine-induced hydroxyl radicals and attenuates dopa-
mine depletion in mouse striatum. Ann. N. Y. Acad. Sci., 738, 222-
229. 
[222]  Kordower, J.H., Emborg, M.E., Bloch, J., Ma, S.Y., Chu, Y., Lev-
enthal, L., McBride, J., Chen, E.Y., Palfi, S., Roitberg, B.Z., 
Brown, W.D., Holden, J.E., Pyzalski, R., Taylor, M.D., Carvey, P., 
Ling, Z., Trono, D., Hantraye, P., Deglon, N., Aebischer, P. (2000) 
Neurodegeneration prevented by lentiviral vector delivery of 
GDNF in primate models of Parkinson's disease. Science, 290, 767-
773. 
[223]  Kordower, J.H., Palfi, S., Chen, E.Y., Ma, S.Y., Sendera, T., Coch-
ran, E.J., Mufson, E.J., Penn, R., Goetz, C.G., Comella, C.D. 
(1999) Clinicopathological findings following intraventricular 
glial-derived neurotrophic factor treatment in a patient with Parkin-
son's disease. Ann. Neurol., 46, 419-424. 
[224]  Kowall, N.W., Pendlebury, W.W., Kessler, J.B., Perl, D.P., Beal, 
M.F. (1989) Aluminum-induced neurofibrillary degeneration af-
fects a subset of neurons in rabbit cerebral cortex, basal forebrain 
and upper brainstem. Neuroscience, 29, 329-337. 
[225]  Kozlowski, D.A., Connor, B., Tillerson, J.L., Schallert, T., Bohn, 
M.C. (2000) Delivery of a GDNF gene into the substantia nigra af-
ter a progressive 6-OHDA lesion maintains functional nigrostriatal 
connections. Exp. Neurol., 166, 1-15. 
[226]  Krack, P., Batir, A., Van Blercom, N., Chabardes, S., Fraix, V., 
Ardouin, C., Koudsie, A., Limousin, P.D., Benazzouz, A., LeBas, 
J.F., Benabid, A.L., Pollak, P. (2003) Five-year follow-up of bilat-
eral stimulation of the subthalamic nucleus in advanced Parkinson's 
disease. N. Engl. J. Med., 349, 1925-1934. 
[227]  Kruger, R., Kuhn, W., Leenders, K.L., Sprengelmeyer, R., Muller, 
T., Woitalla, D., Portman, A.T., Maguire, R.P., Veenma, L., 
Schroder, U., Schols, L., Epplen, J.T., Riess, O., Przuntek, H. 
(2001) Familial parkinsonism with synuclein pathology: clinical 
and PET studies of A30P mutation carriers. Neurology, 56, 1355-
1362. 
[228]  Kubo, S., Nemani, V.M., Chalkley, R.J., Anthony, M.D., Hattori, 
N., Mizuno, Y., Edwards, R.H., Fortin, D.L. (2005) A combinato-
rial code for the interaction of alpha-synuclein with membranes. J. 
Biol. Chem., 280, 31664-31672. 
[229]  Kurlan, R. (2005) "Levodopa phobia": a new iatrogenic cause of 
disability in Parkinson disease. Neurology, 64, 923-924. 
[230]  Kuroda, Y., Mitsui, T., Kunishige, M., Matsumoto, T. (2006) 
Parkin affects mitochondrial function and apoptosis in neuronal and 
myogenic cells. Biochem. Biophys. Res. Commun., 348, 787-793. 
[231]  Kuroda, Y., Mitsui, T., Kunishige, M., Shono, M., Akaike, M., 
Azuma, H., Matsumoto, T. (2006) Parkin enhances mitochondrial 
biogenesis in proliferating cells. Hum. Mol. Genet., 15, 883-895. 
[232]  Lang, A.E., Gill, S., Patel, N.K., Lozano, A., Nutt, J.G., Penn, R., 
Brooks, D.J., Hotton, G., Moro, E., Heywood, P., Brodsky, M.A., 
Burchiel, K., Kelly, P., Dalvi, A., Scott, B., Stacy, M., Turner, D., 
Wooten, V.G., Elias, W.J., Laws, E.R., Dhawan, V., Stoessl, A.J., 
Matcham, J., Coffey, R.J., Traub, M. (2006) Randomized con-
trolled trial of intraputamenal glial cell line-derived neurotrophic 
factor infusion in Parkinson disease. Ann. Neurol., 59, 459-466. 
[233]  Langston, J.W., Ballard, P., Tetrud, J.W., Irwin, I. (1983) Chronic 
Parkinsonism in humans due to a product of meperidine-analog 
synthesis. Science, 219, 979-980. 
[234]  Langston, J.W., Ballard, P.A., Jr. (1983) Parkinson's disease in a 
chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropy-
ridine. N. Engl. J. Med., 309, 310. 
[235]  Lavara-Culebras, E., Paricio, N. (2007) Drosophila DJ-1 mutants 
are sensitive to oxidative stress and show reduced lifespan and mo-
tor deficits. Gene, 400, 158-165. 
[236]  LaVaute, T., Smith, S., Cooperman, S., Iwai, K., Land, W., Mey-
ron-Holtz, E., Drake, S.K., Miller, G., Abu-Asab, M., Tsokos, M., 
Switzer, R., 3rd, Grinberg, A., Love, P., Tresser, N., Rouault, T.A. 
(2001) Targeted deletion of the gene encoding iron regulatory pro-
tein-2 causes misregulation of iron metabolism and neurodegenera-
tive disease in mice. Nat. Genet, 27, 209-214. 
[237]  Lee, C.S., Park, W.J., Ko, H.H., Han, E.S. (2006) Differential 
involvement of mitochondrial permeability transition in cytotoxic-
ity of 1-methyl-4-phenylpyridinium and 6-hydroxydopamine. Mol. 
Cell Biochem., 289, 193-200. 
[238]  Lee, J., Zhu, W.M., Stanic, D., Finkelstein, D.I., Horne, M.H., 
Henderson, J., Lawrence, A.J., O'Connor, L., Tomas, D., Drago, J., 
Horne, M.K. (2008) Sprouting of dopamine terminals and altered 
dopamine release and uptake in Parkinsonian dyskinaesia. Brain,
131, 1574-1587. 
[239]  Lee, M., Hyun, D., Halliwell, B., Jenner, P. (2001) Effect of the 
overexpression of wild-type or mutant alpha-synuclein on cell sus-
ceptibility to insult. J. Neurochem., 76, 998-1009. 
[240]  Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., 
Harta, G., Brownstein, M.J., Jonnalagada, S., Chernova, T., Dehe-
jia, A., Lavedan, C., Gasser, T., Steinbach, P.J., Wilkinson, K.D., 
Polymeropoulos, M.H. (1998) The ubiquitin pathway in Parkin-
son's disease. Nature, 395, 451-452. 
[241]  Leroy, E., Boyer, R., Polymeropoulos, M.H. (1998) Intron-exon 
structure of ubiquitin c-terminal hydrolase-L1. DNA Res., 5, 397-
400. 
[242]  LeVine, S.M. (1997) Iron deposits in multiple sclerosis and Alz-
heimer's disease brains. Brain Res., 760, 298-303. 
[243]  Levites, Y., Weinreb, O., Maor, G., Youdim, M.B., Mandel, S. 
(2001) Green tea polyphenol (-)-epigallocatechin-3-gallate prevents 
N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminer-
gic neurodegeneration. J. Neurochem., 78, 1073-1082. 
[244]  Levites, Y., Youdim, M.B., Maor, G., Mandel, S. (2002) Attenua-
tion of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-
kappaB (NF-kappaB) activation and cell death by tea extracts in 
neuronal cultures. Biochem. Pharmacol., 63, 21-29. 
[245]  Li, W., Lesuisse, C., Xu, Y., Troncoso, J.C., Price, D.L., Lee, M.K. 
(2004) Stabilization of alpha-synuclein protein with aging and fa-
milial parkinson's disease-linked A53T mutation. J. Neurosci., 24,
7400-7409. 
[246]  Liccione, J.J., Maines, M.D. (1988) Selective vulnerability of glu-
tathione metabolism and cellular defense mechanisms in rat stria-
tum to manganese. J. Pharmacol. Exp. Ther., 247, 156-161. 
[247]  Lincoln, S., Vaughan, J., Wood, N., Baker, M., Adamson, J., 
Gwinn-Hardy, K., Lynch, T., Hardy, J., Farrer, M. (1999) Low fre-
quency of pathogenic mutations in the ubiquitin carboxy-terminal 
hydrolase gene in familial Parkinson's disease. Neuroreport, 10,
427-429. 
[248]  Ling, Z.D., Potter, E.D., Lipton, J.W., Carvey, P.M. (1998) Differ-
entiation of mesencephalic progenitor cells into dopaminergic neu-
rons by cytokines. Exp. Neurol., 149, 411-423. 
[249]  Liu, S., Ninan, I., Antonova, I., Battaglia, F., Trinchese, F., Na-
rasanna, A., Kolodilov, N., Dauer, W., Hawkins, R.D., Arancio, O. 
(2004) alpha-Synuclein produces a long-lasting increase in neuro-
transmitter release. EMBO J., 23, 4506-4516. 
[250]  Liu, Y., Fallon, L., Lashuel, H.A., Liu, Z., Lansbury, P.T., Jr. 
(2002) The UCH-L1 gene encodes two opposing enzymatic activi-
ties that affect alpha-synuclein degradation and Parkinson's disease 
susceptibility. Cell, 111, 209-218. 
[251]  Lo Bianco, C., Schneider, B.L., Bauer, M., Sajadi, A., Brice, A., 
Iwatsubo, T., Aebischer, P. (2004) Lentiviral vector delivery of 
parkin prevents dopaminergic degeneration in an alpha-synuclein 
rat model of Parkinson's disease. Proc. Natl. Acad. Sci. USA, 101,
17510-17515. 
[252]  Logroscino, G., Marder, K., Cote, L., Tang, M.X., Shea, S., 
Mayeux, R. (1996) Dietary lipids and antioxidants in Parkinson's 
disease: a population-based, case-control study. Ann. Neurol., 39,
89-94. 
[253]  Logroscino, G., Marder, K., Graziano, J., Freyer, G., Slavkovich, 
V., Lojacono, N., Cote, L., Mayeux, R. (1998) Dietary iron, animal 
fats, and risk of Parkinson's disease. Mov. Disord., 13(Suppl 1), 13-
16. 
[254]  Lotharius, J., Barg, S., Wiekop, P., Lundberg, C., Raymon, H.K., 
Brundin, P. (2002) Effect of mutant alpha-synuclein on dopamine 
homeostasis in a new human mesencephalic cell line. J. Biol. 
Chem., 277, 38884-38894. 
[255]  Lotharius, J., Brundin, P. (2002) Pathogenesis of Parkinson's dis-
ease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci.,
3, 932-942. 
[256]  Lucking, C.B., Abbas, N., Durr, A., Bonifati, V., Bonnet, A.M., de 
Broucker, T., De Michele, G., Wood, N.W., Agid, Y., Brice, A. 
(1998) Homozygous deletions in parkin gene in European and 
North African families with autosomal recessive juvenile parkin-Targeting the Progression of Parkinson’s Disease  Current Neuropharmacology, 2009, Vol. 7, No. 1    31
sonism. The European Consortium on Genetic Susceptibility in 
Parkinson's Disease and the French Parkinson's Disease Genetics 
Study Group. Lancet, 352, 1355-1356. 
[257]  MacMillan-Crow, L.A., Crow, J.P., Thompson, J.A. (1998) Per-
oxynitrite-mediated inactivation of manganese superoxide dismu-
tase involves nitration and oxidation of critical tyrosine residues. 
Biochemistry, 37, 1613-1622. 
[258]  Magaki, S., Mueller, C., Yellon, S.M., Fox, J., Kim, J., Snis-
sarenko, E., Chin, V., Ghosh, M.C., Kirsch, W.M. (2007) Regional 
dissection and determination of loosely bound and non-heme iron 
in the developing mouse brain. Brain Res., 1158, 144-150. 
[259]  Mann, V.M., Cooper, J.M., Daniel, S.E., Srai, K., Jenner, P., Mars-
den, C.D., Schapira, A.H. (1994) Complex I, iron, and ferritin in 
Parkinson's disease substantia nigra. Ann. Neurol., 36, 876-881. 
[260]  Manning-Bog, A.B., McCormack, A.L., Li, J., Uversky, V.N., 
Fink, A.L., Di Monte, D.A. (2002) The herbicide paraquat causes 
up-regulation and aggregation of alpha-synuclein in mice: paraquat 
and alpha-synuclein. J. Biol. Chem., 277, 1641-1644. 
[261]  Maraganore, D.M., Farrer, M.J., Hardy, J.A., Lincoln, S.J., 
McDonnell, S.K., Rocca, W.A. (1999) Case-control study of the 
ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's dis-
ease. Neurology, 53, 1858-1860. 
[262]  Maraganore, D.M., Lesnick, T.G., Elbaz, A., Chartier-Harlin, M.C., 
Gasser, T., Kruger, R., Hattori, N., Mellick, G.D., Quattrone, A., 
Satoh, J., Toda, T., Wang, J., Ioannidis, J.P., de Andrade, M., 
Rocca, W.A. (2004) UCHL1 is a Parkinson's disease susceptibility 
gene. Ann. Neurol., 55, 512-521. 
[263]  Marsden, C.D. (1961) Pigmentation in the nucleus substantiae 
nigrae of mammals. J. Anat., 95, 256-261. 
[264]  Marsden, C.D., Olanow, C.W. (1998) The causes of Parkinson's 
disease are being unraveled and rational neuroprotective therapy is 
close to reality. Ann. Neurol., 44, S189-196. 
[265]  Marsden, C.D., Parkes, J.D. (1976) "On-off" effects in patients 
with Parkinson's disease on chronic levodopa therapy. Lancet, 1,
292-296. 
[266]  Marsden, C.D., Parkes, J.D. (1977) Success and problems of long-
term levodopa therapy in Parkinson's disease. Lancet, 1, 345-349. 
[267]  Martin, W.R., Ye, F.Q., Allen, P.S. (1998) Increasing striatal iron 
content associated with normal aging. Mov. Disord., 13, 281-286. 
[268]  Martyn, C.N., Coggon, D.N., Inskip, H., Lacey, R.F., Young, W.F. 
(1997) Aluminum concentrations in drinking water and risk of 
Alzheimer's disease. Epidemiology, 8, 281-286. 
[269]  Mash, D.C., Ouyang, Q., Pablo, J., Basile, M., Izenwasser, S., 
Lieberman, A., Perrin, R.J. (2003) Cocaine abusers have an over-
expression of alpha-synuclein in dopamine neurons. J. Neurosci.,
23, 2564-2571. 
[270]  Maskri, L., Zhu, X., Fritzen, S., Kuhn, K., Ullmer, C., Engels, P., 
Andriske, M., Stichel, C.C., Lubbert, H. (2004) Influence of differ-
ent promoters on the expression pattern of mutated human alpha-
synuclein in transgenic mice. Neurodegener. Dis., 1, 255-265. 
[271]  Mastakov, M.Y., Baer, K., Symes, C.W., Leichtlein, C.B., Kotin, 
R.M., During, M.J. (2002) Immunological aspects of recombinant 
adeno-associated virus delivery to the mammalian brain. J. Virol.,
76, 8446-8454. 
[272]  Masuda, T., Hida, H., Kanda, Y., Aihara, N., Ohta, K., Yamada, 
K., Nishino, H. (2007) Oral administration of metal chelator ame-
liorates motor dysfunction after a small hemorrhage near the inter-
nal capsule in rat. J. Neurosci. Res., 85, 213-222. 
[273]  Matsumine, H., Saito, M., Shimoda-Matsubayashi, S., Tanaka, H., 
Ishikawa, A., Nakagawa-Hattori, Y., Yokochi, M., Kobayashi, T., 
Igarashi, S., Takano, H., Sanpei, K., Koike, R., Mori, H., Kondo, 
T., Mizutani, Y., Schaffer, A.A., Yamamura, Y., Nakamura, S., 
Kuzuhara, S., Tsuji, S., Mizuno, Y. (1997) Localization of a gene 
for an autosomal recessive form of juvenile Parkinsonism to chro-
mosome 6q25.2-27. Am. J. Hum. Genet., 60, 588-596. 
[274]  Maynard, C.J., Cappai, R., Volitakis, I., Cherny, R.A., White, A.R., 
Beyreuther, K., Masters, C.L., Bush, A.I., Li, Q.X. (2002) Overex-
pression of Alzheimer's disease amyloid-beta opposes the age-
dependent elevations of brain copper and iron. J. Biol. Chem., 277,
44670-44676. 
[275]  McCormack, A.L., Atienza, J.G., Johnston, L.C., Andersen, J.K., 
Vu, S., Di Monte, D.A. (2005) Role of oxidative stress in paraquat-
induced dopaminergic cell degeneration. J. Neurochem., 93, 1030-
1037. 
[276]  McCormack, A.L., Thiruchelvam, M., Manning-Bog, A.B., Thif-
fault, C., Langston, J.W., Cory-Slechta, D.A., Di Monte, D.A. 
(2002) Environmental risk factors and Parkinson's disease: selec-
tive degeneration of nigral dopaminergic neurons caused by the 
herbicide paraquat. Neurobiol. Dis., 10, 119-127. 
[277]  McCown, T.J., Xiao, X., Li, J., Breese, G.R., Samulski, R.J. (1996) 
Differential and persistent expression patterns of CNS gene transfer 
by an adeno-associated virus (AAV) vector. Brain Res., 713, 99-
107. 
[278]  McNaught, K.S., Belizaire, R., Isacson, O., Jenner, P., Olanow, 
C.W. (2003) Altered proteasomal function in sporadic Parkinson's 
disease. Exp. Neurol., 179, 38-46. 
[279]  McNaught, K.S., Bjorklund, L.M., Belizaire, R., Isacson, O., Jen-
ner, P., Olanow, C.W. (2002) Proteasome inhibition causes nigral 
degeneration with inclusion bodies in rats. Neuroreport, 13, 1437-
1441. 
[280]  McNaught, K.S., Mytilineou, C., Jnobaptiste, R., Yabut, J., 
Shashidharan, P., Jennert, P., Olanow, C.W. (2002) Impairment of 
the ubiquitin-proteasome system causes dopaminergic cell death 
and inclusion body formation in ventral mesencephalic cultures. J. 
Neurochem., 81, 301-306. 
[281]  McNaught, K.S., Perl, D.P., Brownell, A.L., Olanow, C.W. (2004) 
Systemic exposure to proteasome inhibitors causes a progressive 
model of Parkinson's disease. Ann. Neurol., 56, 149-162. 
[282]  McNaught, K.S., Shashidharan, P., Perl, D.P., Jenner, P., Olanow, 
C.W. (2002) Aggresome-related biogenesis of Lewy bodies. Eur. J. 
Neurosci., 16, 2136-2148. 
[283]  Meglio, L., Oteiza, P.I. (1999) Aluminum enhances melanin-
induced lipid peroxidation. Neurochem. Res., 24, 1001-1008. 
[284]  Melo, T.M., Larsen, C., White, L.R., Aasly, J., Sjobakk, T.E., 
Flaten, T.P., Sonnewald, U., Syversen, T. (2003) Manganese, cop-
per, and zinc in cerebrospinal fluid from patients with multiple 
sclerosis. Biol. Trace Elem. Res., 93, 1-8. 
[285]  Mendez-Alvarez, E., Soto-Otero, R., Hermida-Ameijeiras, A., 
Lopez-Real, A.M., Labandeira-Garcia, J.L. (2002) Effects of alu-
minum and zinc on the oxidative stress caused by 6-hydroxy-
dopamine autoxidation: relevance for the pathogenesis of Parkin-
son's disease. Biochim. Biophys. Acta, 1586, 155-168. 
[286]  Menzies, F.M., Yenisetti, S.C., Min, K.T. (2005) Roles of Droso-
phila DJ-1 in survival of dopaminergic neurons and oxidative 
stress. Curr. Biol., 15, 1578-1582. 
[287]  Meredith, G.E., Halliday, G.M., Totterdell, S. (2004) A critical 
review of the development and importance of proteinaceous aggre-
gates in animal models of Parkinson's disease: new insights into 
Lewy body formation. Parkinsonism Relat. Disord., 10, 191-202. 
[288]  Meulener, M.C., Xu, K., Thomson, L., Ischiropoulos, H., Bonini, 
N.M. (2006) Mutational analysis of DJ-1 in Drosophila implicates 
functional inactivation by oxidative damage and aging. Proc. Natl. 
Acad. Sci. USA, 103, 12517-12522. 
[289]  Middleton, E., Jr. (1998) Effect of plant flavonoids on immune and 
inflammatory cell function. Adv. Exp. Med. Biol., 439, 175-182. 
[290]  Momose, Y., Murata, M., Kobayashi, K., Tachikawa, M., Nakaba-
yashi, Y., Kanazawa, I., Toda, T. (2002) Association studies of 
multiple candidate genes for Parkinson's disease using single nu-
cleotide polymorphisms. Ann. Neurol., 51, 133-136. 
[291]  Moon, Y., Lee, K.H., Park, J.H., Geum, D., Kim, K. (2005) Mito-
chondrial membrane depolarization and the selective death of do-
paminergic neurons by rotenone: protective effect of coenzyme 
Q10. J. Neurochem., 93, 1199-1208. 
[292]  Moore, P.B., Day, J.P., Taylor, G.A., Ferrier, I.N., Fifield, L.K., 
Edwardson, J.A. (2000) Absorption of aluminium-26 in Alz-
heimer's disease, measured using accelerator mass spectrometry. 
Dement. Geriatr. Cogn. Disord., 11, 66-69. 
[293]  Morris, C.M., Candy, J.M., Oakley, A.E., Taylor, G.A., Mountfort, 
S., Bishop, H., Ward, M.K., Bloxham, C.A., Edwardson, J.A. 
(1989) Comparison of the regional distribution of transferrin recep-
tors and aluminium in the forebrain of chronic renal dialysis pa-
tients. J. Neurol. Sci., 94, 295-306. 
[294]  Morris, C.M., Keith, A.B., Edwardson, J.A., Pullen, R.G. (1992) 
Uptake and distribution of iron and transferrin in the adult rat brain. 
J. Neurochem., 59, 300-306. 
[295]  Morrish, P.K., Rakshi, J.S., Bailey, D.L., Sawle, G.V., Brooks, D.J. 
(1998) Measuring the rate of progression and estimating the pre-
clinical period of Parkinson's disease with [18F]dopa PET. J. Neu-
rol. Neurosurg. Psychiatry, 64, 314-319. 32    Current Neuropharmacology, 2009, Vol. 7, No. 1 George et al. 
[296]  Mosharov, E.V., Staal, R.G., Bove, J., Prou, D., Hananiya, A., 
Markov, D., Poulsen, N., Larsen, K.E., Moore, C.M., Troyer, M.D., 
Edwards, R.H., Przedborski, S., Sulzer, D. (2006) Alpha-synuclein 
overexpression increases cytosolic catecholamine concentration. J. 
Neurosci., 26, 9304-9311. 
[297]  Muenter, M.D., Forno, L.S., Hornykiewicz, O., Kish, S.J., Mara-
ganore, D.M., Caselli, R.J., Okazaki, H., Howard, F.M., Jr., Snow, 
B.J., Calne, D.B. (1998) Hereditary form of parkinsonism--
dementia. Ann. Neurol., 43, 768-781. 
[298]  Muller, T., Hefter, H., Hueber, R., Jost, W.H., Leenders, K.L., 
Odin, P., Schwarz, J. (2004) Is levodopa toxic? J. Neurol., 251 
(Suppl 6), VI/44-46. 
[299]  Mytilineou, C., McNaught, K.S., Shashidharan, P., Yabut, J., Bap-
tiste, R.J., Parnandi, A., Olanow, C.W. (2004) Inhibition of protea-
some activity sensitizes dopamine neurons to protein alterations 
and oxidative stress. J. Neural. Transm, 111, 1237-1251. 
[300]  Narayanan, V., Scarlata, S. (2001) Membrane binding and self-
association of alpha-synucleins. Biochemistry, 40, 9927-9934. 
[301]  Narhi, L., Wood, S.J., Steavenson, S., Jiang, Y., Wu, G.M., Anafi, 
D., Kaufman, S.A., Martin, F., Sitney, K., Denis, P., Louis, J.C., 
Wypych, J., Biere, A.L., Citron, M. (1999) Both familial Parkin-
son's disease mutations accelerate alpha-synuclein aggregation. J. 
Biol. Chem., 274, 9843-9846. 
[302]  Noack, H., Kube, U., Augustin, W. (1994) Relations between toco-
pherol depletion and coenzyme Q during lipid peroxidation in rat 
liver mitochondria. Free Radic. Res., 20, 375-386. 
[303]  Norris, E.H., Giasson, B.I., Ischiropoulos, H., Lee, V.M. (2003) 
Effects of oxidative and nitrative challenges on alpha-synuclein fi-
brillogenesis involve distinct mechanisms of protein modifications. 
J. Biol. Chem., 278, 27230-27240. 
[304]  Obeso, J.A., Rodriguez-Oroz, M., Marin, C., Alonso, F., Zamar-
bide, I., Lanciego, J.L., Rodriguez-Diaz, M. (2004) The origin of 
motor fluctuations in Parkinson's disease: importance of dopa-
minergic innervation and basal ganglia circuits. Neurology, 62,
S17-30. 
[305]  Obeso, J.A., Rodriguez-Oroz, M.C., Lanciego, J.L., Rodriguez 
Diaz, M. (2004) How does Parkinson's disease begin? The role of 
compensatory mechanisms. Trends Neurosci., 27, 125-127; author 
reply 127-128. 
[306]  Obeso, J.A., Rodriguez-Oroz, M.C., Rodriguez, M., Lanciego, J.L., 
Artieda, J., Gonzalo, N., Olanow, C.W. (2000) Pathophysiology of 
the basal ganglia in Parkinson's disease. Trends Neurosci., 23, S8-
19. 
[307]  Odunze, I.N., Klaidman, L.K., Adams, J.D., Jr. (1990) MPTP tox-
icity in the mouse brain and vitamin E. Neurosci. Lett., 108, 346-
349. 
[308]  Ogasahara, S., Yorifuji, S., Nishikawa, Y., Takahashi, M., Wada, 
K., Hazama, T., Nakamura, Y., Hashimoto, S., Kono, N., Tarui, S. 
(1985) Improvement of abnormal pyruvate metabolism and cardiac 
conduction defect with coenzyme Q10 in Kearns-Sayre syndrome. 
Neurology, 35, 372-377. 
[309]  Ohshima, H., Gilibert, I., Bianchini, F. (1999) Induction of DNA 
strand breakage and base oxidation by nitroxyl anion through hy-
droxyl radical production. Free Radic. Biol. Med., 26, 1305-1313. 
[310]  Oikawa, S., Hirosawa, I., Tada-Oikawa, S., Furukawa, A., Nishi-
ura, K., Kawanishi, S. (2006) Mechanism for manganese enhance-
ment of dopamine-induced oxidative DNA damage and neuronal 
cell death. Free Radic. Biol. Med., 41, 748-756. 
[311]  Olanow, C.W., Goetz, C.G., Kordower, J.H., Stoessl, A.J., Sossi, 
V., Brin, M.F., Shannon, K.M., Nauert, G.M., Perl, D.P., Godbold, 
J., Freeman, T.B. (2003) A double-blind controlled trial of bilateral 
fetal nigral transplantation in Parkinson's disease. Ann. Neurol., 54,
403-414. 
[312]  Ossowska, K., Wardas, J., Smialowska, M., Kuter, K., Lenda, T., 
Wieronska, J.M., Zieba, B., Nowak, P., Dabrowska, J., Bortel, A., 
Kwiecinski, A., Wolfarth, S. (2005) A slowly developing dysfunc-
tion of dopaminergic nigrostriatal neurons induced by long-term 
paraquat administration in rats: an animal model of preclinical 
stages of Parkinson's disease? Eur. J. Neurosci., 22, 1294-1304. 
[313]  Ostrerova-Golts, N., Petrucelli, L., Hardy, J., Lee, J.M., Farer, M., 
Wolozin, B. (2000) The A53T alpha-synuclein mutation increases 
iron-dependent aggregation and toxicity. J. Neurosci., 20, 6048-
6054. 
[314]  Pacifici, R.E., Kono, Y., Davies, K.J. (1993) Hydrophobicity as the 
signal for selective degradation of hydroxyl radical-modified he-
moglobin by the multicatalytic proteinase complex, proteasome. J. 
Biol. Chem., 268, 15405-15411. 
[315]  Paik, S.R., Shin, H.J., Lee, J.H., Chang, C.S., Kim, J. (1999) Cop-
per(II)-induced self-oligomerization of alpha-synuclein. Biochem. 
J., 340 ( Pt 3), 821-828. 
[316]  Paisan-Ruiz, C., Jain, S., Evans, E.W., Gilks, W.P., Simon, J., van 
der Brug, M., Lopez de Munain, A., Aparicio, S., Gil, A.M., Khan, 
N., Johnson, J., Martinez, J.R., Nicholl, D., Carrera, I.M., Pena, 
A.S., de Silva, R., Lees, A., Marti-Masso, J.F., Perez-Tur, J., 
Wood, N.W., Singleton, A.B. (2004) Cloning of the gene contain-
ing mutations that cause PARK8-linked Parkinson's disease. Neu-
ron, 44, 595-600. 
[317]  Palhagen, S., Heinonen, E., Hagglund, J., Kaugesaar, T., Maki-
Ikola, O., Palm, R. (2006) Selegiline slows the progression of the 
symptoms of Parkinson disease. Neurology, 66, 1200-1206. 
[318]  Parenti, M., Rusconi, L., Cappabianca, V., Parati, E.A., Groppetti, 
A. (1988) Role of dopamine in manganese neurotoxicity. Brain 
Res., 473, 236-240. 
[319]  Parish, C.L., Drago, J., Stanic, D., Borrelli, E., Finkelstein, D.I., 
Horne, M.K. (2005) Haloperidol treatment reverses behavioural 
and anatomical changes in cocaine-dependent mice. Neurobiol. 
Dis., 19, 301-311. 
[320]  Park, J., Kim, S.Y., Cha, G.H., Lee, S.B., Kim, S., Chung, J. (2005) 
Drosophila DJ-1 mutants show oxidative stress-sensitive locomo-
tive dysfunction. Gene, 361, 133-139. 
[321]  Patel, N.K., Heywood, P., O'Sullivan, K., McCarter, R., Love, S., 
Gill, S.S. (2003) Unilateral subthalamotomy in the treatment of 
Parkinson's disease. Brain, 126, 1136-1145. 
[322]  Pearce, R.K., Owen, A., Daniel, S., Jenner, P., Marsden, C.D. 
(1997) Alterations in the distribution of glutathione in the substan-
tia nigra in Parkinson's disease. J. Neural. Transm., 104, 661-677. 
[323]  Pedersen, W.A., Cashman, N.R., Mattson, M.P. (1999) The lipid 
peroxidation product 4-hydroxynonenal impairs glutamate and glu-
cose transport and choline acetyltransferase activity in NSC-19 mo-
tor neuron cells. Exp. Neurol., 155, 1-10. 
[324]  Perez, R.G., Waymire, J.C., Lin, E., Liu, J.J., Guo, F., Zigmond, 
M.J. (2002) A role for alpha-synuclein in the regulation of dopa-
mine biosynthesis. J. Neurosci., 22, 3090-3099. 
[325]  Perl, D.P. (2006) Exposure to aluminium and the subsequent de-
velopment of a disorder with features of Alzheimer's disease. J. 
Neurol. Neurosurg. Psychiatry, 77, 811. 
[326]  Perl, D.P., Gajdusek, D.C., Garruto, R.M., Yanagihara, R.T., 
Gibbs, C.J. (1982) Intraneuronal aluminum accumulation in 
amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam. 
Science, 217, 1053-1055. 
[327]  Perry, T.L., Yong, V.W., Clavier, R.M., Jones, K., Wright, J.M., 
Foulks, J.G., Wall, R.A. (1985) Partial protection from the dopa-
minergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
by four different antioxidants in the mouse. Neurosci. Lett., 60,
109-114. 
[328]  Perry, T.L., Yong, V.W., Hansen, S., Jones, K., Bergeron, C., 
Foulks, J.G., Wright, J.M. (1987) Alpha-tocopherol and beta-
carotene do not protect marmosets against the dopaminergic neuro-
toxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neu-
rol. Sci., 81, 321-331. 
[329]  Piccardo, P., Yanagihara, R., Garruto, R.M., Gibbs, C.J., Jr., Ga-
jdusek, D.C. (1988) Histochemical and X-ray microanalytical lo-
calization of aluminum in amyotrophic lateral sclerosis and parkin-
sonism-dementia of Guam. Acta Neuropathol., 77, 1-4. 
[330]  Pinero, D., Jones, B., Beard, J. (2001) Variations in dietary iron 
alter behavior in developing rats. J. Nut., 131, 311-318. 
[331]  Pitkanen-Arsiola, T., Tillman, J.E., Gu, G., Yuan, J., Roberts, R.L., 
Wantroba, M., Coetzee, G.A., Cookson, M.S., Kasper, S. (2006) 
Androgen and anti-androgen treatment modulates androgen recep-
tor activity and DJ-1 stability. Prostate, 66, 1177-1193. 
[332]  Polizzi, S., Pira, E., Ferrara, M., Bugiani, M., Papaleo, A., Albera, 
R., Palmi, S. (2002) Neurotoxic effects of aluminium among foun-
dry workers and Alzheimer's disease. Neurotoxicology, 23, 761-
774. 
[333]  Polymeropoulos, M.H., Higgins, J.J., Golbe, L.I., Johnson, W.G., 
Ide, S.E., Di Iorio, G., Sanges, G., Stenroos, E.S., Pho, L.T., Schaf-
fer, A.A., Lazzarini, A.M., Nussbaum, R.L., Duvoisin, R.C. (1996) 
Mapping of a gene for Parkinson's disease to chromosome 4q21-
q23. Science, 274, 1197-1199. Targeting the Progression of Parkinson’s Disease  Current Neuropharmacology, 2009, Vol. 7, No. 1    33
[334]  Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, 
A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Sten-
roos, E.S., Chandrasekharappa, S., Athanassiadou, A., Papapetro-
poulos, T., Johnson, W.G., Lazzarini, A.M., Duvoisin, R.C., Di 
Iorio, G., Golbe, L.I., Nussbaum, R.L. (1997) Mutation in the al-
pha-synuclein gene identified in families with Parkinson's disease. 
Science, 276, 2045-2047. 
[335]  Przedborski, S., Kostic, V., Jackson-Lewis, V., Naini, A.B., Si-
monetti, S., Fahn, S., Carlson, E., Epstein, C.J., Cadet, J.L. (1992) 
Transgenic mice with increased Cu/Zn-superoxide dismutase activ-
ity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-
induced neurotoxicity. J. Neurosci., 12, 1658-1667. 
[336]  Puglielli, L., Friedlich, A.L., Setchell, K.D., Nagano, S., Opazo, C., 
Cherny, R.A., Barnham, K.J., Wade, J.D., Melov, S., Kovacs, 
D.M., Bush, A.I. (2005) Alzheimer disease beta-amyloid activity 
mimics cholesterol oxidase. J. Clin. Invest., 115, 2556-2563. 
[337]  Racette, B.A., Tabbal, S.D., Jennings, D., Good, L., Perlmutter, 
J.S., Evanoff, B. (2005) Prevalence of parkinsonism and relation-
ship to exposure in a large sample of Alabama welders. Neurology,
64, 230-235. 
[338]  Radi, R., Beckman, J.S., Bush, K.M., Freeman, B.A. (1991) Per-
oxynitrite-induced membrane lipid peroxidation: the cytotoxic po-
tential of superoxide and nitric oxide. Arch. Biochem. Biophys.,
288, 481-487. 
[339]  Reinheckel, T., Sitte, N., Ullrich, O., Kuckelkorn, U., Davies, K.J., 
Grune, T. (1998) Comparative resistance of the 20S and 26S pro-
teasome to oxidative stress. Biochem. J., 335 ( Pt 3), 637-642. 
[340]  Ren, Y.R., Nishida, Y., Yoshimi, K., Yasuda, T., Jishage, K., 
Uchihara, T., Yokota, T., Mizuno, Y., Mochizuki, H. (2006) Ge-
netic vitamin E deficiency does not affect MPTP susceptibility in 
the mouse brain. J. Neurochem., 98, 1810-1816. 
[341]  Richardson, D.R., Mouralian, C., Ponka, P., Becker, E. (2001) 
Development of potential iron chelators for the treatment of Frie-
dreich's ataxia: ligands that mobilize mitochondrial iron. Biochim. 
Biophys. Acta, 1536, 133-140. 
[342]  Richter, F., Hamann, M., Richter, A. (2007) Chronic rotenone 
treatment induces behavioral effects but no pathological signs of 
parkinsonism in mice. J. Neurosci. Res., 85, 681-691. 
[343]  Ritchie, C.W., Bush, A.I., Mackinnon, A., Macfarlane, S., Mast-
wyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.X., Tammer, 
A., Carrington, D., Mavros, C., Volitakis, I., Xilinas, M., Ames, D., 
Davis, S., Beyreuther, K., Tanzi, R.E., Masters, C.L. (2003) Metal-
protein attenuation with iodochlorhydroxyquin (clioquinol) target-
ing Abeta amyloid deposition and toxicity in Alzheimer disease: a 
pilot phase 2 clinical trial. Arch. Neurol., 60, 1685-1691. 
[344]  Rogaeva, E., Johnson, J., Lang, A.E., Gulick, C., Gwinn-Hardy, K., 
Kawarai, T., Sato, C., Morgan, A., Werner, J., Nussbaum, R., Petit, 
A., Okun, M.S., McInerney, A., Mandel, R., Groen, J.L., Fernan-
dez, H.H., Postuma, R., Foote, K.D., Salehi-Rad, S., Liang, Y., Re-
imsnider, S., Tandon, A., Hardy, J., St George-Hyslop, P., Single-
ton, A.B. (2004) Analysis of the PINK1 gene in a large cohort of 
cases with Parkinson disease. Arch. Neurol., 61, 1898-1904. 
[345]  Rondeau, V., Commenges, D., Jacqmin-Gadda, H., Dartigues, J.F. 
(2000) Relation between aluminum concentrations in drinking wa-
ter and Alzheimer's disease: an 8-year follow-up study. Am. J. Epi-
demiol., 152, 59-66. 
[346]  Roy, N.S., Cleren, C., Singh, S.K., Yang, L., Beal, M.F., Goldman, 
S.A. (2006) Functional engraftment of human ES cell-derived do-
paminergic neurons enriched by coculture with telomerase-
immortalized midbrain astrocytes. Nat. Med., 12, 1259-1268. 
[347]  Saigoh, K., Wang, Y.L., Suh, J.G., Yamanishi, T., Sakai, Y., Kiyo-
sawa, H., Harada, T., Ichihara, N., Wakana, S., Kikuchi, T., Wada, 
K. (1999) Intragenic deletion in the gene encoding ubiquitin car-
boxy-terminal hydrolase in gad mice. Nat. Genet., 23, 47-51. 
[348]  Salah, N., Miller, N.J., Paganga, G., Tijburg, L., Bolwell, G.P., 
Rice-Evans, C. (1995) Polyphenolic flavanols as scavengers of 
aqueous phase radicals and as chain-breaking antioxidants. Arch. 
Biochem. Biophys., 322, 339-346. 
[349]  Saper, C.B., Petito, C.K. (1982) Correspondence of melanin-
pigmented neurons in human brain with A1-A14 catecholamine 
cell groups. Brain, 105, 87-101. 
[350]  Sapru, M.K., Yates, J.W., Hogan, S., Jiang, L., Halter, J., Bohn, 
M.C. (2006) Silencing of human alpha-synuclein in vitro and in rat 
brain using lentiviral-mediated RNAi. Exp. Neurol., 198, 382-390. 
[351]  Satoh, J., Kuroda, Y. (2001) A polymorphic variation of serine to 
tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene 
is associated with a reduced risk of sporadic Parkinson's disease in 
a Japanese population. J. Neurol. Sci., 189, 113-117. 
[352]  Sawada, H., Ibi, M., Kihara, T., Urushitani, M., Akaike, A., Ki-
mura, J., Shimohama, S. (1998) Dopamine D2-type agonists pro-
tect mesencephalic neurons from glutamate neurotoxicity: mecha-
nisms of neuroprotective treatment against oxidative stress. Ann. 
Neurol., 44, 110-119. 
[353]  Scheider, W.L., Hershey, L.A., Vena, J.E., Holmlund, T., Marshall, 
J.R., Freudenheim (1997) Dietary antioxidants and other dietary 
factors in the etiology of Parkinson's disease. Mov. Disord., 12,
190-196. 
[354]  Schober, A. (2004) Classic toxin-induced animal models of Parkin-
son's disease: 6-OHDA and MPTP. Cell Tissue Res., 318, 215-224. 
[355]  Schwarting, R.K., Huston, J.P. (1996) Unilateral 6-hydroxydopa-
mine lesions of meso-striatal dopamine neurons and their physio-
logical sequelae. Prog. Neurobiol., 49, 215-266. 
[356]  Sestili, P., Piedimonte, G., Cattabeni, F., Cantoni, O. (1986) Induc-
tion of DNA breakage and suppression of DNA synthesis by the 
OH radical generated in a Fenton-like reaction. Biochem. Int., 12,
493-501. 
[357]  Shachar, D.B., Kahana, N., Kampel, V., Warshawsky, A., Youdim, 
M.B. (2004) Neuroprotection by a novel brain permeable iron 
chelator, VK-28, against 6-hydroxydopamine lession in rats. Neu-
ropharmacology, 46, 254-263. 
[358]  Shen, X.M., Dryhurst, G. (1998) Iron- and manganese-catalyzed 
autoxidation of dopamine in the presence of L-cysteine: possible 
insights into iron- and manganese-mediated dopaminergic neuro-
toxicity. Chem. Res. Toxicol., 11, 824-837. 
[359]  Sherer, T.B., Betarbet, R., Stout, A.K., Lund, S., Baptista, M., 
Panov, A.V., Cookson, M.R., Greenamyre, J.T. (2002) An in vitro
model of Parkinson's disease: linking mitochondrial impairment to 
altered alpha-synuclein metabolism and oxidative damage. J. Neu-
rosci., 22, 7006-7015. 
[360]  Sherer, T.B., Kim, J.H., Betarbet, R., Greenamyre, J.T. (2003) 
Subcutaneous rotenone exposure causes highly selective dopa-
minergic degeneration and alpha-synuclein aggregation. Exp. Neu-
rol., 179, 9-16. 
[361]  Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Mi-
noshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., Suzuki, 
T. (2000) Familial Parkinson disease gene product, parkin, is a 
ubiquitin-protein ligase. Nat. Genet., 25, 302-305. 
[362]  Shimura, H., Schlossmacher, M.G., Hattori, N., Frosch, M.P., 
Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K.S., Selkoe, 
D.J. (2001) Ubiquitination of a new form of alpha-synuclein by 
parkin from human brain: implications for Parkinson's disease. Sci-
ence, 293, 263-269. 
[363]  Shinotoh, H., Snow, B.J., Chu, N.S., Huang, C.C., Lu, C.S., Lee, 
C., Takahashi, H., Calne, D.B. (1997) Presynaptic and postsynaptic 
striatal dopaminergic function in patients with manganese intoxica-
tion: a positron emission tomography study. Neurology, 48, 1053-
1056. 
[364]  Shults, C.W., Oakes, D., Kieburtz, K., Beal, M.F., Haas, R., Plumb, 
S., Juncos, J.L., Nutt, J., Shoulson, I., Carter, J., Kompoliti, K., 
Perlmutter, J.S., Reich, S., Stern, M., Watts, R.L., Kurlan, R., 
Molho, E., Harrison, M., Lew, M. (2002) Effects of coenzyme Q10 
in early Parkinson disease: evidence of slowing of the functional 
decline. Arch. Neurol., 59, 1541-1550. 
[365]  Sian, J., Dexter, D.T., Lees, A.J., Daniel, S., Agid, Y., Javoy-Agid, 
F., Jenner, P., Marsden, C.D. (1994) Alterations in glutathione lev-
els in Parkinson's disease and other neurodegenerative disorders af-
fecting basal ganglia. Ann. Neurol., 36, 348-355. 
[366]  Siderowf, A., Stern, M. (2006) Clinical trials with rasagiline: evi-
dence for short-term and long-term effects. Neurology, 66, S80-88. 
[367]  Sies, H., Stahl, W., Sundquist, A.R. (1992) Antioxidant functions 
of vitamins. Vitamins E and C, beta-carotene, and other caro-
tenoids. Ann. N. Y. Acad. Sci., 669, 7-20. 
[368]  Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., 
Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, 
R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, 
C., Cookson, M.R., Muenter, M., Baptista, M., Miller, D., Blan-
cato, J., Hardy, J., Gwinn-Hardy, K. (2003) alpha-Synuclein locus 
triplication causes Parkinson's disease. Science, 302, 841. 34    Current Neuropharmacology, 2009, Vol. 7, No. 1 George et al. 
[369]  Sjogren, B., Iregren, A., Frech, W., Hagman, M., Johansson, L., 
Tesarz, M., Wennberg, A. (1996) Effects on the nervous system 
among welders exposed to aluminium and manganese. Occup. En-
viron. Med., 53, 32-40. 
[370]  Slevin, J.T., Gerhardt, G.A., Smith, C.D., Gash, D.M., Kryscio, R., 
Young, B. (2005) Improvement of bilateral motor functions in pa-
tients with Parkinson disease through the unilateral intraputaminal 
infusion of glial cell line-derived neurotrophic factor. J. Neuro-
surg., 102, 216-222. 
[371]  Smith, A.D., Kozlowski, D.A., Bohn, M.C., Zigmond, M.J. (2005) 
Effect of AdGDNF on dopaminergic neurotransmission in the stria-
tum of 6-OHDA-treated rats. Exp. Neurol., 193, 420-426. 
[372]  Smith, M.P., Cass, W.A. (2006) GDNF reduces oxidative stress in 
a 6-hydroxydopamine model of Parkinson's disease. Neurosci. 
Lett., 412(3), 259-263. 
[373]  Sobotka, T.J., Whittaker, P., Sobotka, J.M., Brodie, R.E., Quander, 
D.Y., Robl, M., Bryant, M., Barton, C.N. (1996) Neurobehavioral 
dysfunctions associated with dietary iron overload. Physiol. Behav.,
59, 213-219. 
[374]  Sofic, E., Lange, K.W., Jellinger, K., Riederer, P. (1992) Reduced 
and oxidized glutathione in the substantia nigra of patients with 
Parkinson's disease. Neurosci. Lett., 142, 128-130. 
[375]  Sofic, E., Riederer, P., Heinsen, H., Beckmann, H., Reynolds, G.P., 
Hebenstreit, G., Youdim, M.B. (1988) Increased iron (III) and total 
iron content in post mortem substantia nigra of parkinsonian brain. 
J. Neural. Transm., 74, 199-205. 
[376]  Somayajulu, M., McCarthy, S., Hung, M., Sikorska, M., Borowy-
Borowski, H., Pandey, S. (2005) Role of mitochondria in neuronal 
cell death induced by oxidative stress; neuroprotection by Coen-
zyme Q10. Neurobiol. Dis., 18, 618-627. 
[377]  Sonsalla, P.K., Jochnowitz, N.D., Zeevalk, G.D., Oostveen, J.A., 
Hall, E.D. (1996) Treatment of mice with methamphetamine pro-
duces cell loss in the substantia nigra. Brain Res., 738, 172-175. 
[378]  Souza, J.M., Giasson, B.I., Chen, Q., Lee, V.M., Ischiropoulos, H. 
(2000) Dityrosine cross-linking promotes formation of stable alpha 
-synuclein polymers. Implication of nitrative and oxidative stress in 
the pathogenesis of neurodegenerative synucleinopathies. J. Biol. 
Chem., 275, 18344-18349. 
[379]  Sparks, D.L., Lochhead, J., Horstman, D., Wagoner, T., Martin, T. 
(2002) Water quality has a pronounced effect on cholesterol-
induced accumulation of Alzheimer amyloid beta (Abeta) in rabbit 
brain. J. Alzheimers Dis., 4, 523-529. 
[380]  Spiegel, J., Hellwig, D., Samnick, S., Jost, W., Mollers, M.O., 
Fassbender, K., Kirsch, C.M., Dillmann, U. (2007) Striatal FP-CIT 
uptake differs in the subtypes of early Parkinson's disease. J. Neu-
ral. Transm., 114, 331-335. 
[381]  Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., 
Jakes, R., Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Na-
ture, 388, 839-840. 
[382]  Spira, P.J., Sharpe, D.M., Halliday, G., Cavanagh, J., Nicholson, 
G.A. (2001) Clinical and pathological features of a Parkinsonian 
syndrome in a family with an Ala53Thr alpha-synuclein mutation. 
Ann. Neurol., 49, 313-319. 
[383]  Stanic, D., Finkelstein, D.I., Bourke, D.W., Drago, J., Horne, M.K. 
(2003) Timecourse of striatal re-innervation following lesions of 
dopaminergic SNpc neurons of the rat. Eur. J. Neurosci., 18, 1175-
1188. 
[384]  Stefani, A., Fedele, E., Galati, S., Pepicelli, O., Frasca, S., Pieran-
tozzi, M., Peppe, A., Brusa, L., Orlacchio, A., Hainsworth, A.H., 
Gattoni, G., Stanzione, P., Bernardi, G., Raiteri, M., Mazzone, P. 
(2005) Subthalamic stimulation activates internal pallidus: evi-
dence from cGMP microdialysis in PD patients. Ann. Neurol., 57,
448-452. 
[385]  Stefanova, N., Kollensperger, M., Hainzer, M., Cenci, A., Poewe, 
W., Wenning, G.K. (2007) High dose levodopa therapy is not toxic 
in multiple system atrophy: experimental evidence. Mov. Disord.,
22, 969-973. 
[386]  Storch, A., Jost, W.H., Vieregge, P., Spiegel, J., Greulich, W., 
Durner, J., Muller, T., Kupsch, A., Henningsen, H., Oertel, W.H., 
Fuchs, G., Kuhn, W., Niklowitz, P., Koch, R., Herting, B., Reich-
mann, H. (2007) Randomized, double-blind, placebo-controlled 
trial on symptomatic effects of coenzyme Q(10) in Parkinson dis-
ease. Arch. Neurol., 64, 938-944. 
[387]  Storch, A., Paul, G., Csete, M., Boehm, B.O., Carvey, P.M., 
Kupsch, A., Schwarz, J. (2001) Long-term proliferation and dopa-
minergic differentiation of human mesencephalic neural precursor 
cells. Exp. Neurol., 170, 317-325. 
[388]  Stover, N.P., Okun, M.S., Evatt, M.L., Raju, D.V., Bakay, R.A., 
Vitek, J.L. (2005) Stimulation of the subthalamic nucleus in a pa-
tient with Parkinson disease and essential tremor. Arch. Neurol.,
62, 141-143. 
[389]  Suh, J.G., Yamanishi, T., Matsui, K., Tanaka, K., Wada, K. (1995) 
Mapping of the gracile axonal dystrophy (gad) gene to a region be-
tween D5Mit197 and D5Mit113 on proximal mouse chromosome 
5. Genomics, 27, 549-551. 
[390]  Sulzer, D., Bogulavsky, J., Larsen, K.E., Behr, G., Karatekin, E., 
Kleinman, M.H., Turro, N., Krantz, D., Edwards, R.H., Greene, 
L.A., Zecca, L. (2000) Neuromelanin biosynthesis is driven by ex-
cess cytosolic catecholamines not accumulated by synaptic vesi-
cles. Proc. Natl. Acad. Sci. USA, 97, 11869-11874. 
[391]  Szabo, C., Zingarelli, B., O'Connor, M., Salzman, A.L. (1996) 
DNA strand breakage, activation of poly (ADP-ribose) synthetase, 
and cellular energy depletion are involved in the cytotoxicity of 
macrophages and smooth muscle cells exposed to peroxynitrite. 
Proc. Natl. Acad. Sci. USA, 93, 1753-1758. 
[392]  Tabrizi, S.J., Orth, M., Wilkinson, J.M., Taanman, J.W., Warner, 
T.T., Cooper, J.M., Schapira, A.H. (2000) Expression of mutant al-
pha-synuclein causes increased susceptibility to dopamine toxicity. 
Hum. Mol. Genet, 9, 2683-2689. 
[393]  Tan, E.K., Puong, K.Y., Fook-Chong, S., Chua, E., Shen, H., Yuen, 
Y., Pavanni, R., Wong, M.C., Puvan, K., Zhao, Y. (2006) Case-
control study of UCHL1 S18Y variant in Parkinson's disease. Mov. 
Disord., 21, 1765-1768. 
[394]  Tarohda, T., Ishida, Y., Kawai, K., Yamamoto, M., Amano, R. 
(2005) Regional distributions of manganese, iron, copper, and zinc 
in the brains of 6-hydroxydopamine-induced parkinsonian rats. 
Anal. Bioanal. Chem., 383, 224-234. 
[395]  Tatton, N.A., Kish, S.J. (1997) In situ detection of apoptotic nuclei 
in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine-treated mice using terminal deoxynucleotidyl 
transferase labelling and acridine orange staining. Neuroscience,
77, 1037-1048. 
[396]  Taylor, G.A., Ferrier, I.N., McLoughlin, I.J., Fairbairn, A.F., 
McKeith, I.G., Lett, D., Edwardson, J.A. (1992) Gastrointestinal 
absorption of aluminium in Alzheimer's disease: response to alu-
minium citrate. Age Ageing, 21, 81-90. 
[397]  Taylor, G.A., Moore, P.B., Ferrier, I.N., Tyrer, S.P., Edwardson, 
J.A. (1998) Gastrointestinal absorption of aluminium and citrate in 
man. J. Inorg. Biochem., 69, 165-169. 
[398]  Teixeira, S., Siquet, C., Alves, C., Boal, I., Marques, M.P., Borges, 
F., Lima, J.L., Reis, S. (2005) Structure-property studies on the an-
tioxidant activity of flavonoids present in diet. Free. Radic. Biol. 
Med., 39, 1099-1108. 
[399]  Testa, C.M., Sherer, T.B., Greenamyre, J.T. (2005) Rotenone in-
duces oxidative stress and dopaminergic neuron damage in organo-
typic substantia nigra cultures. Brain Res. Mol. Brain Res., 134,
109-118. 
[400]  Thomas, B., Beal, M.F. (2007) Parkinson's disease. Hum. Mol. 
Genet., 16(Spec No. 2), R183-194. 
[401]  Toda, T., Momose, Y., Murata, M., Tamiya, G., Yamamoto, M., 
Hattori, N., Inoko, H. (2003) Toward identification of susceptibility 
genes for sporadic Parkinson's disease. J. Neurol., 250(Suppl 3), 
III40-43. 
[402]  Toft, M., Myhre, R., Pielsticker, L., White, L.R., Aasly, J.O., Far-
rer, M.J. (2007) PINK1 mutation heterozygosity and the risk of 
Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 78, 82-84. 
[403]  Trulson, M.E., Cannon, M.S., Faegg, T.S., Raese, J.D. (1985) Ef-
fects of chronic methamphetamine on the nigral-striatal dopamine 
system in rat brain: tyrosine hydroxylase immunochemistry and 
quantitative light microscopic studies. Brain Res. Bull., 15, 569-
577. 
[404]  Turunen, M., Olsson, J., Dallner, G. (2004) Metabolism and func-
tion of coenzyme Q. Biochim. Biophys. Acta, 1660, 171-199. 
[405]  Uchiyama, S., Shimizu, T., Shirasawa, T. (2006) CuZn-SOD defi-
ciency causes ApoB degradation and induces hepatic lipid accumu-
lation by impaired lipoprotein secretion in mice. J. Biol. Chem.,
281, 31713-31719. 
[406]  Uemura, E. (1984) Intranuclear aluminum accumulation in chronic 
animals with experimental neurofibrillary changes. Exp. Neurol.,
85, 10-18. Targeting the Progression of Parkinson’s Disease  Current Neuropharmacology, 2009, Vol. 7, No. 1    35
[407]  Unoki, M., Nakamura, Y. (2001) Growth-suppressive effects of 
BPOZ and EGR2, two genes involved in the PTEN signaling path-
way. Oncogene, 20, 4457-4465. 
[408]  Uversky, V.N., Gillespie, J.R., Fink, A.L. (2000) Why are "natively 
unfolded" proteins unstructured under physiologic conditions? Pro-
teins, 41, 415-427. 
[409]  Uversky, V.N., Li, J., Fink, A.L. (2001) Evidence for a partially 
folded intermediate in alpha-synuclein fibril formation. J. Biol. 
Chem., 276, 10737-10744. 
[410]  Uversky, V.N., Li, J., Fink, A.L. (2001) Pesticides directly acceler-
ate the rate of alpha-synuclein fibril formation: a possible factor in 
Parkinson's disease. FEBS Lett., 500, 105-108. 
[411]  Valente, E.M., Abou-Sleiman, P.M., Caputo, V., Muqit, M.M., 
Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A.R., 
Healy, D.G., Albanese, A., Nussbaum, R., Gonzalez-Maldonado, 
R., Deller, T., Salvi, S., Cortelli, P., Gilks, W.P., Latchman, D.S., 
Harvey, R.J., Dallapiccola, B., Auburger, G., Wood, N.W. (2004) 
Hereditary early-onset Parkinson's disease caused by mutations in 
PINK1. Science, 304, 1158-1160. 
[412]  van der Putten, H., Wiederhold, K.H., Probst, A., Barbieri, S., 
Mistl, C., Danner, S., Kauffmann, S., Hofele, K., Spooren, W.P., 
Ruegg, M.A., Lin, S., Caroni, P., Sommer, B., Tolnay, M., Bilbe, 
G. (2000) Neuropathology in mice expressing human alpha-
synuclein. J. Neurosci., 20, 6021-6029. 
[413]  van Duijn, C.M., Dekker, M.C., Bonifati, V., Galjaard, R.J., Hou-
wing-Duistermaat, J.J., Snijders, P.J., Testers, L., Breedveld, G.J., 
Horstink, M., Sandkuijl, L.A., van Swieten, J.C., Oostra, B.A., 
Heutink, P. (2001) Park7, a novel locus for autosomal recessive 
early-onset parkinsonism, on chromosome 1p36. Am. J. Hum. 
Genet., 69, 629-634. 
[414]  Vila, M., Vukosavic, S., Jackson-Lewis, V., Neystat, M., Jakowec, 
M., Przedborski, S. (2000) Alpha-synuclein up-regulation in sub-
stantia nigra dopaminergic neurons following administration of the 
parkinsonian toxin MPTP. J. Neurochem., 74, 721-729. 
[415]  Voges, D., Zwickl, P., Baumeister, W. (1999) The 26S proteasome: 
a molecular machine designed for controlled proteolysis. Ann. Rev. 
Biochem., 68, 1015-1068. 
[416]  Volles, M.J., Lee, S.J., Rochet, J.C., Shtilerman, M.D., Ding, T.T., 
Kessler, J.C., Lansbury, P.T., Jr. (2001) Vesicle permeabilization 
by protofibrillar alpha-synuclein: implications for the pathogenesis 
and treatment of Parkinson's disease. Biochemistry, 40, 7812-7819. 
[417]  Wagner, G.C., Jarvis, M.F., Carelli, R.M. (1985) Ascorbic acid 
reduces the dopamine depletion induced by MPTP. Neuropharma-
cology, 24, 1261-1262. 
[418]  Walton-Hadlock, J.L. (2005) Levodopa and the progression of 
Parkinson's disease. N. Engl. J. Med., 352, 1386. 
[419]  Wang, D., Qian, L., Xiong, H., Liu, J., Neckameyer, W.S., Old-
ham, S., Xia, K., Wang, J., Bodmer, R., Zhang, Z. (2006) Antioxi-
dants protect PINK1-dependent dopaminergic neurons in Droso-
phila. Proc. Natl. Acad. Sci. USA, 103, 13520-13525. 
[420]  Wang, F., Feng, X., Ma, J., Zou, H., Chan, P. (2006) A common 
A340T variant in PINK1 gene associated with late-onset Parkin-
son's disease in Chinese. Neurosci. Lett., 410, 121-125. 
[421]  Wang, L., Muramatsu, S., Lu, Y., Ikeguchi, K., Fujimoto, K., 
Okada, T., Mizukami, H., Hanazono, Y., Kume, A., Urano, F., 
Ichinose, H., Nagatsu, T., Nakano, I., Ozawa, K. (2002) Delayed 
delivery of AAV-GDNF prevents nigral neurodegeneration and 
promotes functional recovery in a rat model of Parkinson's disease. 
Gene Ther., 9, 381-389. 
[422]  Washbourne, P., McAllister, A.K. (2002) Techniques for gene 
transfer into neurons. Curr. Opin. Neurobiol., 12, 566-573. 
[423]  Weinreb, P.H., Zhen, W., Poon, A.W., Conway, K.A., Lansbury, 
P.T., Jr. (1996) NACP, a protein implicated in Alzheimer's disease 
and learning, is natively unfolded. Biochemistry, 35, 13709-13715. 
[424]  Wesemann, W., Blaschke, S., Solbach, M., Grote, C., Clement, 
H.W., Riederer, P. (1994) Intranigral injected iron progressively 
reduces striatal dopamine metabolism. J. Neural. Transm. Park. 
Dis. Dement. Sect., 8, 209-214. 
[425]  Wettstein, A., Aeppli, J., Gautschi, K., Peters, M. (1991) Failure to 
find a relationship between mnestic skills of octogenarians and 
aluminum in drinking water. Int. Arch. Occup. Environ. Health, 63,
97-103. 
[426]  White, A.R., Reyes, R., Mercer, J.F., Camakaris, J., Zheng, H., 
Bush, A.I., Multhaup, G., Beyreuther, K., Masters, C.L., Cappai, R. 
(1999) Copper levels are increased in the cerebral cortex and liver 
of APP and APLP2 knockout mice. Brain Res., 842, 439-444. 
[427]  Widdowson, P.S., Farnworth, M.J., Simpson, M.G., Lock, E.A. 
(1996) Influence of age on the passage of paraquat through the 
blood-brain barrier in rats: a distribution and pathological examina-
tion. Hum. Exp. Toxicol., 15, 231-236. 
[428]  Wilkins, S., Masters, C.L., Bush, A.I., Cherny, R.A., Finkelstein, 
D.I. (2008) Cliquinol protects against cell death in Parkinson’s dis-
ease models in vivo and in vitro. In: Groenewegen, H. Ed, Ad-
vances in Behavioral Biology. IBAGS IX. New York, Springer. 
[429]  Winkler, C., Kirik, D., Bjorklund, A., Cenci, M.A. (2002) L-
DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine 
model of parkinson's disease: relation to motor and cellular pa-
rameters of nigrostriatal function. Neurobiol. Dis., 10, 165-186. 
[430]  Wintermeyer, P., Kruger, R., Kuhn, W., Muller, T., Woitalla, D., 
Berg, D., Becker, G., Leroy, E., Polymeropoulos, M., Berger, K., 
Przuntek, H., Schols, L., Epplen, J.T., Riess, O. (2000) Mutation 
analysis and association studies of the UCHL1 gene in German 
Parkinson's disease patients. Neuroreport, 11, 2079-2082. 
[431]  Wolters, E.C., Francot, C., Bergmans, P., Winogrodzka, A., Booij, 
J., Berendse, H.W., Stoof, J.C. (2000) Preclinical (premotor) Park-
inson's disease. J. Neurol., 247(Suppl 2), II103-109. 
[432]  Wolters, E.C., Huang, C.C., Clark, C., Peppard, R.F., Okada, J., 
Chu, N.S., Adam, M.J., Ruth, T.J., Li, D., Calne, D.B. (1989) Posi-
tron emission tomography in manganese intoxication. Ann. Neurol.,
26, 647-651. 
[433]  Wong, C.S., Kwok, J.C., Richardson, D.R. (2004) PCTH: a novel 
orally active chelator of the aroylhydrazone class that induces iron 
excretion from mice. Biochim. Biophys. Acta, 1739, 70-80. 
[434]  Yamada, M., Mizuno, Y., Mochizuki, H. (2005) Parkin gene ther-
apy for alpha-synucleinopathy: a rat model of Parkinson's disease. 
Hum. Gene Ther., 16, 262-270. 
[435]  Yang, Y., Gehrke, S., Imai, Y., Huang, Z., Ouyang, Y., Wang, 
J.W., Yang, L., Beal, M.F., Vogel, H., Lu, B. (2006) Mitochondrial 
pathology and muscle and dopaminergic neuron degeneration 
caused by inactivation of Drosophila Pink1 is rescued by Parkin. 
Proc. Natl. Acad. Sci. USA, 103, 10793-10798. 
[436]  Yoo, M.S., Chun, H.S., Son, J.J., DeGiorgio, L.A., Kim, D.J., 
Peng, C., Son, J.H. (2003) Oxidative stress regulated genes in ni-
gral dopaminergic neuronal cells: correlation with the known pa-
thology in Parkinson's disease. Brain Res. Mol. Brain Res., 110, 76-
84. 
[437]  Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E.R., 
Mizuno, Y. (1996) Immunohistochemical detection of 4-
hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. 
Acad. Sci. USA, 93, 2696-2701. 
[438]  Youdim, M.B., Stephenson, G., Ben Shachar, D. (2004) Ironing 
iron out in Parkinson's disease and other neurodegenerative dis-
eases with iron chelators: a lesson from 6-hydroxydopamine and 
iron chelators, desferal and VK-28. Ann. N. Y. Acad. Sci., 1012,
306-325. 
[439]  Yuan, H., Sarre, S., Ebinger, G., Michotte, Y. (2005) Histological, 
behavioural and neurochemical evaluation of medial forebrain 
bundle and striatal 6-OHDA lesions as rat models of Parkinson's 
disease. J. Neurosci. Methods, 144, 35-45. 
[440]  Zarranz, J.J., Alegre, J., Gomez-Esteban, J.C., Lezcano, E., Ros, R., 
Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atares, B., 
Llorens, V., Gomez Tortosa, E., del Ser, T., Munoz, D.G., de Ye-
benes, J.G. (2004) The new mutation, E46K, of alpha-synuclein 
causes Parkinson and Lewy body dementia. Ann. Neurol., 55, 164-
173. 
[441]  Zecca, L., Pietra, R., Goj, C., Mecacci, C., Radice, D., Sabbioni, E. 
(1994) Iron and other metals in neuromelanin, substantia nigra, and 
putamen of human brain. J. Neurochem., 62, 1097-1101. 
[442]  Zecca, L., Swartz, H.M. (1993) Total and paramagnetic metals in 
human substantia nigra and its neuromelanin. J. Neural. Transm. 
Park. Dis. Dement. Sect., 5, 203-213. 
[443]  Zhang, J., Graham, D.G., Montine, T.J., Ho, Y.S. (2000) Enhanced 
N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice de-
ficient in CuZn-superoxide dismutase or glutathione peroxidase. J. 
Neuropathol. Exp. Neurol., 59, 53-61. 
[444]  Zhang, J., Hattori, N., Leroy, E., Morris, H.R., Kubo, S., Kobaya-
shi, T., Wood, N.W., Polymeropoulos, M.H., Mizuno, Y. (2000) 
Association between a polymorphism of ubiquitin carboxy-terminal 36    Current Neuropharmacology, 2009, Vol. 7, No. 1 George et al. 
hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease. 
Parkinsonism Relat. Disord., 6, 195-197. 
[445]  Zhang, J., Perry, G., Smith, M.A., Robertson, D., Olson, S.J., Gra-
ham, D.G., Montine, T.J. (1999) Parkinson's disease is associated 
with oxidative damage to cytoplasmic DNA and RNA in substantia 
nigra neurons. Am. J. Pathol., 154, 1423-1429. 
[446]  Zhang, L., Shimoji, M., Thomas, B., Moore, D.J., Yu, S.W., Maru-
pudi, N.I., Torp, R., Torgner, I.A., Ottersen, O.P., Dawson, T.M., 
Dawson, V.L. (2005) Mitochondrial localization of the Parkinson's 
disease related protein DJ-1: implications for pathogenesis. Hum. 
Mo.l Genet., 14, 2063-2073. 
[447]  Zhang, S.M., Hernan, M.A., Chen, H., Spiegelman, D., Willett, 
W.C., Ascherio, A. (2002) Intakes of vitamins E and C, caro-
tenoids, vitamin supplements, and PD risk. Neurology, 59, 1161-
1169. 
[448]  Zhang, X., Xie, W., Qu, S., Pan, T., Wang, X., Le, W. (2005) Neu-
roprotection by iron chelator against proteasome inhibitor-induced 
nigral degeneration. Biochem. Biophys. Res. Commun., 333, 544-
549. 
[449]  Zheng, H., Gal, S., Weiner, L.M., Bar-Am, O., Warshawsky, A., 
Fridkin, M., Youdim, M.B. (2005) Novel multifunctional neuropro-
tective iron chelator-monoamine oxidase inhibitor drugs for neu-
rodegenerative diseases: in vitro studies on antioxidant activity, 
prevention of lipid peroxide formation and monoamine oxidase in-
hibition. J. Neurochem., 95, 68-78. 
[450]  Zheng, J.S., Tang, L.L., Zheng, S.S., Zhan, R.Y., Zhou, Y.Q., Gou-
dreau, J., Kaufman, D., Chen, A.F. (2005) Delayed gene therapy of 
glial cell line-derived neurotrophic factor is efficacious in a rat 
model of Parkinson's disease. Brain Res. Mol. Brain Res., 134, 155-
161. 
[451]  Zhou, W., Schaack, J., Zawada, W.M., Freed, C.R. (2002) Overex-
pression of human alpha-synuclein causes dopamine neuron death 
in primary human mesencephalic culture. Brain Res., 926, 42-50. 
[452]  Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lin-
coln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B., 
Stoessl, A.J., Pfeiffer, R.F., Patenge, N., Carbajal, I.C., Vieregge, 
P., Asmus, F., Muller-Myhsok, B., Dickson, D.W., Meitinger, T., 
Strom, T.M., Wszolek, Z.K., Gasser, T. (2004) Mutations in 
LRRK2 cause autosomal-dominant parkinsonism with pleomorphic 
pathology. Neuron, 44, 601-607. 
[453]  Zou, L., Jankovic, J., Rowe, D.B., Xie, W., Appel, S.H., Le, W. 
(1999) Neuroprotection by pramipexole against dopamine- and 
levodopa-induced cytotoxicity. Life Sci., 64, 1275-1285. 
Received: May 15, 2008  Revised: August 15, 2008  Accepted: September 09, 2008 